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Introduction and outline of the thesis
InTroDucTIon
Gastric cancer is the fourth most common cancer and second leading cause of cancer-related 
death worldwide. (1) The highest incidences are observed in Eastern Asia, Eastern Europe 
and South America, whereas the incidence in Western countries is much lower. For example, 
in Japan, the incidence of gastric cancer is approximately 44.1 cases/100 000 persons/year 
(world standardized rate, WSR). (1) In comparison, in the Netherlands, the incidence of gastric 
cancer is relatively low with approximately 6.9 cases/100 000 persons/year (WSR). (2) The inci-
dence of gastric cancer is declining, in particular in Western countries. However, the absolute 
number of new cases per year increases, due to aging of the world population and expansion 
of the population in developing countries with a high gastric cancer incidence.
As symptoms are often absent or non-specific in patients with an early stage of disease, 
gastric cancer is usually diagnosed at an advanced stage. In advanced gastric cancer, curative 
options are frequently limited and in these cases only palliative treatment can be offered. 
During palliative treatment, most responses to chemotherapy are partial and of short dura-
tion, rendering a relatively small effect on survival. (3;4) Consequently, gastric cancer carries 
a poor prognosis, with an overall five-year survival rate of less than 20 percent. (2;5) In order 
to reduce its mortality, detection and intervention in an early stage are essential for gastric 
cancer prevention.
Gastric cancer is a heterogeneous disease with a complex pathogenesis. Proximal gastric 
carcinomas have probably a mixed etiology, partly related to the etiology of distal esophageal 
carcinomas and partly to the etiology of distal gastric cancer. (6;7) The vast majority of distal 
gastric malignancies are adenocarcinomas, which are commonly divided into intestinal type 
and diffuse (undifferentiated) type carcinomas. (8) Intestinal type gastric carcinomas account 
for at least 60 to 75 percent of cancers. (9;10)
In 1994, the International Agency for Research on Cancer classified Helicobacter pylori as 
a class I (definite) carcinogen, as H. pylori infection is considered an important trigger in the 
process of carcinogenesis of distal gastric cancer. (11) For the development of gastric cancer, 
the presence of H. pylori may even be a conditio sine qua non, as in more than 90% of gastric 
cancer patients current or past H. pylori colonization can be demonstrated. (12;13)
Infection with H. pylori results in chronic active gastritis, which persists lifelong in virtually 
all infected subjects. In a considerable number of subjects, this will eventually lead to loss 
of gastric glands and thus a reduction of gastric secretory function, commonly defined as 
atrophic gastritis. (14) Atrophic gastritis can subsequently progress to intestinal metaplasia 
and dysplasia. In intestinal metaplasia, gastric columnar epithelial cells are replaced by cells 
of intestinal morphology, whereas dysplasia is histologically characterized by a variation 
in size, shape, and orientation of epithelial cells and enlargement and atypia of nuclei. The 
hypothesis of a multi-step carcinogenic cascade of H. pylori-induced chronic active gastritis 
progressing through several pre-malignant stages, i.e. atrophic gastritis, intestinal metaplasia 
Chapter 1
10
and dysplasia, to eventually gastric cancer was originally proposed by Correa et al. and has 
later been supported by several prospective studies. (15-18) The progression of pre-malignant 
gastric lesions to gastric cancer generally takes decades and may thus provide a basis for 
cancer prevention by early intervention, in particular H. pylori eradication, and potentially 
also for early detection and treatment of advanced precursors and gastric carcinomas.
AIm
The general aim of this thesis is to explore the potential contribution of detection, surveillance 
and treatment of pre-malignant gastric lesions, i.e. atrophic gastritis, intestinal metaplasia 
and dysplasia, to the prevention of gastric cancer.
ouTLIne of The TheSIS
Since symptoms are most frequently absent in patients with pre-malignant gastric lesions, 
epidemiology of these lesions is largely unknown, especially in regions with a relatively low 
incidence of gastric cancer. However, epidemiological data of pre-malignant gastric lesions 
are relevant as determinant in the evaluation of screening and surveillance practices. In this 
thesis, we therefore firstly aimed to evaluate the epidemiology of pre-malignant gastric le-
sions in the Netherlands (Chapter 3).
As gastric cancer incidence is low in Western countries, population-based screening for 
pre-malignant gastric lesions seems inappropriate. Therefore, a subpopulation at increased 
risk in comparison to the rest of the general population needs to be selected. As symptoms 
cannot predict the presence of pre-malignant gastric lesions, epidemiological risk factors 
need to identify this subpopulation. In Western countries, a possible risk factor may be migra-
tion from regions with a high H. pylori prevalence. Therefore, we investigated the prevalence 
of H. pylori infection and atrophic gastritis in a Dutch migrant population (Chapter 4).
In addition to the association of pre-malignant gastric lesions with subsequent develop-
ment of gastric cancer, an association with other gastro-esophageal conditions has also been 
suggested in previous studies. Several studies claimed that pre-malignant gastric lesions in 
particular increased the risk for esophageal squamous cell carcinomas. In this thesis, we in-
vestigated the association between pre-malignant gastric lesions and the risk of esophageal 
squamous cell carcinomas (Chapter 5), and the risk of gastric cancer in patients with gastric 
MALT lymphomas (Chapter 6). 
The need of endoscopic follow-up (surveillance) of patients after a diagnosis of pre-ma-
lignant gastric lesions is controversial. The most important reason for this controversy is that 
quantification of gastric cancer risk in these patients is unclear. In this thesis, we therefore 
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Introduction and outline of the thesis
next assessed gastric cancer risk of patients with pre-malignant gastric lesions, and evaluated 
whether the current surveillance practice of patients with these pre-malignant gastric lesions 
matches their cancer risk (Chapter 8).
It can be assumed that only a minority of patients with atrophic gastritis and intestinal 
metaplasia will develop gastric cancer. Therefore, surveillance of these patients should pref-
erably be limited to patients at high risk of gastric cancer. Previous studies have shown that 
the intragastric extent of intestinal metaplasia is an important indicator of gastric cancer risk. 
In this thesis, we therefore studied clinical characteristics, histological assessment of routine 
gastric biopsies, and serological markers as predictive parameters for extensive intestinal 
metaplasia at surveillance endoscopy (Chapter 9).
Although advanced endoscopic techniques may improve the detection of pre-malignant 
gastric lesions, current detection and surveillance in routine practice still relies on histologi-
cal assessment of random biopsies, obtained during conventional endoscopy. However, the 
appropriate biopsy locations and number of biopsies, and the yield of random versus tar-
geted biopsies are unclear. In order to determine the appropriate biopsy regimen for optimal 
detection of pre-malignant gastric lesions, we assessed the yield of endoscopic surveillance 
by standardized and targeted biopsy protocols in this thesis (Chapter 10).
With advancing insights into the pivotal role of H. pylori in gastric carcinogenesis, the pre-
vention of gastric cancer by eradication of H. pylori seems increasingly important. A preven-
tive effect of H. pylori eradication has been demonstrated in patients with H. pylori-induced 
chronic active gastritis, without pre-malignant gastric lesions. However, controversy remains 
whether eradication halts the progression or can even cause regression of pre-malignant 
gastric lesions. In this thesis, we evaluated the effect of H. pylori eradication in patients with 
pre-malignant gastric lesions in a systematic review of randomized controlled trials (Chapter 
11) and a case report with long-term follow-up (Chapter 12).
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AbSTrAcT
Gastric cancer is one of the most common cancers worldwide; however, gastric cancer 
incidence varies greatly between different geographic areas. As gastric cancer is usually 
diagnosed at an advanced stage, the disease causes considerable morbidity and mortality. 
To detect gastric carcinomas at an early and curable stage, screening and surveillance seem 
necessary. Premalignant gastric lesions are well known risk factors for the development of 
intestinal type gastric adenocarcinomas. In a multistep cascade, chronic Helicobacter pylori 
–induced gastritis progresses through premalignant stages of atrophic gastritis, intestinal 
metaplasia and dysplasia, to eventually gastric cancer. Therefore, this cascade may provide a 
basis for early detection and treatment of gastric cancer. Epidemiology of gastric cancer and 
premalignant gastric lesions should guide the development of screening and surveillance 
strategies, as distinct approaches are required in countries with low and high gastric cancer 
incidences.
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InTroDucTIon
The past 20 years have yielded an abundance of data and knowledge on the etiology of 
gastric cancer and its relation with Helicobacter pylori gastritis. The European Helicobacter 
Study Group has in its 20 years history greatly contributed to this understanding and aims 
to continue to do so in the coming decade, among others by repeated updates of the Maas-
tricht guidelines on management of H. pylori infection, for example, as regards patients with 
gastric (pre)neoplastic lesions and their relatives (1). This is important because gastric cancer 
remains one of the most common forms of cancer worldwide with approximately 937,000 
new cases per year, accounting for nearly 10% of all new cancers (2). In recent decades, the 
incidence of gastric cancer has declined rapidly in the Western world, but it remains high 
in many developing regions. As a result, the absolute annual number of new cases will un-
doubtedly increase, mainly because of the aging of the world population and the expansion 
of populations in developing countries with a high gastric cancer incidence.
The vast majority of gastric malignancies are adenocarcinomas, which are commonly 
divided into intestinal type and diffuse (undifferentiated) type carcinomas (3). Most gastric 
carcinomas are of the intestinal type. Both types of gastric adenocarcinoma are strongly 
associated with H. pylori infection. Colonization with this bacterium increases the risk of de-
veloping gastric cancer at least sixfold and is therefore considered an important carcinogenic 
trigger (4). Premalignant gastric lesions are well-known risk factors for the development of 
intestinal-type gastric adenocarcinomas. A multistep sequence of these recognizable precur-
sor lesions generally precedes these tumors. In this cascade, H. pylori causes chronic inflam-
mation of the gastric mucosa, which slowly progresses through the premalignant stages of 
atrophic gastritis, intestinal metaplasia and dysplasia to gastric adenocarcinoma (5). Estimates 
of progression rates of premalignant lesions are primarily based on historic cohort studies. 
Data from these studies generally suggest that among 100 H. pylori positive subjects, 50 will 
develop atrophic gastritis, 40 will develop intestinal metaplasia, eight will develop dysplasia, 
and one or two will eventually develop gastric cancer (6). Each of these subsequent steps in 
particular occurs in subjects who already have a previous lesion, and the risk of progression 
to the next step depends on the severity of the preexistent pathology, e.g. atrophic gastritis 
occurs mostly in subjects with more severe and diffuse chronic active gastritis, and intestinal 
metaplasia often in subjects with more severe and diffuse atrophic gastritis. Gastric cancer 
has a poor prognosis as it is usually diagnosed at an advanced stage. The progression of 
premalignant gastric lesions to gastric cancer generally takes decades and may thus provide 
a basis for early detection and treatment of gastric carcinomas, and furthermore potentially 
for cancer prevention by early intervention, such as H. pylori eradication.
Nationwide mass screening programs in Japan have resulted in the detection of more 
gastric carcinomas at an early stage. Several uncontrolled trials have suggested that cancer 
mortality has thereby been reduced (7–10), but nationwide data are lacking. In contrast to 
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these data from a country with a high gastric cancer incidence, an invasive mass-screening 
program in countries with a relatively low incidence of gastric cancer seems inappropriate, 
considering for instance the burden for the population, ethical objections, and costs. In 
these countries, a more targeted approach would be required to detect gastric cancer at an 
early and curable stage. In this approach, selection of a population sample from the general 
population that should be offered gastric cancer screening is needed. This selection should 
be based primarily on epidemiologic risk factors, as symptoms cannot predict the presence 
of premalignant lesions or early gastric cancer. In addition, serologic markers of the status of 
the gastric mucosa, such as pepsinogens I, II, and gastrin, for the identification of atrophic 
gastritis may be of great importance for population-based screening (11).
Apart from case finding, the necessity of reevaluation or surveillance of patients with 
premalignant gastric lesions is controversial (12–22). For the development of surveillance 
strategies, individuals with premalignant lesions at high risk of progression need to be identi-
fied, most likely based on epidemiologic factors and the severity and extent of the lesions.
However, premalignant gastric lesions presumably remain undetected in the majority of 
affected subjects. Therefore, epidemiologic observations of these lesions are scarce. In this 
review, we will provide an overview of current knowledge on the prevalence of premalignant 
gastric lesions and risk factors for the development and progression of these lesions. In addi-
tion, the implications of these epidemiologic observations for the development of screening 
and surveillance strategies will be described.
ePIDemIoLoGy
The prevalence of premalignant gastric lesions shows considerable geographic differences 
and is clearly associated with the regional prevalence of H. pylori infection (23). Nonetheless, 
some reports describe regions with a low prevalence of gastric cancer and premalignant 
gastric lesions despite a high H. pylori infection rate (24). Therefore, other factors, including 
diet, H. pylori strain characteristics and host-immune response presumably also play a role in 
explaining the geographic variation in the prevalence of gastric cancer and its precursors.
The prevalence of premalignant gastric lesions has been investigated with both endoscopy 
and serologic markers. Reported prevalence rates vary widely, not only between populations 
but also within populations (25,26). These variations can probably be explained by a variety 
of factors such as the heterogeneity of selected populations, sample size, and variations in 
definitions of premalignant gastric lesions (27).
In the Western European population, H. pylori infection prevalence is approximately 
30–40%. Atrophic gastritis is present in about 25–30% of H. pylori -infected individuals, and 
intestinal metaplasia in about 45% of H. pylori –infected individuals, whereas 5–10% of unin-
fected individuals are affected with these lesions (23,28,29). In Asia, the overall prevalence of 
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H. pylori infection is approximately 60% and is more often associated with pan-gastritis (30). 
Atrophic gastritis and intestinal metaplasia in these countries are thus also more common 
and present in a considerable proportion of H. pylori -positive subjects, compared to only 
10% of uninfected individuals (31). Prevalence of dysplasia varies from 0.5 to 4% in Western 
populations and from 9 to 20% in high-risk areas for gastric carcinomas (26). Gastric cancer 
is more common in men than in women; however, differences in the prevalence of premalig-
nant lesions by gender have rarely been observed (25,32).
The prevalence of premalignant gastric lesions increases with age, as has been demon-
strated in several studies worldwide (23,33,34). Within a specific cohort, this is the result of 
progressive damage as a result of persistent H. pylori -induced gastritis. Furthermore, this 
increase with age is explained by a cohort phenomenon, as has been demonstrated by 
repeated cross-sectional investigations within the same population (35). This and other 
studies showed that the prevalence of chronic H. pylori -induced gastritis is lower in younger 
birth cohorts, whereas the prevalence of chronic H. pylori gastritis is stable over time within 
a specific birth cohort, as only a few adults become infected or spontaneously eradicate the 
infection (36). Thus, H. pylori infection rates in childhood can presumably predict the later 
incidence rates of premalignant lesions and gastric cancer within a specific birth cohort. This 
is supported by the observation that the decline in H. pylori prevalence over the past 20 years 
was accompanied by a steady decline in the prevalence of atrophic gastritis, intestinal meta-
plasia, and gastric dysplasia (37). This ongoing decline, both in men and in women, predicts 
that the gastric cancer incidence will further drop by at least 20–25% within a few decades 
without any specific intervention.
reLATIon wITh H. pylori GASTrITIS
Infection with H. pylori results in persistent chronic gastritis lasting lifelong in virtually all 
infected subjects. In a considerable number of subjects, this will eventually lead to loss of 
gastric glands leading to atrophic gastritis. This is associated with a loss of specialized cells 
and thus a reduction of gastric secretory function (38). Atrophic gastritis can subsequently 
progress to intestinal metaplasia and dysplasia. In intestinal metaplasia, gastric columnar epi-
thelial cells are replaced by cells of intestinal morphology, whereas dysplasia is histologically 
characterized by a variation in size, shape, and orientation of epithelial cells and enlargement 
and atypia of nuclei. The hypothesis of precursor lesions progressing to gastric cancer was 
originally proposed by Correa et al. and was later supported by several prospective analyses 
(5,23,39–42). This sequence explains the increased risk for gastric cancer in H. pylori -infected 
subjects, as has been shown in various cross-sectional and longitudinal studies (4,43).
The risk for progression of H. pylori-induced gastritis towards premalignant lesions and 
gastric cancer depends on the duration, distribution, and severity of chronic active H. pylori 
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gastritis. Prospective follow-up studies have shown that progression of H. pylori via prema-
lignant lesions to gastric cancer takes several decades (23). A nested case-control study in 
a cohort of Japanese American men in Hawaii supported the concept that the earlier in life 
an individual becomes infected with H. pylori , the greater the probability that infection will 
progress to premalignant lesions and cancer (44).
In a Japanese cohort of 1526 patients, gastric cancers developed in 36 of 1246 H. pylori -posi-
tive patients as compared to none in the uninfected patients. In addition to the presence of 
severe atrophic gastritis and intestinal metaplasia at baseline, corpus-predominant gastritis 
was identified as an important risk factor for the development of intestinal-type gastric can-
cer (45). Similarly, patients with gastric ulcers, typically associated with atrophic gastritis and 
corpus-predominant gastritis, are at increased risk of gastric cancer, whereas patients with 
duodenal ulcers, commonly associated with few atrophic changes and antrum-predominant 
gastritis, are at low risk (46). It has been suggested that these differences in clinical outcome 
of H. pylori infection are caused by differences in local acid output between patients. Patients 
with increased acid output have antral-predominant gastritis, whereas patients with low acid 
output have widespread inflammation causing pan-gastritis (47). H. pylori –induced gastritis 
is most severe in zones between different types of gastric mucosa, in particular between 
the antrum and the corpus (48). The severity of gastritis determines the severity of mucosal 
damage, resulting in gastric pathology; therefore atrophy and intestinal metaplasia arise 
most often in this transitional zone. According to this transitional zone hypothesis, the border 
between different types of gastric glands will extend proximally with replacement of normal 
gastric mucosa as a result of inflammation (48). Therefore, the transitional zone between the 
antrum and the corpus moves upward in patients with low acid output and pan-gastritis. 
This continuous process predisposes to a further decrease in acid secretion as a result of the 
more proximal extension of inflammation, which further reinforces the process of proximal 
extension of inflammation associated with progressive gland loss.
The reversal of gastritis from antral-predominant to a corpus-predominant pan-gastritis in 
a low acid-producing stomach can also be induced by the use of profound acid suppressive 
medication (49). Increased corpus gastritis activity associated with long-term acid suppres-
sive therapy can thus accelerate the development of atrophic gastritis in the corpus mucosa 
over a time frame of years. This hypothesis was supported by several longitudinal studies 
comparing cohorts of H. pylori -infected patients receiving or not receiving long-term acid 
suppression (50–52).
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rISk fAcTorS
H. pylori virulence
H. pylori strain variability plays an important role in determining the severity of gastritis and 
thus the risk for occurrence of clinically overt H. pylori-associated disease (53–55). Carriage 
of strains with the cag pathogenicity island (PAI), a large chromosomal region that encodes 
virulence genes, including the cag A gene, is associated with an increased risk of develop-
ing peptic ulcer disease as well as premalignant gastric lesions and gastric cancer (43,56). 
In Asian countries these associations are absent, as almost all H. pylori positive individuals 
carry cag A-positive strains (56–58). In addition, vac A- and bab A-positive H. pylori strains 
are also associated with an increased gastric cancer risk (59,60). A combination of different 
virulence genes adds to the risk of severe gastric inflammation, atrophic gastritis, and gastric 
adenocarcinoma (61).
Host genetics
Genetic susceptibility has also been shown to affect the risk of development of gastric cancer 
in the presence of H. pylori infection. Polymorphisms in a number of genes from the inflam-
matory cascade are involved, such as genes encoding cytokines IL-1, IL-10, IL-8, and TNF-α, 
each of which have been reported to affect the risk of gastric cancer in the presence of H. 
pylori (62–68). Functional polymorphisms in these genes affect the severity of the inflamma-
tory process to H. pylori. For example, a significant association has recently been shown to 
exist between polymorphisms in the promoter region of the IL-8 gene and the development 
of dysplasia in a high-risk population (69). Future research studies will no doubt identify other 
genetic polymorphisms that increase the risk of premalignant gastric lesions.
Evidence from large epidemiologic studies shows a slight increase in the risk of gastric can-
cer in relatives of gastric cancer patients with intestinal-type carcinomas and a significantly 
increased risk of diffuse-type carcinoma (70). In addition, relatives of gastric cancer patients 
have an increased prevalence of premalignant gastric lesions in comparison to matched 
controls. To what extent this risk is independent from H. pylori infection status remains to be 
determined (71–73).
Environmental factors
Smoking has been associated with an increased risk of developing premalignant gastric 
lesions and gastric cancer (74). Among cigarette smokers the risk of developing intestinal 
metaplasia is increased fourfold compared to nonsmokers (33). In addition, cigarette smok-
ing nearly doubles the risk of transition of intestinal metaplasia to dysplasia (75,76). A diet 
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high in nitrates, complex carbohydrates and salt, and low in fresh fruits and vegetables is also 
associated with an increased risk of premalignant gastric lesions (75,77,78). Moreover, alcohol 
use has been described as an independent risk factor for the progression of premalignant 
gastric lesions (79).
Interaction
As only approximately 50% of H. pylori-infected patients progress beyond chronic nonatro-
phic gastritis, the risk of premalignant lesions for each individual after infection is presumably 
determined to a large extent by a combination of the described factors previously mentioned 
(80). Indeed, interaction between H. pylori virulence, environmental, and host genetic factors 
has been described to strongly influence gastric cancer risk. For instance, in a case-control 
study the risk of gastric cancer increased from an odds ratio (OR) of 1.8 for the IL-1β-511T 
polymorphism in the human interleukin-1 beta (IL-1β) gene (IL-1β-511T) to an OR of 25 in 
cag A-positive/IL-1β-511T carriers, and an OR of 87 in vac As1-positive IL-1β-511T carriers 
(64,80). Similarly, an increased risk of development of dysplasia was described in Venezuelan 
subjects with a combined carriage of a cag A-positive H. pylori strain and a proinflammatory 
IL-8 genotype. The OR for the development of dysplasia was 1.34 and 2.0 in heterozygotic 
and homozygotic carriers of the IL8–251 A allele, respectively, as compared to the TT geno-
type. This was in particular true for subjects infected with a cag A-positive H. pylori strain, 
suggesting that the A-allele increased the risk of dysplasia only when cag A was present (69). 
This is in line with the concept that the host response to environmental triggers determines 
the susceptibility for progression of inflammation and the development of gastric adeno-
carcinomas. It seems that H. pylori in particular initiates the carcinogenic cascade and plays a 
role in the early progression of gastritis since development of atrophic gastritis and intestinal 
metaplasia is often associated with a decreased colonization density, and ultimately with a 
frequent loss of H. pylori colonization. This indicates that further progression of premalignant 
lesions is less dependent on H. pylori and more related to other environmental and host 
genetic factors.
DeTecTIon
Serology
Screening for H. pylori antibodies seems to be a suitable serologic test to noninvasively diag-
nose premalignant gastric lesions, given its central role in gastric carcinogenesis. However, 
the sensitivity of this test for the detection of (pre)malignant lesions is low, since the pres-
ence of H. pylori antibodies does not differentiate between chronic, nonatrophic gastritis and 
23
Epidemiology of premalignant gastric lesions
Ch
ap
te
r 2
(pre)malignant lesions. In addition, with longstanding, widespread atrophic gastritis or the 
presence of intestinal metaplasia, H. pylori colonization can disappear and therefore serol-
ogy can ultimately become negative. Antibodies against specific, virulent strains of H. pylori 
containing cag A and vac A persist long after H. pylori eradication (81). Thus testing for these 
markers increases the sensitivity and specificity of H. pylori tests to detect (pre)malignant 
lesions (82). However, additional markers are needed for adequate diagnoses.
Serologic testing of pepsinogens I, II and gastrin provides valuable information on the 
status of the gastric mucosa. Pepsinogen I is produced by chief and mucous neck cells in 
the fundic glands, whereas pepsinogen II is produced throughout the whole stomach by 
mucous neck cells and also by cells in the pyloric glands and Brunner’s glands. Gastric inflam-
mation causes an increased release of both pepsinogens into the bloodstream, with a greater 
increase in pepsinogen II production in comparison to that of pepsinogen I. Atrophic gastritis 
causes a decreased production of both pepsinogens, with a more pronounced decrease in 
the production of pepsinogen I in comparison to that of pepsinogen II. As a result of these 
changes, chronic gastritis is associated with a reduced pepsinogen I/II ratio, and this ratio 
decreases even further when atrophic gastritis occurs (83). In addition, gastrin is synthesized 
and secreted almost solely from antral G-cells. H. pylori gastritis tends to raise the serum 
levels of gastrin, probably due to hyperplasia of the antral G-cells and also often due to an 
acid-suppressive effect of chronic gastritis when affecting the corpus mucosa. Increased 
production of gastrin also occurs in patients with atrophic gastritis in the corpus in response 
to reduced acid secretion, whereas in patients with antral-predominant atrophic gastritis the 
level of gastrin decreases (84). By using a combination of pepsinogens, gastrin levels and H. 
pylori serology, it is possible to establish the presence of gastritis, distinguish atrophic gastri-
tis and locate atrophic changes with high sensitivity and specificity (85–87). In a prospective 
Japanese study a significantly higher risk of gastric cancer during follow-up was shown for 
patients with a pepsinogen status indicative of atrophic gastritis as compared to patients 
with normal pepsinogen levels (11). In this study, the gastric cancer risk was even higher 
in atrophic gastritis patients who were H. pylori-negative as compared to H. pylori-positive 
patients. As a result of this adequate predictive value, these tests have been implemented in 
gastric cancer screening in some regions in Japan. A Portuguese study reported high negative 
predictive values but low positive predictive values using pepsinogen and H. pylori antibody 
testing to diagnose extensive intestinal metaplasia and dysplasia in patients with previously 
diagnosed premalignant gastric lesions (88). Therefore, the value of these tests in high-risk 
populations in Western countries, i.e. during follow-up of patients with premalignant gastric 
lesions, seems limited to the exclusion of more advanced lesions, although further investiga-
tions are required.
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Histology
Premalignant gastric lesions are often diagnosed on histologic examination of random 
biopsy samples. At present, the updated Sydney System is generally used both in clinical 
practice and research to grade gastritis (38). In this classification system several features of 
inflammation, atrophy and intestinal metaplasia are assessed separately and graded. Assess-
ment of dysplasia is often difficult and interobserver agreement in grading dysplasia is poor. 
In addition, differences exist between Japanese and Western gastrointestinal pathologists 
concerning the classification of gastric dysplasia and cancer. Japanese pathologists diagnose 
cancer based on cellular and structural abnormalities, whereas Western pathologists focus 
on the presence of tissue invasion as a prerequisite for a diagnosis of cancer (27). In 2000, the 
unified Padova classification was proposed, which divided dysplasia and adenocarcinoma 
into 5 categories. The Vienna classification further subdivided the categories of low-grade 
dysplasia and high-grade dysplasia (89–91). It is unclear whether these renewed classifica-
tions improved the pre-existing lack of observer agreement for the diagnosis and grading 
of dysplasia.
Endoscopy
Although image quality of standard endoscopes has improved dramatically over the last 
decades, findings during conventional endoscopy still often correlate poorly with histologic 
diagnoses of premalignant gastric lesions (92–96). This is primarily due to the nonspecific 
macroscopic appearance of these lesions, but without a doubt the lack of experience in 
recognizing subtle macroscopic changes indicative of the presence of preneoplastic changes 
of the mucosa, and lack of attention during routine diagnostic endoscopy also contribute to 
the poor correlation between endoscopic and histologic findings. As a consequence, several 
alternative and supplementary strategies have been developed to overcome the limitations 
of standard endoscopic imaging. Magnification endoscopy has been shown to improve the 
correlation between the endoscopic findings and histology (97–102). Furthermore, several 
in-vivo staining techniques such as staining with methylene blue and indigo carmine, can 
be used as adjuncts to plain visualization of gastric mucosal lesions using conventional or 
magnifying endoscopy (103). In addition, several other endoscopic techniques have been 
suggested, including narrow band imaging and autofluorescence endoscopy, however, 
their value in the detection of premalignant gastric lesions has not yet been established 
(104,105).
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ScreenInG AnD SurveILLAnce
As suitable screening tests exist for (pre)malignant gastric lesions, effective screening seems 
feasible, although gastric cancer incidence, the burden for patients, costs and the availability 
of specific therapeutic interventions need to be taken into consideration (106).
As gastric cancer incidence varies largely between different geographic regions, develop-
ment of uniform worldwide screening strategies seems inappropriate. In low incidence coun-
tries, a stepwise strategy with detailed selection criteria for screening is essential to meet all 
screening criteria, including cost-effectiveness (107). A high individual risk justifies invasive 
investigation by endoscopy, whereas in inhabitants of low-risk regions a more conservative 
approach is more appropriate and ethically acceptable. The initial selection of subjects for 
screening in low incidence countries should probably be based solely on epidemiologic 
factors, such as age, country of birth and socioeconomic class, as risk factors for H. pylori 
infection. Initial screening would consist of serologic testing with aforementioned specific 
gastric markers. A serologic diagnosis of atrophic gastritis, should be followed by endoscopy 
with histologic confirmation of the diagnosis. On the other hand, in high incidence countries, 
serologic and endoscopic screening could be offered to the general population, as has been 
common practice in Japan for several decades.
In addition, in countries with a high gastric cancer incidence, the cost of gastric cancer 
screening can be more easily balanced economically in relation to total expenditure on 
medical care compared to low incidence countries. Screening for gastric cancer by serology 
or endoscopy can potentially be cost-effective, however, the efficacy of early treatment needs 
to be established first (108–112).
H. pylori eradication therapy is frequently prescribed in patients with premalignant gastric 
lesions. In addition, adequate therapeutic options exist to treat severe dysplasia and early 
invasive cancers, since endoscopic alternatives to gastrectomy, such as endoscopic mucosal 
resection, have been developed over the past decades (113,114). Rokkas et al. provide 
a detailed overview of the influence of these treatment modalities on the progression of 
premalignant gastric lesions in another part of this issue. Clear conclusions on the efficacy 
to prevent gastric cancer of both H. pylori eradication and early endoscopic treatment in pa-
tients with premalignant gastric lesions are required to draw conclusions about the efficacy 
of gastric cancer screening (115).
Apart from screening, endoscopic surveillance of patients with premalignant lesions seems 
to be an important approach to reduce gastric cancer morbidity and mortality. It is surprising 
that clear guidelines are not available for the surveillance of patients with atrophic gastritis, 
intestinal metaplasia or gastric dysplasia, even more so since guidelines for surveillance of 
other gastrointestinal premalignant conditions have been widely developed, for instance 
for Barrett’s esophagus or colonic adenomas. This is most likely due to the concept that 
preneoplastic gastric lesions are still associated with a low gastric cancer risk. However, this 
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concept is not supported by the published literature. Several studies have investigated the 
risk of malignant progression of premalignant lesions (107). The reported progression rates 
to gastric cancer vary between 0% and 2% per year for atrophic gastritis (22,116,117). For 
intestinal metaplasia and dysplasia, reported progression rates to gastric cancer vary greatly, 
from 0 to 10% per year for intestinal metaplasia and from 0 to 73% per year for dysplasia 
(22,116,118–120). These differences could be explained by geographic differences, variation 
in diagnostic criteria, or methodological flaws (107). Nevertheless, the gastric cancer risk 
seems very similar to the cancer risk of other preneoplastic lesions of the gastrointestinal 
tract for which follow-up guidelines have been widely introduced.
Follow-up guidelines are therefore needed to provide consistent management for patients 
with premalignant gastric lesions and to guide the clinician on how and when to perform 
surveillance endoscopies. In order to develop such guidelines, more research is needed to 
design the most optimal random biopsy schemes for the surveillance of premalignant gastric 
lesions. As previously mentioned, premalignant gastric lesions are most frequently localized 
in the antrum up into the transitional zone between the antrum and the corpus, with the 
exception of atrophic gastritis related to pernicious anemia which tends to be corpus-
predominant. At present, the Sydney System recommends two biopsies from the corpus, 
two from the antrum and one from the incisura angularis during gastroscopy to classify and 
grade gastritis. However, this scheme is insufficient to reliably detect premalignant gastric 
lesions (121). As knowledge of the exact intragastric distribution of premalignant lesions 
should guide biopsy sampling during surveillance endoscopy, clarification of their distribu-
tion by further research is essential to develop tailored endoscopic guidelines for different 
geographic areas (26).
As only a minority of patients with premalignant lesions will eventually develop gastric 
cancer, selection of patients for surveillance based on sensitive progression markers seems 
attractive. In addition to the extent and severity of the lesions, a combination of H. pylori 
virulence factors and genetic polymorphisms of the host, as previously mentioned, may pos-
sibly identify high-risk subjects (11). These markers are probably only suited for the selection 
of subjects for screening in low incidence countries because high susceptibility markers are 
less discriminatory in populations at high risk of gastric cancer with a high proportion of 
individuals carrying the markers.
concLuSIonS
Early detection and treatment of gastric cancer are essential to improve survival. The cascade 
from H. pylori induced gastritis via premalignant stages to gastric cancer can provide the 
basis for gastric cancer prevention, especially in low incidence countries. The cancer risk as-
sociated with these premalignant lesions is often underestimated but, in fact, is very similar 
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to the cancer risk associated with other premalignant conditions of the gastrointestinal tract. 
Screening, surveillance and possible treatment of premalignant gastric conditions should 
therefore be carefully evaluated despite many limitations, such as the burden for patients 
and cost-effectiveness. To overcome these limitations, suitable screening and surveillance 
strategies should therefore be developed in relation to gastric cancer incidence in different 
geographic areas. At present, the lack of surveillance protocols leads to a lack of proper 
follow-up of patients once they are diagnosed with a preneoplastic condition of the stomach. 
The introduction of such guidelines, with adequate advice regarding follow-up intervals and 
endoscopic or serologic follow-up methods, would benefit these patients.
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AbSTrAcT
background: The pre-malignant gastric lesions atrophic gastritis (AG), intestinal metaplasia 
(IM) and dysplasia (DYS) have long been identified as principal risk factors for gastric cancer.
objective: To evaluate epidemiological time trends of pre-malignant gastric lesions in the 
Netherlands.
methods: Patients with a first diagnosis of AG, IM or DYS between 1991 and 2005 were identi-
fied in the Dutch nationwide histopathology registry. The number of new diagnoses per year 
were evaluated relative to the total number of patients with a first gastric biopsy. Time trends 
were evaluated with age–period–cohort models using logistic regression analysis.
results: In total, 23 278 patients were newly diagnosed with AG, 65 937 patients with IM, 
and 8517 patients with DYS. The incidence of AG declined similarly in men and women with 
8.2% per year [95% CI 7.9% to 8.6%], and DYS with 8.1% per year [95% CI 7.5% to 8.6%]. The 
proportional number of new IM cases declined with 2.9% per year [95% CI 2.7% to 3.1%] in 
men and 2.4% [95% CI 2.2% to 2.6%] in women. With age–period–cohort models a cohort 
phenomenon was demonstrated for all categories of pre-malignant gastric lesions in men 
and in women with IM and DYS. Period phenomena with a larger decline in number of diag-
noses after 1996 were also demonstrated for AG and IM.
conclusions: The incidence of pre-malignant gastric lesions is declining. Period and cohort 
phenomena were demonstrated for diagnoses of AG and IM. These findings imply that a 
further decrease of at least 24% in the incidence of gastric cancer in the coming decade may 
be anticipated in Western countries without specific intervention.
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InTroDucTIon
Gastric cancer represents the fourth most common cancer and second leading cause of 
cancer-related death worldwide. The estimated current incidence of gastric cancer is approxi-
mately 16.2/100 000 persons/year (world standardised rate, WSR), with highest incidences 
in Eastern Asia, Eastern Europe and South America. (1) For example, in Japan, the incidence 
of gastric cancer is approximately 44.1 cases/100 000 persons/year (WSR). In comparison, 
in the Netherlands, the incidence of gastric cancer is relatively low with approximately 6.9 
cases/100 000 persons/year (WSR). (2) Although the incidence of gastric cancer has declined 
over the past decades, especially in Western countries, mortality remains high. As symptoms 
are frequently absent or only vague until the disease reaches an advanced stage, curative 
therapeutic options are usually limited at the time of diagnosis. (3)
The vast majority of gastric malignancies are adenocarcinomas, which can be divided into 
carcinomas of the intestinal and diffuse (undifferentiated) type. Intestinal type gastric carci-
nomas account for approximately 60% of cancers and are generally preceded by a sequence 
of precursor lesions. This multi-step model of gastric carcinogenesis is strongly associated 
with Helicobacter pylori colonisation; especially corpus-predominant H. pylori-induced gastri-
tis has been identified as an important risk factor for gastric cancer development. (4) Chronic 
inflammation of the gastric mucosa can progress through the pre-malignant stages of atro-
phic gastritis, intestinal metaplasia and dysplasia to eventually gastric adenocarcinoma over 
a time frame of several years to decades. (5–8) The recognition of this long-term cascade may 
provide a basis for early detection, surveillance and treatment of advanced precursors and 
early gastric carcinomas and thereby improve survival.
The prevalence of H. pylori has declined significantly in Western countries during the past 
decades. (9) However, since symptoms are most frequently absent in patients with pre-malig-
nant gastric lesions, epidemiology of these lesions is largely unknown, especially in regions 
with a relatively low incidence of gastric cancer. (10) Epidemiological data of pre-malignant 
gastric lesions are, however, relevant as an accurate predictor of gastric cancer incidence 
in the coming decade, and as determinant in the evaluation of screening and surveillance 
practices.
Therefore, the aim of the present study was to evaluate the incidence and time trends 
of atrophic gastritis, intestinal metaplasia and dysplasia in the Netherlands. As reliable inci-
dence data are lacking, the prevalence of pre-malignant conditions as recorded in pathology 
reports was analysed alternatively.
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meThoDS
Histopathology database
In the Netherlands all histopathology and cytopathology reports are collected in a national 
archive (PALGA database), which has nationwide coverage since 1991. (11) Patients in this 
database are identified by date of birth, gender and the first four characters of their family 
name. Every record in the database contains a summary of a pathology report and diagnostic 
codes similar to the Systematized Nomenclature of Medicine (SNOMED) classification of the 
College of American Pathologists. (12) The diagnostic code contains a term indicating the 
anatomical location, type of sample, and a morphological term describing the finding, for 
example, ‘‘stomach*biopsy*intestinal metaplasia’’. Details about the number and intragastric 
location of biopsies and presence of H. pylori are not uniformly registered. After a report has 
been coded, it is submitted online to the central database. At present, the PALGA database 
contains 38 million records from approximately 10 million individuals. The present study was 
based on data recorded in the PALGA database between 1991 and 2005. The following items 
were made available for each report: gender, date of birth, date of pathology review, sum-
mary text and diagnostic code.
Incidence analysis
All patients with a histopathologically confirmed diagnosis of a pre-malignant gastric lesion 
were identified in the database. Pre-malignant gastric lesions were defined as atrophic gas-
tritis, intestinal metaplasia or dysplasia. The SNOMED codes that were used to identify the 
lesions are described in the appendix. For each patient only the most severe pre-malignant 
lesion at baseline, that is, the first observation of a pre-malignant lesion, was evaluated. This 
means that patients with atrophic gastritis without a diagnosis of concomitant intestinal 
metaplasia were classified as having atrophic gastritis, patients with atrophic gastritis and in-
testinal metaplasia as intestinal metaplasia, and patients with gastric dysplasia as dysplasia.
Patients who had undergone gastric or oesophageal surgery, as far as could be determined 
from the database, or had been diagnosed with an oesophageal or gastric malignancy prior 
to or simultaneously with the first diagnosis of a pre-malignant gastric lesion were excluded 
from analysis.
In order to correct for possible changes in the frequency of upper gastrointestinal (GI) 
endoscopies with gastric biopsy sampling, rather than prevalence changes of pre-malignant 
gastric lesions, we also studied the trend in total number of patients with a first time bi-
opsy of the stomach. The ratio of the number of new patients with a positive biopsy for 
pre-malignant gastric lesions to the number of new patients with a first time gastric biopsy 
was determined.
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To evaluate the incidence of pre-malignant gastric lesions in different age classes, preva-
lence numbers in different periods were calculated within five-year age groups. 
Statistical analysis
Age-standardised prevalence rates (WSR) of histopathologically confirmed pre-malignant 
lesions were calculated for the years 1991–2005. (13) Prevalence trends were evaluated with 
age–period–cohort models using logistic regression analysis. This analysis produces odds 
ratios (ORs) that quantify changes in time. Since these ORs (per year) are always close to 1.00 
we present them as percentual annual changes (PAC). Calculations were corrected for age. 
In the age–period–cohort models, estimated drift parameters reproduce these PACs, which 
can be interpreted as linear period or cohort changes. For calculating non-linear period and 
cohort effects, linear splines were used. This means that to assess the presence of a period 
effect in the incidence of pre-malignant gastric lesions, the linear relationship between year 
and prevalence was replaced by a line consisting of three joined linear pieces, with knots at 
1995 and 2000. For the estimation of cohort models a mean year of birth was calculated for 
each five-year age group and changes in prevalence were allowed to change in 1920, 1935, 
1950 and 1965. Likelihood ratio tests (comparison of scaled deviances) showed whether 
significant non-linear period or cohort effects were present. (14, 15)
reSuLTS
Between 1991 and 2005, 97 732 patients were newly diagnosed with a pre-malignant gas-
tric lesion, with a 1:1 male:female ratio (Table 1). The study population consisted of 23 278 
patients with a first diagnosis of atrophic gastritis as the most severe pre-malignant lesion 
at initial diagnosis, 65 937 patients with intestinal metaplasia and 8517 patients with gastric 
dysplasia. Significantly more women were present in the atrophic gastritis group (male:female 
1.0:1.2) than in the group of patients with intestinal metaplasia (1.0:0.9) or dysplasia (1.0:0.8) 
(p<0.001). The median age at diagnosis was 65.7 years (10 th–90th percentile 41.7–82.2 years); 
age at diagnosis was significantly higher with increasing severity of the categories of pre-
Table 1. Baseline characteristics.
Total Atrophic gastritis Intestinal 
metaplasia
Dysplasia
Number of patients (n) (%) 97 732 23 278 (24%) 65 937 (67%) 8 517 (9%)
Male/ Female 1.0/ 1.0 1.0/ 1.2 1.0/ 0.9 1.0/ 0.8
Age 
 median
 10th-90th percentile
65.7 yrs
41.7 – 82.2 yrs
60.8 yrs
34.3 – 80.9 yrs
66.5 yrs
44.3 – 82.4 yrs 
69.2 yrs
46.1 – 83.7 yrs
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malignant gastric lesions (p<0.001). Within all categories of pre-malignant gastric lesions, 
female patients were significantly older than male patients (p<0.001).
Incidence
The number of patients with a first gastric biopsy increased by 3.7% per year over the study 
period, with a distinct maximum in 1998 (Figure 1). For all patients who were biopsied, the 
proportion of patients with a first time diagnosis of a pre-malignant gastric lesion, however, 
gradually declined (Figure 2). As expected, the proportion of patients with a diagnosis of a 
pre-malignant gastric lesion increased with age (Figure 3).
Figure 1. Number of patients with a first gastric biopsy during investigated period 1991-2005.
to 32% during the investigated period based on serological
analyses of 918 and 1600 subjects in 1989 and 2006,
respectively, in the age groups of 18 to 70 years.19 20
Similar observations have been made in a Finnish study,
which showed a parallel decrease in the age-related prevalence
of atrophic gastritis, intestinal metaplasia and gastric cancer in
the period from 1977 to 1992.21 The decline in the incidence of
all pre-malignant gastric lesions in our study is larger than the
current decline of gastric cancer in the Netherlands, which was
2.13% [95% CI 1.83% to 2.43%] annually over the period 1991–
2003.3 Therefore, a more rapid decline of gastric cancer
incidence may be anticipated within the next decades. Based
on our findings, a decline of approximately 24% may be
expected within the coming 10 years, which corresponds to a
decreasing incidence from 6.9 to 5.2/100 000/year (WSR): this
incidence is lower than the current incidence in any Western
country.1
A cohort phenomenon for the prevalence of H pylori has
previously been demonstrated by analysing individu l long-
itudinal data, which showed that the prevalence of chronic H
pylori-induced gastritis is much lower in younger birth cohorts
and that H pylori infection is rarely acquired after childhood.9 22
The presence of a similar cohort phenomenon in the incidence
of pre-malignant gastric lesions confirms the central role of H
pylori in gastric carcinogenesis and gastric cancer cascade
described by Correa.7 Although gastric carcinogenesis is a
complex and multifactorial process, H pylori infection rates in
childhood can presumably predict the occurrence rates of pre-
malignant lesions later in life and possibly even gastric cancer
in different birth cohorts.
A cohort effect was clearly demonstrated in this study for
male patients. For female patients, a nearly linear decline was
demonstrated for the diagn sis of atrophic gastritis, whereas
for intestinal metaplasia a decline was almost absent in
younger birth cohorts. These findings can probably not be
explained by a differ ce in H pylori prevalence ifferences
between the sexes. Conversely, lifestyle factors, predominantly
smoking, are the most probable explanation for these findings,
as smoking seems an important factor in gastric carcinogen-
esis.23–25 Gender differences in smoking habits in consecutive
cohorts were previously observed in an observational Dutch
study. This study demonstrated that the relative risk of lung
cancer, as an indicator of smoking, is declining for men born
after 1914. In contrast, the risk of lung cancer, and smoking has
steadily increased in women.26
In addition, we observed that pre-malignant gastric lesions
were diagnosed at a significantly older age in female patients
(fig 3). These findings are in accordance with the male
predominance in gastric cancer incidence and imply that
female patients enter the carcinogenic cascade at an older
age. Similar observations have previously been made in patients
with Barrett’s oesophagus.27 The most probable explanations for
our findings are greater use of non-steroidal anti-inflammatory
drugs and less smoking in absolute numbers in female patients,
although an influence of other factors, such as sex hormones,
can not be excluded.26
Atrophic gastritis and intestinal metaplasia have traditionally
been evaluated as one entity, in which intestinal metaplasia
was considered evidence of atrophic gastritis since specialised
glands had been replaced by intestinal crypts.28–30 As the multi-
step cascade of gastric carcinogenesis has increasingly been
recognised, intestinal metaplasia is now mostly evaluated as a
separate entity in accordance with the updated Sydney system.
In this study, we also assessed atrophic gastritis and intestinal
metaplasia separately. This approach seems valid, as significant
differences existed between both groups. For instance, patients
with an initial diagnosis of intestinal metaplasia were
significantly older than patients with atrophic gastritis
(p,0.001). Neverthele s, as only the most severe diagnosis at
baseline is evaluated in this study, the incidence of atrophic
gastritis has probably been underestimated. For a true calcula-
tion of the incidence of atrophic gastritis, the numbers of
atrophic gastritis, intestinal metaplasia and dysplasia may be
added, as it can be assumed that all patients with intestinal
metaplasia suffer from atrophic gastritis and similarly, dyspla-
sia in intestinal metaplasia-negative patients can be considered
an exception. These calculations result in a decline of 4.4% per
year [95% CI 4.2% to 4.6%] for men and women with atrophic
changes of the gastric mucosa, and a decline of 3.4% per year
[95% CI 3.1% o 3.6%] for men and 2.9% per year [95% CI 2.7%
to 3.2%] for women with intestinal metaplasia.
Potential weaknesses of our study are first that this study has
been based on the number of histological diagnoses of pre-
malignant lesions after upper GI endoscopy. Our findings could
be influenced by altered indications for upper GI endoscopy
over the past 15 years or by an altered attitude towards
obtaining biopsies from macroscopic normal gastric mucosa, for
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Table 1 Baseline characteristics
Total
Atrophic
gastritis
Intestinal
metaplasia Dysplasia
Number of patients
(n) (%)
97 732 23 278
(24%)
65 937
(67%)
8517
(9%)
Male/female 1.0/1.0 1.0/1.2 1.0/0.9 1.0/0.8
Age (years)
Median 65.7 60.8 66.5 69.2
10th–90th
percentile
41.7–82.2 34.3–80.9 44.3–82.4 46.1–83.7
Figure 1 Number of patients with a first
gastric biopsy during investigated period
1991–2005.
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Figure 2. The prevalence of atrophic gastritis, intestinal metaplasia and dysplasia (WSR, world standardised 
rate) relative to total number of patients with a first gastric biopsy over time.
example, increasing interest in diagnosing H pylori for which
biopsies from both antrum and corpus are at present commonly
obtained. In case the total number of patients with a first
gastric biopsy increases, a merely relative decline in the number
of diagnoses of pre-malignant lesions could have been
misinterpreted as a declining incidence of pre-malignant
diagnoses in our study. However, the number of patients with
a first gastric biopsy increased sharply before 1998, and
thereafter a decline was followed by a slower incline until
2005 (fig 1). This trend has previously been observed, and is
most likely explained by the introduction of Dutch general
practitioner guidelines on dyspepsia in 1993, with a revision in
1996, in which restrictions in referrals for upper GI endoscopy
were advised.31 This non-linear pattern was not observed in our
period analysis of pre-malignant gastric lesions. Therefore, a
true decline in the incidence of pre-malignant gastric lesions
has been demonstrated in this study.
Second, changing trends in the assessment of gastric biopsies
by pathologists could have attributed to the declining incidence
of pre-neoplastic conditions of the stomach. The histological
diagnosis and grading of pre-malignant gastric lesions have
been subject of debate for years. At present, the updated Sydney
system is most commonly used to grade gastritis.32 In this
classification system several features of inflammation, atrophy
and intestinal metaplasia are being assessed individually.
Grading of gastric dysplasia is now in particular performed by
means of the (updated) Vienna classification.33 34 At present,
dysplasia is commonly defined as intraepithelial or non-
invasive neoplasia. We preferred to maintain the term dysplasia
in this study, as this was the original diagnosis in our cases and
was used as a search term, but it should be recognised that
currently pathologists refer to these lesions as intraepithelial or
non-invasive neoplasia. Although it has been shown that
considerable differences between pathologists on diagnosing
pre-malignant gastric lesions still exist, it can be speculated
that the use of these specific grading classifications led to an
increase in inter-observer agreement in more recent years.35–38
Stricter criteria for assessment of dysplasia have been proposed
recently, which in theory may have contributed to a decline in
the number of new cases in recent years.34 39 Yet, it is unclear
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Figure 2 The prevalence of atrophic
gastritis, intestinal metaplasia and dysplasia
(WSR) relative to total number of patients
with a first gastric biopsy over time. AG:
atrophic gastritis; DYS: dysplasia; IM:
intestinal metaplasia; WSR: world
standardised rate.
Figure 3 Proportion of patients with pre-
malignant gastric lesions relative to total
number of patients with a first gastric biopsy
within 5-year age groups for total cohort and
complete study period. AG: atrophic
gastritis; DYS: dysplasia; IM: intestinal
metaplasia.
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Legend: WSR: world standardised rate; AG: atrophic gastritis; IM: intestinal metaplasia; DYS: dysplasia
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The incidence of atrophic gastritis declined over the study period by 8.2% per year [95% CI 
7.9% to 8.6%], and the incidence of gastric dysplasia declined by 8.1% per year [95% CI 7.5% 
to 8.6%]. These trends were similar for men and women (p values for differences were respec-
tively 0.32 and 0.73). The decline in the number of diagnoses of intestinal metaplasia was 
2.4% per year [95% CI 2.2% to 2.6%] for women and 2.9% per year [95% CI 2.7% to 3.1%] for 
men (p value for difference 0.02). Age–period–cohort analysis was used to further investigate 
these drift values, that is, to differentiate between a period and a cohort effect. Significant 
period effects were demonstrated for atrophic gastritis (p values for men and women <0.001) 
and intestinal metaplasia (p=0.03 for men, p<0.001 for women), but not for dysplasia (p=0.07 
for men, p=0.93 for women). The period pattern showed an accelerating decline after 1996 
for both atrophic gastritis and intestinal metaplasia (Figure 4). There were no apparent dif-
ferences between men and women. In addition, the non-linear cohort effects for atrophic 
gastritis were significant for men (p<0.001), but not for women (p=0.22) (Figure 5). For men, 
the proportional decline increased over the whole period, except in the cohort born after 
1965. However, the decline for women was almost linear. For intestinal metaplasia, the cohort 
effect for men was similar to the effect in men with atrophic gastritis, although less clear: the 
proportional annual change varied from –2% to almost –4% over the cohorts (p<0.001). In 
Figure 3. Proportion of patients with pre-malignant gastric lesions relative to total number of patients with 
a first gastric biopsy within 5-year age groups for total cohort and complete study period.
example, increasing interest in diagnosing H pylori for which
biopsies from both antrum and corpus are at present commonly
obtained. In case the total number of patients with a first
gastric biopsy increases, a merely relative decline in the number
of diagnoses of pre-malignant lesions could have been
misinterpreted as a declining incidence of pre-malignant
diagnoses in our study. However, the number of patients with
a first gastric biopsy increased sharply before 1998, and
thereafter a decline was followed by a slower incline until
2005 (fig 1). This trend has previously been observed, and is
most likely explained by the introduction of Dutch general
practitioner guidelines on dyspepsia in 1993, with a revision in
1996, in which restrictions in referrals for upper GI endoscopy
were advised.31 This non-linear pattern was not observed in our
period analysis of pre-malignant gastric lesions. Therefore, a
true decline in the incidence of pre-malignant gastric lesions
has been demonstrated in this study.
Second, changing trends in the assessment of gastric biopsies
by pathologists could have attributed to the declining incidence
of pre-neoplastic conditions of the stomach. The histol gical
diagnosis and grading of pre-malignant gastric lesions have
been subject of debate for years. At present, the updated Sydney
system is most commonly used to grade gastritis.32 In this
classification system several features of inflammation, atrophy
and intestinal metaplasia are being assessed individually.
Grading of gastric dysplasia is now in particular performed by
means of the (updated) Vienna classification.33 34 At present,
dysplasia is commonly defined as intraepithelial or non-
invasive neoplasia. We preferred to maintain the term dysplasia
in this study, as this was the original diagnosis in our cases and
was used as a search term, but it should be recognised that
currently pathologists refer to these lesions as intraepithelial or
non-invasive neoplasia. Although it has been shown that
considerable differences between pathologists on diagnosing
pre-malignant gastric lesions still exist, it can be speculated
that the use of these specific grading classifications led to an
increase in inter-observer agreement in more recent years.35–38
Stricter criteria for assessment of dysplasia have been proposed
recently, which in theory may have contributed to a decline in
the number of new cases in recent years.34 39 Yet, it is unclear
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Figure 2 The prevalence of atrophic
gastritis, intestinal metaplasia and dysplasia
(WSR) relative to total number of patients
with a first gastric biopsy over time. AG:
atrophic gastritis; DYS: dysplasia; IM:
intestinal metaplasia; WSR: world
standardised rate.
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number of patients with a first gastric biopsy
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Legend: AG: atrophic gastritis; IM: intestinal metaplasia; DYS: dysplasia
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women, the decline became less in the younger cohorts and was almost 0 in cohorts born 
after 1950 (p<0.001 for non-linear cohort effect). For dysplasia, men and women showed 
the same significant pattern again (p<0.001; p=0.004): a sharper decline for younger cohorts 
except the cohort born after 1965, possibly because the occurrence rates are low.
Figure 4. Period effects for pre-malignant gastric lesions for (A) male patients and (B) female patients. 
Symbols refer to age standardised prevalences, using the study population as standard. Lines are the 
linear splines from the age–period model; dotted lines show the results of the drift model, that is, the 
situation where there is a constant PAC over the whole range of years.
whether th s truly had any effect on the observed declining
incidence of dysplasia, as a clear period effect has not been
demonstrated in this study. Furthermore, the fact that over the
complete period of observation less than 10% of all patients
diagnosed with pre-malignant abnormalities of their gastric
mucosa were classified as having dysplasia supports the
restrictive use of this diagnosis over the whole time period.
On the other hand, the declining incidence of atrophic
gastritis and intestinal metaplasia partly results from a period
effect. This study showed an accelerating decline after 1996 for
these diagnoses. This finding can in part be related to changing
histological definitions, in particular with respect to atrophic
gastritis in relation to the introduction of the updated Sydney
system around 1996.32 However, as such an effect is less likely
for intestinal metaplasia as a relatively straightforward diag-
nosis not affected by changing histological definitions, other
effects must also have played a role. This can in part have been
du to the widespread int oduction of H pylori diagnosis and
treatment starting in the early 1990s.
Moreover, it is plausible that indications for upper GI
endoscopy, for example, symptoms, led to a specific selection
of the general population in this study. Therefore, these data
are only suited to studying prevalence trends within patients
with an indication for upper GI endoscopy. However, as
differences in prevalence between our population and the
general population are presumably small, it can be assumed
that trend, period and cohort patterns observed here do reflect
incidence patterns in general. To evaluate prevalence in the
general Dutch population a prospective endoscopic population-
based study would be necessary. However, this study design
would evidently be time-consuming and costly. Possibly,
serological markers can serve as an alternative for this purpose
when evaluating atrophic gastritis, however, its value in
diagnosing intestinal metaplasia and dysplasia is still unclear.40
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Figure 4 Period effects for pre-malignant gastric lesions for (A) male
patients and (B) female patients. Symbols refer to age standardised
prevalences, using the study population as standard. Lines are the linear
splines from the age–period model; dotted lines show the results of the drift
model, that is, the situation where there is a constant PAC over the whole
range of years. AG: atrophic gastritis; DYS: dysplasia; IM: intestinal
metaplasia.
Figure 5 Cohort effects for pre-malignant gastric lesions for (A) male
patients and (B) female patients. Symbols refer to age standardised
prevalences, using the study population as standard. Lines are the linear
splines from the age–cohort model; dotted lines show the results of the drift
model, that is, the situation where there is a constant PAC over the whole
range of birth years. AG: atrophic gastritis; DYS: dysplasia; IM: intestinal
metaplasia.
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DIScuSSIon
This study shows that pre-malignant gastric lesions are frequently encountered in routine 
biopsies obtained during upper GI endoscopies in a Western population, especially in older 
people. Atrophic gastritis is the most common pre-malignant gastric condition, as it can be 
assumed that all subsequent stages have underlying atrophic changes of the gastric mucosa. 
Figure 5. Cohort effects for pre-malignant gastric lesions for (A) male patients and (B) female patients. 
Symbols refer to age standardised prevalences, using the study population as standard. Lines are the 
linear splines from the age–cohort model; dotted lines show the results of the drift model, that is, the 
situation where there is a constant PAC over the whole range of birth years.
whether this truly had any effect on the observed declining
incidence of dysplasia, as a clear period effect has not been
demonstrated in this study. Furthermore, the fact that over the
complete period of observation less than 10% of all patients
diagnosed with pre-malignant abnormalities of their gastric
mucosa were classified as having dysplasia supports the
restrictive use of this diagnosis over the whole time period.
On the other hand, the declining incidence of atrophic
gastritis and intestinal metaplasia partly results from a period
effect. This study showed an accelerating decline after 1996 for
these diagnoses. This finding can in part be related to changing
histological definitions, in particular with respect to atrophic
gastritis in relation to the introduction of the updated Sydney
system around 1996.32 However, as such an effect is less likely
for intestinal metaplasia as a relatively straightforward diag-
nosis not affected by changing histological definitions, other
effects must also have played a role. This can in part have been
due to the widespread introduction of H pylori diagnosis and
treatment starting in the early 1990s.
Moreover, it is plausible that indications for upper GI
endoscopy, for example, symptoms, led to a specific selection
of the general population in this study. Therefore, these data
are only suited to studying prevalence trends within patients
with an indication for upper GI endoscopy. However, as
differences in prevalence between our population and the
general population are presumably small, it can be assumed
that trend, period and cohort patterns observed here do reflect
incidence patterns in general. To evaluate prevalence in the
general Dutch population a prospective endoscopic population-
based study would be necessary. However, this study design
would evidently be time-consuming and costly. Possibly,
serological markers can serve as an alternative for this purpose
when evaluating atrophic gastritis, however, its value in
diagnosing intestinal metaplasia and dysplasia is still unclear.40
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prevalences, using the study population as standard. Lines are the linear
splines from the age–period model; dotted lines show the results of the drift
model, that is, the situation where there is a constant PAC over the whole
range of years. AG: atrophic gastritis; DYS: dysplasia; IM: intestinal
metaplasia.
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However, the incidence of these lesions has declined significantly over the past 15 years. 
The PAC increase in incidence in male patients was found to become stronger for men born 
after 1920. This matches the declining gastric cancer incidence in the Netherlands in the past 
20 years and is thought first of all to be related to a decrease in the prevalence of H. pylori 
infection in younger cohorts. (16–18) In the Netherlands, the prevalence of H. pylori has de-
clined from approximately 40% to 32% during the investigated period based on serological 
analyses of 918 and 1600 subjects in 1989 and 2006, respectively, in the age groups of 18 to 
70 years. (19, 20)
Similar observations have been made in a Finnish study, which showed a parallel decrease 
in the age-related prevalence of atrophic gastritis, intestinal metaplasia and gastric cancer in 
the period from 1977 to 1992. (21) The decline in the incidence of all pre-malignant gastric 
lesions in our study is larger than the current decline of gastric cancer in the Netherlands, 
which was 2.13% [95% CI 1.83% to 2.43%] annually over the period 1991–2003. (3) Therefore, 
a more rapid decline of gastric cancer incidence may be anticipated within the next decades. 
Based on our findings, a decline of approximately 24% may be expected within the coming 
10 years, which corresponds to a decreasing incidence from 6.9 to 5.2/100 000/year (WSR): 
this incidence is lower than the current incidence in any Western country. (1)
A cohort phenomenon for the prevalence of H. pylori has previously been demonstrated 
by analysing individual longitudinal data, which showed that the prevalence of chronic H. 
pylori-induced gastritis is much lower in younger birth cohorts and that H. pylori infection 
is rarely acquired after childhood. (9, 22) The presence of a similar cohort phenomenon in 
the incidence of pre-malignant gastric lesions confirms the central role of H. pylori in gastric 
carcinogenesis and gastric cancer cascade described by Correa. (7) Although gastric carcino-
genesis is a complex and multifactorial process, H. pylori infection rates in childhood can 
presumably predict the occurrence rates of pre-malignant lesions later in life and possibly 
even gastric cancer in different birth cohorts.
A cohort effect was clearly demonstrated in this study for male patients. For female patients, 
a nearly linear decline was demonstrated for the diagnosis of atrophic gastritis, whereas for 
intestinal metaplasia a decline was almost absent in younger birth cohorts. These findings 
can probably not be explained by a difference in H. pylori prevalence differences between the 
sexes. Conversely, lifestyle factors, predominantly smoking, are the most probable explanation 
for these findings, as smoking seems an important factor in gastric carcinogenesis. (23–25) 
Gender differences in smoking habits in consecutive cohorts were previously observed in an 
observational Dutch study. This study demonstrated that the relative risk of lung cancer, as an 
indicator of smoking, is declining for men born after 1914. In contrast, the risk of lung cancer 
and smoking has steadily increased in women. (26)
In addition, we observed that pre-malignant gastric lesions were diagnosed at a sig-
nificantly older age in female patients (Figure 3). These findings are in accordance with the 
male predominance in gastric cancer incidence and imply that female patients enter the 
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carcinogenic cascade at an older age. Similar observations have previously been made in 
patients with Barrett’s oesophagus. (27) The most probable explanations for our findings are 
greater use of non-steroidal anti-inflammatory drugs and less smoking in absolute numbers 
in female patients, although an influence of other factors, such as sex hormones, cannot be 
excluded. (26)
Atrophic gastritis and intestinal metaplasia have traditionally been evaluated as one entity, 
in which intestinal metaplasia was considered evidence of atrophic gastritis since specialized 
glands had been replaced by intestinal crypts. (28–30) As the multistep cascade of gastric 
carcinogenesis has increasingly been recognised, intestinal metaplasia is now mostly evalu-
ated as a separate entity in accordance with the updated Sydney system. In this study, we 
also assessed atrophic gastritis and intestinal metaplasia separately. This approach seems 
valid, as significant differences existed between both groups. For instance, patients with an 
initial diagnosis of intestinal metaplasia were significantly older than patients with atrophic 
gastritis (p<0.001). Nevertheless, as only the most severe diagnosis at baseline is evaluated 
in this study, the incidence of atrophic gastritis has probably been underestimated. For a true 
calculation of the incidence of atrophic gastritis, the numbers of atrophic gastritis, intestinal 
metaplasia and dysplasia may be added, as it can be assumed that all patients with intestinal 
metaplasia suffer from atrophic gastritis and similarly, dysplasia in intestinal metaplasia-
negative patients can be considered an exception. These calculations result in a decline of 
4.4% per year [95% CI 4.2% to 4.6%] for men and women with atrophic changes of the gastric 
mucosa, and a decline of 3.4% per year [95% CI 3.1% to 3.6%] for men and 2.9% per year [95% 
CI 2.7% to 3.2%] for women with intestinal metaplasia.
Potential weaknesses of our study are first that this study has been based on the number of 
histological diagnoses of pre-malignant lesions after upper GI endoscopy. Our findings could 
be influenced by altered indications for upper GI endoscopy over the past 15 years or by an 
altered attitude towards obtaining biopsies from macroscopic normal gastric mucosa, for 
example, increasing interest in diagnosing H. pylori for which biopsies from both antrum and 
corpus are at present commonly obtained. In case the total number of patients with a first 
gastric biopsy increases, a merely relative decline in the number of diagnoses of pre-malignant 
lesions could have been misinterpreted as a declining incidence of pre-malignant diagnoses 
in our study. However, the number of patients with a first gastric biopsy increased sharply 
before 1998, and thereafter a decline was followed by a slower incline until 2005 (Figure 1). 
This trend has previously been observed, and is most likely explained by the introduction of 
Dutch general practitioner guidelines on dyspepsia in 1993, with a revision in 1996, in which 
restrictions in referrals for upper GI endoscopy were advised. (31) This non-linear pattern was 
not observed in our period analysis of pre-malignant gastric lesions. Therefore, a true decline 
in the incidence of pre-malignant gastric lesions has been demonstrated in this study.
Second, changing trends in the assessment of gastric biopsies by pathologists could have 
attributed to the declining incidence of pre-neoplastic conditions of the stomach. The histo-
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logical diagnosis and grading of pre-malignant gastric lesions have been subject of debate 
for years. At present, the updated Sydney system is most commonly used to grade gastritis. 
(32) In this classification system several features of inflammation, atrophy and intestinal 
metaplasia are being assessed individually. Grading of gastric dysplasia is now in particular 
performed by means of the (updated) Vienna classification. (33, 34) At present, dysplasia is 
commonly defined as intraepithelial or noninvasive neoplasia. We preferred to maintain the 
term dysplasia in this study, as this was the original diagnosis in our cases and was used as 
a search term, but it should be recognised that currently pathologists refer to these lesions 
as intraepithelial or non-invasive neoplasia. Although it has been shown that considerable 
differences between pathologists on diagnosing pre-malignant gastric lesions still exist, it 
can be speculated that the use of these specific grading classifications led to an increase 
in inter-observer agreement in more recent years. (35–38) Stricter criteria for assessment of 
dysplasia have been proposed recently, which in theory may have contributed to a decline in 
the number of new cases in recent years. (34, 39) Yet, it is unclear whether this truly had any 
effect on the observed declining incidence of dysplasia, as a clear period effect has not been 
demonstrated in this study. Furthermore, the fact that over the complete period of observa-
tion less than 10% of all patients diagnosed with pre-malignant abnormalities of their gastric 
mucosa were classified as having dysplasia supports the restrictive use of this diagnosis over 
the whole time period.
On the other hand, the declining incidence of atrophic gastritis and intestinal metaplasia 
partly results from a period effect. This study showed an accelerating decline after 1996 for 
these diagnoses. This finding can in part be related to changing histological definitions, in 
particular with respect to atrophic gastritis in relation to the introduction of the updated Syd-
ney system around 1996. (32) However, as such an effect is less likely for intestinal metaplasia 
as a relatively straightforward diagnosis not affected by changing histological definitions, 
other effects must also have played a role. This can in part have been due to the widespread 
introduction of H. pylori diagnosis and treatment starting in the early 1990s.
Moreover, it is plausible that indications for upper GI endoscopy, for example, symptoms, 
led to a specific selection of the general population in this study. Therefore, these data are 
only suited to studying prevalence trends within patients with an indication for upper GI 
endoscopy. However, as differences in prevalence between our population and the general 
population are presumably small, it can be assumed that trend, period and cohort patterns 
observed here do reflect incidence patterns in general. To evaluate prevalence in the general 
Dutch population a prospective endoscopic population based study would be necessary. 
However, this study design would evidently be time-consuming and costly. Possibly, serologi-
cal markers can serve as an alternative for this purpose when evaluating atrophic gastritis, 
however, its value in diagnosing intestinal metaplasia and dysplasia is still unclear. (40)
Unfortunately, we could not evaluate the number of biopsies and intragastric distribution of 
pre-malignant lesions in this study. For instance, it would be interesting to evaluate whether 
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extension has decreased in subsequent periods and whether this extension progresses with 
age. At present, the Sydney system recommends two biopsies from the corpus, two from 
the antrum and one from the incisura angularis during gastroscopy to classify and grade 
gastritis. However, for the purpose of evaluation of pre-malignant lesions a more extensive 
biopsy scheme may be required. As knowledge of the exact intragastric distribution of pre-
malignant lesions should guide biopsy sampling during surveillance endoscopy, future re-
search should be focused on clarification of the extension and distribution of pre-malignant 
gastric lesions.
In conclusion, the incidence of pre-malignant gastric lesions is declining in countries with 
a low gastric cancer incidence within subsequent birth cohorts, probably caused by a declin-
ing incidence of H. pylori infections. Therefore, a considerable further decline in gastric cancer 
incidence of at least 24% in the coming decade may be anticipated in these countries and 
this will occur without any specific intervention.
APPenDIx
SNOMED-like codes used in the analysis:
Atrophic gastritis: M58000, M58001, M58010.
Intestinal metaplasia: M73000, M73200, M73320, M73321, M73300.
Dysplasia: M74000, M74006, M74007, M74008, M74009.
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AbSTrAcT
objective: Pre-selection of individuals with epidemiological risk factors for Helicobacter pylori 
infection and atrophic gastritis could increase the efficiency of serologic screening to prevent 
peptic ulcer disease and gastric cancer in Western countries. The aim of this study was to 
determine the prevalence of and risk factors for H. pylori infection and atrophic gastritis in a 
migrant community in The Netherlands.
material and methods: Inhabitants from an urban district in Rotterdam, The Netherlands 
with a large proportion of immigrants were randomly selected. Information was collected 
on demographic factors, socioeconomic status, lifestyle, history of dyspeptic symptoms and 
medication use. In addition, serologic H. pylori and CagA status and the presence of atrophic 
gastritis were evaluated
results: In total, 288 subjects were included. Surinamese or Antillean, Turkish, Cape Verdian 
and Moroccan subjects were H. pylori-infected in 65%, 82%, 86% and 96% of cases, respec-
tively, whereas the infection rate in Dutch subjects was 46% (all p<0.05). Within multivariate 
logistic regression analysis, ethnicity and number of persons in a household were identified 
as independent risk factors for H. pylori infection. In addition, mean pepsinogen I level and 
pepsinogen I/II ratio were significantly lower in subjects of non-Dutch origin as compared 
to Dutch subjects (both p<0.001). No Dutch subjects suffered from atrophic gastritis, as 
compared with 12 subjects of non-Dutch origin (p=0.13).
conclusions: The prevalence of H. pylori is high in migrant populations in The Netherlands. 
Furthermore, markers of atrophic gastritis are increased in subjects of foreign origin. There-
fore, these migrant communities may constitute a target group for serologic screening to 
prevent H. pylori-related complications in Western countries.
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InTroDucTIon
Helicobacter pylori infection is an important risk factor for the development of peptic ulcer 
disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. 
The findings of recent studies suggest that H. pylori may even be a strong prerequisite for the 
development of gastric cancer (1). Moreover, H. pylori eradication seems to prevent gastric 
cancer in subjects with chronic H. pylori-induced gastritis who have not yet developed the 
precancerous conditions of atrophic gastritis and intestinal metaplasia (2). Therefore, early H. 
pylori detection and eradication are considered to be important targets for the prevention of 
associated diseases (3-5).
Yet, the prevalence of H. pylori is decreasing in most Western countries, especially in 
younger birth cohorts (6,7). In parallel, the incidence of H. pylori-associated diseases is also 
decreasing. For instance, an incidence shift from mostly H. pylori-associated duodenal ulcers 
towards predominantly non-steroidal anti-inflammatory drugs (NSAIDs)-associated gastric 
ulcers has been observed (8,9). In addition, a decrease in the incidence of premalignant gas-
tric lesions in the past 15 years indicates that gastric cancer incidence will most likely decline 
further in the next few decades (10). The need for prevention of H. pylori-associated diseases 
in Western countries on a population basis thus becomes less significant and treatment on an 
individual basis is the current widespread approach. Nevertheless, morbidity and mortality of 
these H. pylori-associated diseases still remain considerable and therefore a primary preven-
tive strategy may be valuable, even in low incidence countries (8,9,11). In these countries, 
stepwise identification of individuals at increased risk of H. pylori-associated diseases seems 
essential to detect gastric cancer at an early and curable stage and to prevent the develop-
ment of peptic ulcer disease (3). Some small subpopulations have been identified in the past, 
for instance, a high prevalence of H. pylori among inhabitants and long-term employees of 
institutes for the intellectually disabled has been reported, but other subgroups are less clear 
(12).
The combination of serum pepsinogen levels and H. pylori antibodies is used in population-
based serologic screening for H. pylori infection and atrophic gastritis in countries with a high 
gastric cancer incidence, such as Japan (13,14). However, a screening strategy of this kind 
would be costly and inefficient in most Western countries with currently low prevalences of 
H. pylori (15). Therefore, identification of individuals at high risk of H. pylori infection and atro-
phic changes of the gastric mucosa based on epidemiological criteria may be an adequate 
pre-selection strategy for serologic screening programs.
As the prevalence of H. pylori infection varies among different countries, and infection seems 
to be mainly acquired in early childhood, immigrants from countries with a high prevalence 
of H. pylori may constitute a high-risk population for H. pylori infection in developed countries 
(6,16,17). However, there is a scarcity of prevalence data on H. pylori infection and atrophic 
gastritis from population-based studies in this potential risk group.
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The aim of the present epidemiological study was to determine the actual prevalence 
and risk factors of H. pylori infection and atrophic gastritis in a migrant community in The 
Netherlands, i.e. ethnicity, environmental setting and socio-demographic factors, in order to 
identify a possible target group for preventive strategies in Western countries.
mATerIAL AnD meThoDS
Study population
A balanced sample of 1787 subjects was drawn from the civil registration system in a district 
with a large proportion of immigrants in Rotterdam, The Netherlands (Oud-Charlois). The dis-
trict is in an old part of the city, with predominantly 19th- and early 20th-century housing and 
around 13,000 inhabitants. This sample was drawn in order to gain insight into the prevalence 
and feasibility of screening for several infectious diseases in the general population such as 
hepatitis A, B and C and H. pylori infection. Subjects of Dutch, Surinamese, Turkish, Moroccan, 
Antillean or Cape Verdian origin and aged from 18 to 65 years were included in the sample. 
To obtain groups of comparable size, non-Dutch subjects were oversampled in anticipation 
of a lower response in these groups. Subjects were recruited from April 2004 to December 
2005 by letter and invited to take part in an interview and subsequently a blood sample was 
obtained. All subjects provided written informed consent and the study was approved by the 
Institutional Review Board of the Erasmus MC Rotterdam.
Interview
Subjects were interviewed in their native language by trained interviewers. Information was 
collected on demographic factors (age, gender and ethnicity), socio-economic status (educa-
tional level, occupational status), lifestyle (smoking habits, alcohol consumption), history of 
dyspeptic symptoms and peptic ulcer and medication use (e.g. anti-dyspeptic agents).
Serologic data
To determine H. pylori and CagA status, and pepsinogen levels, a blood sample was obtained 
from all subjects. Serologic testing for H. pylori and CagA status and pepsinogen I and II levels 
was performed using commercial ELISA tests (Orion Diagnostica, Ravo Diagnostica, and Bio-
Hit). Based on the manufacturer’s recommendation, an IgG antibody index of ≥20 U/ml was 
considered to be H. pylori positive. Atrophic gastritis was defined as either pepsinogen I <70 
µg/L in combination with a pepsinogen I/II ratio <3.0, or pepsinogen I <28 µg/L (18,19).
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Statistical analysis
To generalize H. pylori and atrophic gastritis prevalence numbers within this study sample 
to the district population, reverse probability weighting was used, based on gender and 
ethnicity distribution in the district population. X2 tests and t-tests were used to compare 
categorical and continuous characteristics, respectively. Comparisons between more than 
two groups were corrected with the Bonferroni test. Odds ratios (ORs) with 95% confidence 
intervals (CI) were calculated by logistic regression. A two-sided p-value of less than 0.05 was 
considered statistically significant.
reSuLTS
In total, 1787 persons were identified and invited by letter to participate; 288 (16%) subjects 
responded to the letter and were included in the study (Table I). Non-response was signifi-
cantly more common in men than in women (p=0.006) and in subjects younger than 45 years 
(p<0.001).
In total, 55 (19%) subjects of Dutch origin were included, 107 (37%) of Surinamese or Antil-
lean origin, 62 (22%) of Turkish origin, 50 (17%) of Moroccan and 14 (5%) of Cape Verdian 
origin (Table I). The mean age of the study population was 39.4 years (range 19-65 years), 
subjects of Dutch origin were significantly older (mean age 43.6 years) in comparison to 
subjects of Surinamese or Antillean origin (36.8 years) (p=0.008).
Table I. Baseline characteristics and H. pylori status.
Total study 
population
n=288
H. pylori
positive
n=206
H. pylori
negative
n=82 p-value
Mean age (years) (range) 39.4 (19-65) 40.0 (19-65) 38.3 (20-65) 0.30
Sex
- Male
- Female
123
165
89 (72%)
117 (71%)
34 (28%)
48 (29%)
0.90
Ethnicity
- Dutch
- non-Dutch:
o Surinamese, Antillean/Aruba
o Turkish
o Moroccan
o Cape Verdian
55
233
107
62
50
14
25 (46%)
181 (78%)
70 (65%)
51 (82%)
48 (96%)
12 (86%)
30 (55%)
52 (22%)
37 (35%)
11 (18%)
2 (4%)
2 (14%)
<0.001
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H. pylori infection
Two hundred and six (72%) subjects tested H. pylori positive; the infection rate was not 
significantly different between men and women (p=0.90). The weighted overall prevalence 
of H. pylori in this migrant community was 57% (95% CI, 51-63%). Subjects of Surinamese 
or Antillean, Turkish, Moroccan and Cape Verdian origin were infected in, respectively, 65%, 
Table II. Evaluation of risk factors for H. pylori infection.
H. pylori
positive
n/N %
OR
univariate 95% CI
OR 
multivariate 95% CI
Gender
- Male
- Female
89/123
117/165
72%
71%
1.0
0.93 0.55-1.56
- -
Age
- <30 years
- 31-40 years
- 41-50 years
- 51-65 years
51/75
59/87
50/67
46/59
68%
68%
75%
78%
1.0
0.99
1.38
1.67
0.51-1.92
0.67-2.88
0.76-3.65
- -
Ethnicity
- Dutch
-  Surinamese, Antillean/ 
Aruba 
- Moroccan
- Turkish
- Cape Verdian
25/55
70/107
48/50
51/62
12/14
45%
65%
96%
82%
86%
1.0
2.27
28.80
5.56
7.20
1.17-4.41
6.36-130.47
2.40-12.89
1.47-35.25
1.0
2.08
21.85
4.35
7.39
1.05-4.11
4.69-101.86
1.80-10.53
1.47-37.10
Residence childhood (main 
residence during first 10 
years)
- The Netherlands
- Other
44/81
119/154
54%
77%
1.0
2.86 1.61-5.09
- -
Educational level 
- Low (primary school)
- Middle (high school)
- High (college/ university)
112/144
76/110
12/26
78%
69%
46%
1.0
0.64
0.25
0.36-1.12
0.10-0.58
- -
Number of persons in 
household 
- 1-2
- 3-4
- ≥5
85/134
68/97
52/56
63%
70%
93%
1.0
1.35
7.49
0.77-2.36
2.56-21.98
1.0
0.90
4.01
0.49-1.67
1.30-12.39
Number of siblings 
- ≤1
- 2-3
- 4-6
- ≥7
28/49
51/72
63/88
61/76
57%
71%
72%
80%
1.0
1.82
1.89
3.05
0.85-3.90
0.91-3.93
1.37-6.78
- -
OR= odds ratio; CI= confidence interval
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82%, 96% and 86% of cases, whereas the infection rate in subjects of Dutch origin was 46% 
(all p<0.05) (Table I). In total, 120 (44%) patients tested CagA positive. Overall, infection 
with a CagA-positive H. pylori strain was more common in Surinamese or Antillean (48%), 
Turkish (52%), Moroccan (42%) and Cape Verdian subjects (54%) as compared to Dutch 
subjects (25%) (p=0.009, resp. p=0.004, p=0.09 and p=0.09). However, within the subgroup 
of H. pylori-infected subjects, no significant differences in CagA status were observed either 
between native Dutch subjects and immigrants, or between specific ethnic groups (p=0.38, 
resp. p=0.24).
Within univariate logistic regression analysis, non-Dutch ethnicity (OR 4.18, 95% CI 2.26-
7.72), foreign residence in childhood (OR 2.86, 95% CI, 1.61-5.09), educational level (high edu-
cational level OR 0.25, 95% CI, 0.10-0.58) and crowding reflected by the number of persons 
in the household (≥5 persons, OR 7.49, 95% CI, 2.56-21.98) were significantly associated with 
H. pylori status (Table II). Within multivariate analysis, non-Dutch ethnicity and high number 
of persons in the household were identified as independent risk factors for H. pylori infection 
(Table II).
Atrophic gastritis
Mean pepsinogen I level was 118.4 µg/L (SD 55.9) in subjects of Dutch origin as compared to 
91.1 µg/L (SD 42.3) in subjects of non-Dutch origin (p<0.001), specifically 90.3 µg/L (SD 41.7) 
in Surinamese or Antillean subjects, 97.0 µg/L (SD 48.3) in Turkish subjects, 85.5 µg/L (SD 38.0) 
in Moroccan subjects and 91.9 µg/L (SD 34.0) in Cape Verdian subjects (p=0.002, resp. p=0.12, 
p=0.003 and p=0.52) (Table III). Mean pepsinogen I/II ratio was 11.7 (SD 4.7) in Dutch subjects 
as compared to 9.1 (SD 4.5) in subjects of non-Dutch origin (p<0.001), i.e. 10.3 (SD 5.1) in Suri-
namese or Antillean subjects, 8.0 (SD 3.4) in Turkish subjects, 8.2 (SD 3.9) in Moroccan subjects 
and 8.6 (SD 3.2) in Cape Verdian subjects (p=0.60, resp. p<0.001, p=0.001 and p=0.21).
Table III. Pepsinogen levels.
Pepsinogen I
(mean)
Pepsinogen I/ II ratio
(mean)
Atrophic gastritis*
(n)
Ethnicity
- Dutch
- non-Dutch
o Surinamese, Antillean/ Aruba
o Moroccan
o Turkish
o Cape Verdian
118.4 µg/L
91.1 µg/L
90.3 µg/L
85.5 µg/L
97.0 µg/L
91.9 µg/L
11.7
9.1
10.3
8.2
8.0
8.6
0/54 (0%)
12/233 (5.2%)
5/107 (4.7%)
4/50 (8.0%)
3/62 (4.8%)
0/14 (0%)
Age
- <40 years
- >40 years
90.6 µg/L
103.6 µg/L
9.8
11.3
6/162 (3.7%)
6/125 (4.8%)
* Atrophic gastritis: pepsinogen I< 70 µg/L and pepsinogen I/II ratio<3.0, or pepsinogen I <28 µg/L.
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Overall, serologic evidence of atrophic gastritis was present in 12 subjects (4.2%). The 
weighted prevalence of atrophic gastritis in the total study population was 2.0% (95% CI, 
0.3-3.6%). The prevalence of atrophic gastritis was 3.7% in subjects younger than 40 years as 
compared to 4.8% in subjects older than 40 years (p=0.77). No subjects of Dutch origin suf-
fered from atrophic gastritis, as compared to 12 (5.2%) of the immigrant population (p=0.13) 
(mean age 38.9; SD 11.0), specifically 5 (4.7%) subjects of Surinamese or Antillean origin, 
3 (4.8%) subjects of Turkish origin and 4 (8.0%) subjects of Moroccan origin (p=0.17, resp. 
p=0.25 and p=0.05) (Table III). 
Dyspeptic complaints
One or more dyspeptic symptoms were present in 131 (46%) of the subjects, but no sig-
nificant differences existed between H. pylori-positive and H. pylori-negative subjects with 
respect to the prevalence of these symptoms (p=0.36) and the nature of these complaints 
(all p>0.05) (Table IV). The overall prevalence of dyspeptic complaints was not significantly 
different between ethnic groups (p= 0.24). However, Turkish and Moroccan subjects reported 
significantly more upper abdominal pain as compared with Dutch subjects (p=0.03, resp. 
p=0.03).
Seventy (24%) of the interviewed subjects used anti-dyspeptic agents on prescription dur-
ing the 12 months prior to the interview, but there were no significant differences between 
different ethnic groups (p=0.11). Thirty-eight (13%) subjects had a previous history of peptic 
ulcer disease, 79% of whom tested positive for H. pylori infection.
Table IV. Dyspeptic symptoms.
Total study 
population
n=283*
H. pylori
positive
n=202
H. pylori
negative
n=81 p-value
Abdominal discomfort (one or more 
symptoms)
131 (46%) 90 (45%) 41 (51%) 0.36
- Upper abdominal pain 82 (29%) 54 (27%) 28 (35%) 0.25
- Heartburn 87 (31%) 63 (31%) 24 (30%) 0.89
- Nausea 63 (22%) 45 (22%) 18 (22%) 1.00
- Vomiting after meal 23 (8%) 16 (8%) 7 (9%) 0.81
* missing data from 5 patients
DIScuSSIon
This study clearly shows a high H. pylori infection rate in a migrant community in a popula-
tion-based sample in The Netherlands. Strikingly even among autochthonous inhabitants 
of this multiethnic district, the H. pylori infection rate is high, especially in case of crowding. 
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Moreover, significantly more infections with CagA-positive H. pylori strains and serological 
evidence of atrophic gastritis were observed in subjects of foreign origin.
Although a relatively small number of subjects were included in this study, it adds to the 
existing knowledge as these epidemiological findings resemble the actual prevalence of H. 
pylori in a Western multiethnic population. The response rate in this study was only 16%, 
therefore there may have been a selection bias. Given the general aim of this study to evalu-
ate the prevalence and feasibility of screening for several infectious diseases, it is unlikely 
that (non-) participation in the study was directly associated with the exposure to H. pylori 
or dyspeptic symptoms and therefore this is probably not a systematic error. However, selec-
tion of particularly patients with concerns about their health for various reasons cannot be 
excluded, as well as selection of subjects who were not receiving medical care elsewhere. As 
the response rate in subjects younger than 45 years was low, our results are mainly represen-
tative of H. pylori status and prevalence of atrophic gastritis in first-generation immigrants. 
Multiethnic populations are common; cities like Rotterdam and many others in Western 
countries have a 40-60% immigrant population. A high H. pylori infection rate in immigrants 
in Western countries has previously been described and this observation has been confirmed 
in this unselected population (20-22). The vast majority of immigrants included in our study 
were born abroad and migrated to The Netherlands at varying ages, yet mostly after the 
age of 10 years (Table II). Studies evaluating second-generation migrants showed lower H. 
pylori infection rates (23). This suggests that migration after childhood does not strongly 
affect infection rate and confirms the common idea that H. pylori infection is mainly acquired 
during childhood.
To the best of our knowledge, a significant lower level of pepsinogens in immigrants has 
not been described previously. Although our study population is too small and too young 
for significant differences to be detected in the actual prevalence of atrophic gastritis, we 
can assume that a significant lower level of pepsinogens at a relatively young age indicates a 
higher risk of development of atrophic gastritis in later life (24).
The H. pylori prevalence in autochthonous subjects in our study is higher than that previ-
ously demonstrated in other Dutch epidemiological studies, in which a prevalence of ap-
proximately 30% was observed in healthy blood donors (20,25). The most likely explanation 
for this dissimilar observation is the clustering of inhabitants of lower socio-economic class in 
multiethnic districts, as reflected in this study by the large number of persons per household. 
Low socio-economic status and crowded living conditions during childhood have previously 
been described as important risk factors for H. pylori infection (22,26-28). This finding confirms 
that not only immigration from a country with a high prevalence of H. pylori infection, but 
also socio-economic class can be used as epidemiological risk factors for the identification of 
high-risk individuals in the development of screening strategies.
To confirm the importance of prevention of H. pylori-related complications in migrant 
communities in Western countries, an increased risk of gastric cancer and peptic ulcer dis-
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ease in this subpopulation needs to be established prior to the development of screening 
strategies. In fact, a significantly increased risk of gastric cancer has been demonstrated for 
immigrants from the Antilles, Aruba, Japan and Turkey to Western countries (29-33). Gastric 
cancer risk is highest in persons born abroad, where especially the first two decades of life 
seem to determine cancer risk, and seem principally to concern distal gastric cancer (29,33). 
The difference in risk of gastric cancer between first- and second-generation immigrants sug-
gests an important aetiologic role of environmental factors, i.e. H. pylori infection, smoking 
and dietary habits. Yet, an increased risk of gastric cancer in autochthonous inhabitants of 
multiethnic districts has not been established.
We did not observe any correlation between dyspeptic symptoms and H. pylori infec-
tion; this observation is in accordance with previous findings (34-36). Selection for H. pylori 
screening on the basis of symptoms therefore seems inappropriate, which underlines the 
need for the identification of a high-risk population for H. pylori-associated diseases. In ad-
dition, nearly 80% of subjects who reported a history of peptic ulcer disease tested positive 
for H. pylori infection. This finding emphasizes the need for monitoring H. pylori status in this 
population.
Where serologic screening for H. pylori and CagA antibodies and pepsinogens is used, sub-
sequent endoscopic follow-up of patients with serologic proof of atrophic gastritis should 
be carried out. In this way, a stepwise screening approach can be developed in which the 
use of increasingly invasive procedures is proportional to gastric cancer risk. Still, the cost-
effectiveness of this approach in the prevention of H. pylori-related diseases requires further 
investigation.
In conclusion, migrant communities constitute a possible target group for serologic screen-
ing to prevent H. pylori-related complications in countries with an overall low incidence of 
these diseases. More research is needed to specify the most suitable epidemiological selec-
tion criteria and screening strategy to prevent H. pylori-associated diseases.
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AbSTrAcT
An association between gastric atrophy and esophageal squamous cell carcinomas (ESCC) 
has been described. However, the mechanism of this association is unknown. In this study, 
we aimed to examine this relation in a cohort of patients with varying grades of gastric 
atrophy to increase the understanding about the causality of the association. Patients diag-
nosed with gastric atrophy between 1991 and 2005 were identified in the Dutch nationwide 
histopathology registry (PALGA). The incidence of ESCC and, presumably unrelated, small cell 
lung carcinomas (SCLC) observed in these patients was compared with that in the general 
Dutch population. Relative risks and 95% confidence intervals were calculated by a Poisson 
model. At baseline histological examination, 97 728 patients were diagnosed with gastric 
atrophy, of whom 23 278 with atrophic gastritis, 65 934 with intestinal metaplasia, and 8516 
with dysplasia. During follow-up, 126 patients were diagnosed with ESCC and 263 with SCLC 
(overall rates 0.19, respectively 0.39/ 1000 person years at risk). Compared with the general 
Dutch population, patients with gastric atrophy ran a relative risk of developing ESCC of 2.2 
[95% CI 1.8-2.6], and of SCLC of 1.8 [95% CI 1.6-2.1]. The risk of ESCC did not increase with 
increasing severity of gastric atrophy (p=0.90). In conclusion, this study found an association 
between gastric atrophy and both ESCC and SCLC, but the risk of ESCC did not increase with 
the severity of gastric atrophy. Therefore, a causal relationship seems unlikely. Confounding 
factors, such as smoking, may explain both associations.
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InTroDucTIon
Chronic Helicobacter pylori infection has been widely accepted as predisposing condition for 
a number of gastric and duodenal disorders, such as peptic ulcer disease, MALT lymphoma, 
and gastric cancer. (1) However, over the past years, interest has been directed towards the 
potential role of H. pylori infection in the etiology of esophageal diseases. (2) This new focus 
has emerged from epidemiological studies demonstrating a negative association between H. 
pylori infection and gastro-esophageal reflux disease (GERD), and its related complications, in 
particular Barrett’s esophagus and esophageal adenocarcinoma. (3-6) 
In addition, recent studies have demonstrated an elevated risk of esophageal squamous 
cell carcinomas (ESCC) in patients with atrophic changes of the gastric mucosa. (3;7-10) A 
hypothesis explaining this unexpected association is, however, lacking. (11) Confounding by 
joint risk factors such as lifestyle, was not observed in case-control studies, thus suggesting a 
direct causal relationship between both conditions. (3;9) A causal relation would strengthen 
the importance of H. pylori eradication in the prevention of upper gastro-intestinal malignan-
cies. In case causality exists, the magnitude of the association would be expected to increase 
with the severity of gastric atrophy. On the other hand, were the association between gastric 
atrophy and ESCC based on confounding by shared risk factors, similar associations would 
be expected between gastric atrophy and other carcinomas with the same risk factors. An 
obvious candidate shared risk factor for the development of both gastric atrophy and ESCC 
is smoking. (12-14)
In order to examine the existence of a causal relationship between ESCC and gastric at-
rophy, we investigated the correlation between the severity of gastric atrophy and risk of 
ESCC within a large cohort of patients with varying histological stages of gastric atrophy, 
i.e. atrophic gastritis, intestinal metaplasia and dysplasia. The cascade from chronic H. pylori 
gastritis via atrophic gastritis, intestinal metaplasia, dysplasia towards gastric cancer has 
been widely accepted. (15) In line with this cascade, patients with intestinal metaplasia or 
dysplasia have been demonstrated to suffer from more extensive atrophic changes of the 
gastric epithelium as compared to patients with only atrophic gastritis. (16) In addition, we 
also investigated the risk of small cell lung carcinoma (SCLC) in the same study cohort, as this 
tumor is anatomically unrelated to the gastric and esophageal conditions and is known to be 
strongly associated with smoking. (17)
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mATerIAL AnD meThoDS
Histopathology database
All histo- and cyto-pathology reports in the Netherlands are collected in a national archive 
(PALGA database), which since 1991 has had nationwide coverage. (18) Patients in this 
database are identified by date of birth, gender and the first four characters of their family 
name. Every record in the database contains a summary of a pathology report and diagnostic 
codes similar to the Systematized Nomenclature of Medicine (SNOMED) classification of the 
College of American Pathologists. (19) The diagnostic code contains a term indicating the 
anatomical location, type of sample, and a morphological term describing the finding, e.g. 
‘stomach*biopsy*intestinal metaplasia’. Details with regard to the number and intragastric 
location of biopsies and presence of H. pylori are not uniformly registered. After a report has 
been coded, it is submitted online to the central database. The present study was based on 
data recorded in the PALGA database between 1991 and 2006. The following items were 
made available for each report: gender, date of birth, date of pathology review, summary 
text and diagnostic code. 
Patient selection
All patients with a first histologically confirmed diagnosis of gastric atrophy, i.e. atrophic 
gastritis, intestinal metaplasia and dysplasia, between 1991 and 2005 were identified in the 
database which had complete nationwide coverage since 1991. The most severe stage of 
gastric atrophy at baseline was evaluated as initial diagnosis. This meant that patients with 
atrophic gastritis without a diagnosis of concomitant intestinal metaplasia were classified as 
having atrophic gastritis, patients with atrophic gastritis and intestinal metaplasia as intesti-
nal metaplasia, and patients with gastric dysplasia as dysplasia. 
As far as could be determined from the database, all patients who had undergone gastric 
or esophageal surgery, or had been diagnosed with an esophageal or gastric malignancy 
prior to, or simultaneously with the first diagnosis of a pre-malignant gastric lesion, were 
excluded from analysis. 
Statistical analysis
The incidences of ESCC and SCLC in the cohort of patients with gastric atrophy were calcu-
lated on the basis of the total number of ESCC and SCLC registered in the PALGA database 
within the cohort in relation to the number of person-years at risk. The relative risk of ESCC 
and SCLC in patients with pre-malignant lesions of the gastric mucosa was then calculated 
by comparing these incidences with those for ESCC and SCLC within the general Dutch 
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population from 1991 until 2006. Unless an autopsy had been performed, the date of death 
of patients registered in the PALGA database is not recorded. Therefore, censoring because 
of death was imputed to evaluate the number of person-years at risk for all patients that 
did not develop esophageal or gastric cancer during follow-up, using survival data from the 
general Dutch population. (Dutch Cancer Registry, personal communication, October 2007) 
The incidence of ESCC and SCLC in the general Dutch population were calculated on the basis 
of the total number of ESCC and SCLC registered in the PALGA database and the midyear 
Dutch population. (20) As less than 1% of all ESCC within the general Dutch population occur 
in patients aged below 40 years, relative risks were only calculated for patients aged over 
40 years. (21) The size of and incidence within the general Dutch population was corrected 
for the number of and incidence of ESCC and SCLC within patients with gastric atrophy. To 
explore the presence of selection bias, ESCC risk was calculated for the first year of follow-
up, between one year to four years follow-up and after more than four years follow-up after 
the initial diagnosis of gastric atrophy. The relative risks and 95% confidence intervals (CIs) 
were calculated by a Poisson model, corrected for age categories, gender and calendar year. 
Comparisons of relative risks between different groups were also calculated with the Poisson 
model.
reSuLTS
The study cohort consisted of 97 728 patients (49 739 men/ 47 989 women) with a first 
histological diagnosis of gastric atrophy registered between 1991 and 2005. It comprised 
atrophic gastritis in 23 278 (24%) patients, intestinal metaplasia in 65 934 (67%) patients, and 
dysplasia in 8516 (9%) patients (Table 1). Overall, mean age at diagnosis was 63.5 years (SD 
15.6). Data on the incidence of gastric atrophy over the study period have been published 
previously. (22)
Table 1. Baseline characteristics of our study cohort with gastric atrophy.
Total cohort Atrophic gastritis Intestinal metaplasia Dysplasia
Number of patients (n) 
(%)
97 728 23 278 
(24%)
65 934 
(67%)
8 516 
(9%)
Male/ Female 
(%)
49 739/ 47 989
(51%/ 49%)
10 527/ 12 751
(45%/ 55%)
34 573/ 31 361
(52%/ 48%)
4 639/ 3 877
(54%/ 46%)
Age (years) (mean)
25th-75th percentile
63.5
53.2- 75.5
59.2
46.6- 73.4
64.7
55.0- 75.9
66.7
57.3- 77.6
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Esophageal squamous cell carcinomas
Between 1991 and 2006, ESCC was diagnosed in 126 patients (77 men/ 49 women) from the 
cohort at a mean age of 68.7 years (SD 11.3). The rate of developing ESCC was 0.19/ 1000 
person years at risk in patients older than 40 years. 
For all patients with gastric atrophy, the long-term relative risk (RR) of ESCC was 1.98 [95% 
CI 1.58-2.48] in male patients and 2.52 [95% CI 1.90-3.34] in female patients as compared 
to the general Dutch population aged over 40 years (Table 2). The overall relative risk of 
ESCC within the first year of follow-up after the diagnosis of gastric atrophy was significantly 
higher as compared to one to four years or more than four years follow-up (RR 5.99 [95% CI 
4.48-8.01], respectively RR 1.57 [95% CI 1.11-1.21] and RR 1.53 [95% CI 1.16-2.03]) (p<0.001). 
In patients with atrophic gastritis as the most severe diagnosis at baseline, the relative risk 
was 1.90 [95% CI 1.15- 3.16] for men and 2.84 [95% CI 1.71- 4.72] for women. In patients with 
intestinal metaplasia and dysplasia the relative risks were respectively 2.06 [95% CI 1.60-2.68] 
in men and 2.16 [95% CI 1.49- 3.14] in women, and 1.53 [95% CI 0.69- 3.40] in men and 4.10 
[95% CI 1.96- 8.56] in women. Therefore, for both men and women, the risk of ESCC did not 
increase with the severity of pre-malignant gastric lesions at baseline (p=0.82, respectively 
p=0.83). Similarly, no significant difference was demonstrated for the risk of ESCC between 
different histological diagnoses at baseline within the first year of follow-up, one to four years 
follow-up, or more than four years follow-up (p=0.69, respectively p=0.14 and p=0.11).
Table 2. Relative risk of esophageal squamous cell carcinomas and small cell lung carcinomas in patients 
with gastric atrophy (n=97 728) in comparison to the general Dutch population. The relative risks and 95% 
confidence intervals (CIs) were calculated by a Poisson model, corrected for age categories, gender and 
calendar year. 
Number 
of cases
ESCC
Relative risk
ESCC
95% CI Number 
of cases
SCLC
Relative risk 
SCLC
95% CI
Overall 126 2.16 [1.81-2.57] 263 1.84 [1.63-2.07]
Sex
- Male
- Female
77
49
1.98 
2.52 
[1.58-2.48]
[1.90-3.34]
182
81
1.64
2.55
[1.41-1.90]
[2.05-3.17]
Age at baseline
- 40-54 years
- 55-69 years
- ≥ 70 years
19
40
67
3.56
1.77
2.19
[2.27-5.59]
[1.30-2.42]
[1.72-2.80]
17
119
127
2.97
2.32
1.47
[1.85-4.77]
[1.93-2.78]
[1.23-1.75]
Most severe grade of gastric 
atrophy at baseline
- Atrophic gastritis
- Intestinal metaplasia
- Dysplasia
30
83
13
2.28
2.09
2.31
[1.59-3.26]
[1.69-2.59]
[1.35-3.97]
36
200
27
1.19
2.02
1.88
[0.87-1.63]
[1.76-2.32]
[1.29-2.74]
Legend: ESCC: esophageal squamous cell carcinoma; SCLC: small cell lung carcinoma
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Small cell lung carcinomas
In total, 263 patients (182 men/ 81 women) from the cohort were diagnosed with SCLC at 
a mean age of 69.0 years (SD 8.5). The rate of developing SCLC was 0.39/ 1000 person years 
at risk in patients older than 40 years. For all patients with gastric atrophy, the relative risk 
of SCLC was 1.64 [95% CI 1.41-1.90] in male patients and 2.55 [95% CI 2.05-3.17] in female 
patients as compared to the general Dutch population. Here, again there was no relation 
between the severity of gastric atrophy and the risk of development of SCLC (Table 2).
DIScuSSIon
This large, nationwide study confirms a positive association between gastric atrophy and 
the risk of ESCC. Our findings showed an overall relative risk of 2.2 for the development of 
ESCC in patients with gastric atrophy. However, the risk of ESCC in our population did not 
increase with the severity of gastric atrophy, with relative risks of 2.3 for atrophic gastritis, 2.1 
for intestinal metaplasia and 2.3 for dysplasia being observed.
There were considerable variations in the magnitude of the association between gastric 
atrophy and ESCC observed in previous studies from Sweden and Japan and in our study. 
(3;7-9) These differences may have resulted from the fact that all studies used different study 
populations and detection methods of gastric atrophy. In the Swedish studies the diagnosis 
of gastric atrophy was based on surrogate markers, i.e. either clinically diagnosed perni-
cious anemia, gastric ulcer disease, or pepsinogen I serology, resulting in elevated risks of 
respectively 3.3, 1.8 and 4.3 times for the development of ESCC as compared to the general 
population. In the Japanese study the diagnosis of gastric atrophy was based on both pep-
sinogen I serology and histology, resulting in elevated risks of 8.2 and 4.2 respectively. In 
contrast, instead of employing such surrogate markers, our study was able to estimate the 
ESCC risk within a population with histologically confirmed gastric atrophy. The selection of 
patients aged above 40 years has not influenced the generalisability of our observations to 
the whole population, as the incidence of ESCC is extremely low under this age both in our 
cohort (none of the cases) and in the general Dutch population (considerably less than one 
percent of all ESCC cases). In addition, our study shows that the risk of developing ESCC is 
especially high within the first year of follow-up. The high number of ESCC diagnoses shortly 
after the diagnosis of gastric atrophy suggests the presence of selection bias, as this could for 
instance have resulted from overlooking an incipient cancer or sampling error during the first 
endoscopy. The presence of selection bias has probably overestimated the overall relative 
risk of ESCC in this and previous studies.
Although this risk of developing ESCC was significantly higher in patients with gastric 
atrophy than in the general Dutch population, this association lacks clinical relevance, as the 
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magnitude of the association was far too small to direct surveillance practices. Nevertheless, 
this association could provide important insights into the pathogenesis of both conditions.
The positive association between ESCC and gastric atrophy is not easily explained, it could 
either be causal or the result of confounding risk factors involving both conditions. Previous 
case-control studies from Sweden and Japan reported gastric atrophy to increase the risk of 
ESCC independently of patently obvious confounding risk factors, such as smoking. (3;9;12) 
In addition, the Japanese investigators observed the ESCC risk to correlate positively to the 
severity of gastric atrophy. (9) Possible mechanisms for a causal relation were suggested, for 
instance that achlorhydria in patients with gastric atrophy may constitute an intragastric en-
vironment favoring bacterial overgrowth and bacterial n-nitrosation resulting in an increased 
exposure of the esophageal mucosa to carcinogenic endogenous nitrosamines. (11) Since 
patients with intestinal metaplasia have more extensive and generally longer existing atro-
phic changes of the gastric mucosa as compared to patients with merely atrophic gastritis, 
an increased formation of carcinogenic mediators and thus a higher incidence of ESCC may 
be expected in patients with intestinal metaplasia.
Our findings in this large cohort study of patients with histologically confirmed cases of 
gastric atrophy, however, contradict these observations. The absence of any association 
between the severity of gastric atrophy and the risk of ESCC undermines the presence of 
a causal relation between both conditions. The absence of a causal relation is further sup-
ported by the finding that within different intervals of follow-up no significant difference in 
ESCC risk was demonstrated between patients with atrophic gastritis, intestinal metaplasia or 
dysplasia. As no causal relation was demonstrated, H. pylori eradication is unlikely to prevent 
the development of ESCC. Moreover, the demonstration of a similar association between gas-
tric atrophy and SCLC in this study not only demonstrates the spuriousness of the previously 
assumed relationship but also points to joint causal risk factors for all three conditions, the 
most prominent of which is obviously smoking. The discrepancy between our data and those 
of previous studies is probably explained by the relatively small number of patients included 
in previous studies. For example, in the study from Japan only 29 patients with intestinal 
metaplasia were included.
Nevertheless, other explanations for the positive association between gastric atrophy and 
ESCC are worth exploring. It may well be that both conditions do share genetically determined 
pathogenetic mechanisms facilitating a similar destructive process, which damages both the 
gastric and esophageal epithelium, for instance via inflammatory response or defective DNA 
repair. (23-25) Prospective studies into these mechanisms may elucidate such an association. 
In addition, the observed association between gastric atrophy and SCLC may result from an 
unidentified interaction between the upper gastrointestinal tract and the lung. Such an as-
sociation has been described, as for instance an increased prevalence of asthma in subjects 
with gastro-esophageal reflux. (26) Moreover, the production of carcinogenic nitrosamines in 
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the atrophic stomach may theoretically cause lung cancer via a haematogenous route. (27) 
These hypotheses are also worth exploring in future research.
Strengths of our study are the nationwide selection of individuals and the large number 
of patients with histologically confirmed diagnoses included in this study. Nevertheless, in 
spite of its large size, the selection of our study population will not have been complete, 
as not all subjects with gastric atrophy in the general population have undergone endos-
copy with biopsy sampling and thus been diagnosed. Therefore, the general population that 
was used as control-group in this study would certainly include patients with undetected 
gastric atrophy, which could have resulted in underestimating the true relative risks of the 
association between both conditions. Secondly, it was impossible to calculate ESCC risk for 
different intragastric locations of gastric atrophy, as the intragastric location of biopsies is not 
uniformly registered in the PALGA database. However, it has been recognized for long that 
pre-malignant gastric lesions occur most commonly in the antrum and incisura angularis. 
Subsequently, these lesions spread along the lesser curvature to the proximal stomach and at 
the same time increase in severity. Biopsies from the antrum are commonly obtained during 
routine upper gastrointestinal endoscopy. Therefore, the diagnoses in this study most likely 
reflect the most severe gastric lesions at baseline. As patients with intestinal metaplasia or 
dysplasia have generally more extensive and longer existing atrophic changes of the gastric 
mucosa, they also demonstrate a higher prevalence of fundic atrophy. Therefore, no differ-
ence in the risk of ESCC and gastric atrophy between patients with distal gastric atrophy and 
patients with fundic atrophy was demonstrated in this study. Thirdly, as patients were treated 
in all hospitals throughout the country, differences in histological assessment cannot be ex-
cluded. However, the large number of patients in this study most likely compensates for these 
variations. Fourthly, we lack information on possible confounding risk factors. However, as we 
demonstrated an association between gastric atrophy and SCLC, we can presume that these 
confounders are present. Finally, we used imputation of survival estimates to calculate the 
relative risks. The imputation of survival estimates was based on the assumption that patients 
with gastric atrophy had a life expectancy similar to the general population. However, as they 
may well suffer from increased co-morbidity and mortality, this assumption could have led to 
an overestimation of the cohort at risk and consequently, an underestimation of its relative 
risk of developing ESCC and SCLC. (28) Nevertheless, we think that these co-morbidities have 
only slightly influenced the reported relative risks, as the large size of this study presumably 
compensated these inaccuracies and their limited effect on overall mortality.
In conclusion, although this study confirms a positive association between gastric atrophy 
and ESCC, the risk of ESCC does not increase in parallel with the increasing severity of gastric 
atrophy. Therefore, a causal relationship between gastric atrophy and ESCC seems unlikely. 
Moreover, as a similar association was demonstrated between gastric atrophy and the ana-
tomically unrelated SCLC, these associations are best explained by confounding factors, such 
as smoking.
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AbSTrAcT
background: Gastric marginal zone non-Hodgkin lymphomas MALT type (gMALT) and gastric 
adenocarcinomas (GC) are long-term complications of chronic Helicobacter pylori gastritis, 
however, the incidence of gMALT and the GC risk in these patients is unclear.
objective: To evaluate epidemiological time trends of gMALT in the Netherlands and to 
estimate GC risk.
methods: Patients with a first diagnosis of gMALT between 1991 and 2006 were identified 
in the Dutch nationwide histopathology registry (PALGA). Age-standardised incidence rates 
were calculated. The incidences of GC in patients with gMALT and in the Dutch population 
were compared. Relative risks were calculated by a Poisson Model.
results: In total, 1419 patients were newly diagnosed with gMALT, compatible with an inci-
dence of 0.41/100,000/year. GC was diagnosed in 34 (2.4%) patients of the cohort. Patients 
with gMALT had a sixfold increased risk for GC in comparison to the general population (p < 
0.001). This risk was 16.6 times higher in gMALT patients aged between 45 and 59 years than 
in the Dutch population (p < 0.001).
conclusions: GC risk in patients with gMALT is six times higher than in the Dutch population 
and warrants accurate re-evaluation after diagnosis and treatment for gMALT.
Ch
ap
te
r 6
81
Gastric MALT lymphoma: epidemiology and gastric cancer risk
InTroDucTIon
Helicobacter pylori causes chronic inflammation of the gastric mucosa in virtually all infected 
subjects. This inflammatory process can progress through the pre-malignant stages of atro-
phic gastritis, intestinal metaplasia and dysplasia to gastric adenocarcinomas. (1,2) As such, 
H. pylori infection is the most important risk factor for the development of gastric adenocar-
cinomas. Although, the incidence of gastric cancer is declining in the Western world, gastric 
cancer remains the 4th most common cancer and second leading cause of cancer-related 
death worldwide. (3,4) The declining incidence of gastric cancer in Western countries is simi-
lar to the declining incidence of peptic ulcer disease, attributed to the declining H. pylori 
prevalence. (5,6)
In addition, H. pylori infection has increasingly been recognised in the pathogenesis of gas-
tric mucosa-associated lymphoid tissue lymphomas (gMALT). (7,8) Although gMALTs are also 
strongly associated with H. pylori infection, the incidence of this condition has, in contrast to 
the gastric cancer incidence, been reported to increase. (8–12) It is controversial whether this 
is a true increase with a shift in outcomes of H. pylori infection. Alternatively, changes in the 
number of endoscopic procedures, biopsy sampling protocols and histological criteria could 
have influenced the number of diagnoses. (12) Progression of low-grade gMALT is slow, and 
H. pylori eradication alone leads to partial or complete remission in 60–80% of patients, in 
particular those without a specific API2-MALT1 t(11;18) chromosomal translocation. (2,13) 
On the contrary, gastric cancer is usually diagnosed at an advanced stage with only limited 
curative options and consequently a low 5-year survival rate. Although both conditions are 
long-term complications of chronic H. pylori infection, the potential interrelation is unclear 
and it is controversial whether gastric cancer risk is increased in patients with gMALT. Previ-
ous case series and small cohort studies described the occurrence of adenocarcinomas 
simultaneously or during follow-up of gMALT, (14–18) however, other studies could not 
confirm these observations. (11,19–21) In addition, a recent study observed increased pro-
gression of pre-malignant gastric lesions in patients with gMALT as compared to patients 
with non-complicated gastritis. (13) On the basis of these contrasting data and in the absence 
of long-term data in larger cohorts, the risk for gastric cancer in patients with gMALT remains 
unclear.
Therefore, the aim of this study was to evaluate epidemiological time trends of gMALT in 
the Netherlands and to evaluate gastric cancer risk in patients with a diagnosis of gMALT.
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meThoDS
Histopathology database
In the Netherlands, all histopathology and cytopathology reports are collected in a national 
archive (PALGA database), which has nationwide coverage since 1991. (22) Patients in this 
database are identified by date of birth, gender and the first four characters of their family 
name. Though sometimes identities of two patients are falsely matched, this identification 
string enables the linkage of different tests belonging to the same patient, and therefore 
also to follow individual testing histories (dates and diagnoses) irrespective of the facility of 
treatment. (23) 
All specimens receive a diagnostic code, similar to the Systematised Nomenclature of 
Medicine (SNOMED) classification of the College of American Pathologists. (24) This code 
consists of a term indicating the anatomical location, type of sample and a morphological 
term describing the finding. The records in the database contain these codes and the sum-
mary of the pathology report. In this study, data recorded in the PALGA database between 
1991 and 2006 were included. For each report, gender, date of birth, date of pathology report, 
summary text and diagnostic codes were made available.
Patient selection
All patients with a histologically confirmed diagnosis of gMALT were identified in the data-
base. The diagnostic codes that were used to identify the patients with gMALT are described 
in Appendix. To evaluate the incidence of gMALT in different age classes, incidence numbers 
in different periods were calculated within the 5-year age groups. The ratio of the number of 
new patients with a positive biopsy for gMALT to the number of new patients with a first time 
gastric biopsy was calculated, in order to correct for possible changes in frequency of upper 
gastro-intestinal endoscopies with biopsy sampling. 
Within the cohort of patients with a gMALT, all patients with a histologically confirmed 
diagnosis of gastric cancer were identified. Timing of gastric cancer diagnosis was evaluated 
with regard to diagnosis of gMALT. In this evaluation, patients with a gastric cancer diagnosis 
simultaneously with, or within one year prior to or after diagnosis of gMALT were considered 
concomitant diagnoses.
In addition, all patients with a diagnosis of atrophic gastritis, intestinal metaplasia or dys-
plasia prior to, simultaneous with, or after the diagnosis of gMALT were identified. 
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Statistical analysis
Age-standardised incidence rates (World standardised rate, WSR) of histologically confirmed 
gMALT were evaluated for the study period. To compare categorical and continuous variables 
between patients with low, intermediate to high and undefined grade gMALT, χ2-tests, t-tests 
and one way ANOVA tests were used, considering a two-sided p-value <0.05 as statistically 
significant.
To calculate the relative risk of gastric cancer in patients with gMALT, the incidence of 
gastric cancer observed in patients with gMALT was compared to the incidence of gastric 
cancers in the general Dutch population from 1991 to 2006 and aggregated over age and sex. 
As the PALGA registry does not contain date of death of patients, unless an autopsy had been 
performed, the person-years at risk would be overestimated. Therefore, we imputed death 
to get a correct estimate of the number of person-years at risk for all patients that did not 
develop gastric cancer during follow-up. Starting from the calendar year, age and gender of 
the persons, we collected the survival data from the general Dutch population for ever open-
ended follow-up. Drawing from a binomial distribution for every year then yielded a dataset 
with an approximately unbiased number of years at-risk. The number of patients is large, but 
we tried multiple imputation, that did not change the results, as was to be expected. The 
incidence of gastric cancer in the Dutch population was calculated on the basis of the total 
number of gastric cancers registered in the PALGA database and the midyear Dutch popula-
tion. (25) A Poisson Model, corrected for age categories, gender and calendar year, was used 
for calculating the relative risks and 95% confidence intervals (CIs).
reSuLTS
Between 1991 and 2006, 1419 patients were newly diagnosed with gMALT, 972 patients 
were initially diagnosed with a low-grade lymphoma, 357 patients with an intermediate to 
high-grade lymphoma and in 90 patients the grade of the lymphoma was undefined (Table 
Table 1. Baseline characteristics.
Total Low grade Intermediate to 
high grade
Undefined grade
Number of patients with 
gastric MALT lymphoma
1419 972 (68.5%) 357 (25.2%) 90 (6.3%)
Male/Female (%) 51.9/48.1 51.3/48.7 53.5/46.5 52.2/47.8
Age
 Median (yrs)
 Percentile 25th and 75th 
68.0
57.6/76.7
67.0
57.1/75.4
70.6
58.9/78.7
68.7
57.1/76.2
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1). Within the group of patients with a low-grade lymphoma, 32 (3.3%) patients developed a 
high-grade lymphoma within 1 to 8 years.
Epidemiology
Overall, the mean age of patients at diagnosis of gMALT was 66.1 (SD 14.1) years (range 
13.7–98.2 years), and the peak incidence of gMALT both in men and women was between 
70 and 74 years (Figure 1). The proportion of male to female patients in the cohort was 
51.9 to 48.1% (Table 1). No significant differences in male to female ratios were observed 
between patients with low-grade, intermediate to high-grade or undefined grade gMALT (p 
= 0.78). Patients with an initial diagnosis of low-grade gMALT (median age 67.0 years) were 
significantly younger compared to patients with intermediate to high-grade gMALT (median 
age 70.6 years) (p = 0.002). Age at diagnosis was significantly higher in females as compared 
to males, both in patients with low-grade gMALT (p = 0.03) and intermediate to high-grade 
gMALT (p = 0.001). 
Figure 1. Age at gastric MALT lymphoma diagnosis.
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Figure 2. The incidence of gastric MALT lymphoma (WSR, World standardised rate) in the Netherlands.
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Over the whole study period, the average number of new diagnoses of gMALT was 88.7 
cases per year, and the age standardized incidence rate was 0.41 per 100,000 per year (WSR) 
(Figure 2). This incidence was not stable over the total study period. At first, the incidence of 
gMALT increased with 5.8% (95% CI 1.9–9.9%) per year in the period from 1991 to 1997. This 
was followed by an annual 8.8% (95% CI 6.2–11.4%) decline until 2006 (Figure 2). Altogether, 
this corresponded with an annual WSR of 0.28 per 100,000 in 1991, increasing to a maximum 
of 0.72 in 1997, followed by a decrease to 0.27 in 2006. Gastric MALT lymphoma was diag-
nosed significantly more often in the period from 1991 to 2000 as compared to the period 
from 2001 to 2006 (p < 0.001). 
Gastric cancer risk
In total, 34 (2.4%) gMALT patients (18 males, 16 females) were diagnosed with gastric cancer 
at a median age of 72.0 years (SD 9.6). This comprised 2.7% of 1244 patients in whom no 
gastrectomy was performed after diagnosis of gMALT. Gastric cancer was diagnosed prior to 
the diagnosis of gMALT in 3 (8.8%) patients, in 18 (52.9%) patients both malignancies were 
diagnosed simultaneously (i.e. within a time frame of one year), and in 13 (38.2%) patients 
gastric cancer was diagnosed more than one year after the gMALT diagnosis (Table 2). The 
median interval between gastric cancer and gMALT in patients with gastric cancer develop-
ment after diagnosis of gMALT was 6.0 (range 1.1–7.4) years. 
Details on stage of gastric cancer were provided in 15 (44%) patients. Five (15%) patients 
were diagnosed at a stage of early gastric cancer, however, in 10 (29.4%) patients the tumour 
was already invading the lamina propria, submucosa or beyond. In addition, lymph nodes 
were involved in 4 (11.8%) patients, as demonstrated by histological evaluation after gastric 
resection. 
Table 2. Gastric MALT lymphoma and gastric cancer diagnosis.
Total Low grade Intermediate to 
high grade
Undefined grade
Timing of gastric cancer 
diagnosis
  Prior to MALT lymphoma 
(%)
  Concomitant with MALT 
lymphoma (%)
 After MALT lymphoma (%)
3(8.8)
18(52.9)
13(38.2)
3(10.7)
16(57.1)
9(32.1)
0
1(20.0)
4(80.0)
0
1(100)
0
Male/Female (%) 52.9/47.1 60.7/39.3 20.0/80.0 0/100
Age
 Median (yrs)
 Percentile 25th and 75th 
72.0
65.5/78.7
73.2
64.2/78.2
70.2
61.0/86.9
72.2
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Overall, the study population contained 440 (31%) patients with a diagnosis of a pre-
malignant gastric lesion prior to, simultaneously with, or after the diagnosis of gMALT, of 
which 65 (4.6%) patients were diagnosed with atrophic gastritis, 302 (21.3%) patients with 
intestinal metaplasia and 73 (5.1%) patients with dysplasia. In 21% of these patients a diag-
nosis of atrophic gastritis, intestinal metaplasia or dysplasia preceded the diagnosis of gastric 
cancer.
Gastric cancer risk was not significantly different between patients with low, intermediate 
to high or undefined grade gMALT (p = 0.21). In addition, no significant differences in gastric 
cancer risk were demonstrated between male and female patients (p = 0.91).
Overall, patients with a diagnosis of gMALT were at a six times higher risk of developing 
gastric cancer as compared to the general Dutch population (Table 3). Males with gMALT had 
a 4.4 times higher risk as compared to the general population (p < 0.001), whereas females 
had a 10.0 times higher risk (p < 0.001). The relative risk of gastric cancer was significantly 
higher in female patients with a gMALT as compared to male patients (p = 0.02). However, the 
absolute risk of gastric cancer for males and females older than 45 years was not significantly 
different (respectively, 4.0/1000 person-years and 4.3/1000 person-years; p = 0.81). Gastric 
cancer risk was 16.6 times increased in patients aged between 45 and 59 years as compared 
to the general Dutch population (p < 0.001), 10-fold increased in patients aged between 60 
years and 74 years and threefold increased in those above 74 years (Table 3). These differ-
ences in relative risk for the age groups were significant (p = 0.004). However, the absolute 
gastric cancer risk in patients with gMALT did not differ between those aged 45 to 59 years 
and those above 59 years (p = 0.07).
DIScuSSIon
First of all this study provides long-term nationwide data on the incidence of gMALT in a 
Western population. It shows an overall incidence of gMALT of approximately 0.4/100,000/
year. Secondly, our data show that this incidence has considerably changed over the past 
18 years, initially increasing between 1991 and 1997, which was followed by a rapid decline. 
Table 3. The relative risk of gastric cancer (GC) in patients with gastric MALT lymphoma (gMALT) as 
compared to the general Dutch population.
GC in Dutch 
population
GC in gMALT 
patients
Relative risk 95% CI P value for 
difference
Overall 36,577 30 6.11 [4.28-8.72]
Sex Male
Female
22,778
13,799
15
15
4.39
10.04
[2.65-7.28]
[6.07-16.60]
0.02
Age at 
baseline
45-59 yrs
60-74 yrs
≥ 75 yrs
6,229
15,253
13,666
5
17
8
16.64
10.64
3.43
[5.45-50.80]
[6.52-17.4]
[1.91-6.13]
0.004
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Thirdly, we provide long-term data that confirm the suggestion from previous case reports 
that gMALT patients have a considerably higher gastric cancer risk than the general popula-
tion. In most cases, gastric cancer is diagnosed within one year prior to or after the diagnosis 
of gMALT. Therefore, on the basis of our data, accurate evaluation of gMALT seems to be 
warranted for a diagnosis of gastric cancer concomitantly or after the diagnosis of gMALT.
Our data demonstrate that gMALT is a relatively rare disease in a Western population. 
Previous studies in Western countries have demonstrated incidences varying between 
0.21/100,000 (England) and 13/100,000 (Italy). (2,26,27) These differences are probably ex-
plained by differences in the prevalence of H. pylori between the studied populations, study 
power based on the magnitude of the study population, the period of follow-up and the 
timing of the study. (2,26,28) In our population, a diagnosis of gMALT was not extremely rare 
as approximately 0.2% of the total number of patients with a first gastric biopsy over the 
study period were diagnosed with a gMALT.
Previous studies described an increasing incidence of gastric lymphomas in contrast to the 
declining incidences of H. pylori infection, peptic ulcer disease, atrophic gastritis, intestinal 
metaplasia and gastric adenocarcinomas. (5,6,12) Our data similarly demonstrate that the 
incidence of gMALT increased from 1991 to 1997, but decreased rather rapidly thereafter. The 
initial increase is probably related to the increasing interest in this diagnosis after the discov-
ery of an association between H. pylori infection and gMALT in 1991. (8) The importance of H. 
pylori as risk factor for MALT lymphoma was confirmed by the regression of low-grade MALT 
lymphoma after H. pylori eradication. (19,29) Thereby, gMALT became an infection-associated 
malignant disease. (2) This led in a change of primary treatment strategy from chemoradio-
therapy and surgery to H. pylori eradication therapy. This major change may have contrib-
uted to an increase in the number of new cases diagnosed with gMALT during those years. 
Furthermore, improved endoscopic and histological diagnostic procedures may also have 
contributed to the increasing incidence of gMALTs. (30–32) For several years, all non-Hodgkin 
lymphomas (NHLs) were classified following the Working Formulation (WF) in low-grade 
and high-grade lymphomas. This working formulation did not include several morphologic 
and clinical distinct entities, including gMALT. Consensus for a more multifaceted approach 
to NHLs was reached in a revised European–American lymphoma (REAL) classification in 
1993, which recognised the mucosa-associated lymphomas. (33) Thereafter, gMALTs were 
considered a specific entity. (2) Currently their incidence is rapidly declining. This decline is 
likely in part related to the current decline in the prevalence of H. pylori in Western countries. 
However, the decline of incidence of gMALT is much more rapid than the declining H. pylori 
prevalence. (5,34,35) Therefore, other factors must additionally play a role and need to be 
further investigated.
Although several case series were published on synchronous and metachronous occur-
rence of both gastric cancer and gMALT, it remained unclear whether gastric cancer risk was 
increased in gMALT patients compared to the general population. (11,14,16,19,36–38) Our 
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study demonstrates this risk is indeed about six times increased (Table 3). The absolute risk 
was equal in male and female gMALT patients, which contrasts with the general population, 
where the risk for gastric cancer is considerably higher in men. Thus, the relative risk of gastric 
cancer in MALT patients is higher in women than in men. Similarly, the gastric cancer risk was 
the same in younger and elderly gMALT patients, and thus the relative risk for gastric cancer 
was significantly higher in younger MALT lymphoma patients (Table 3). The relative risks of 
gastric cancer after a diagnosis of gMALT described in our study could even be higher since 
gastrectomy was performed in 175 patients after diagnosis of a gMALT, in particular in the 
early years when H. pylori eradication was not yet an accepted treatment method.
As patients with gastric MALT lymphoma are already at an increased risk of developing 
gastric cancer by being H. pylori positive, a further comparison between H. pylori-positive 
subgroups is essential. Previous studies demonstrated that H. pylori infection increased 
gastric cancer risk at least twofold resulting for H. pylori-positives in an estimated lifetime 
risk for gastric cancer of approximately 1%. (39,40) In addition, we recently published a study 
describing the risk of gastric cancer in a large cohort of patients with atrophic gastritis and 
intestinal metaplasia, which occurs like MALT lymphoma against a background of H. pylori 
infection. This study demonstrated that within ten years of follow-up the gastric cancer risk 
in these subjects with a pre-neoplastic condition varied between the two and three percent. 
(41) This background supports the conclusion that patients with gMALT are at increased risk 
for gastric cancer compared to H. pylori-positive subjects, and that this risk is in fact very 
similar to patients with atrophic gastritis and intestinal metaplasia. (41)
In 38% of patients with diagnosis of gastric cancer, gastric cancer was diagnosed after 
gMALT with a median interval of 6.0 years (range 1–7). This interval is similar to the interval 
observed in a review of previous cases on metachronous occurrence of gMALT which re-
ported 6 months to 5 years. (16) However, the exact period between diagnosis of a gMALT 
and cancer or remission is difficult to interpret, since different histological scoring systems 
have been used to evaluate lymphoma response to therapy over the past decade. (29,42) 
As these grading systems demonstrated low interobserver reproducibility, a new grading 
system based on evaluation of diagnostic features of lymphoepithelial changes was put 
forward. (43) According to this grading system, a recent study described a favourable disease 
course of patients treated with H. pylori eradication, after 42.2 months of follow-up, in which 
one-third of the patients went into complete remission. (21,43) However, the findings in 
our study emphasise the need of accurate endoscopic and histological re-evaluation of the 
gastric mucosa after diagnosis of a gMALT, since the majority who developed gastric cancer 
was diagnosed with adenocarcinoma concomitantly (52.9%) with their gMALT or during later 
surveillance (38.2%).
Although this study describes a large nationwide cohort of patients with gMALT with long-
term follow-up, potential limitations of this study warrant consideration. Firstly, for most of 
the period under study, MALT lymphomas were classified as either low- or high-grade, and 
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it is therefore that our report included cases under these search terms. At present, gMALTs 
are considered as a specific disease entity of marginal zone lymphoma (mucosa-associated 
lymphoid tissue lymphoma (MALT) type), which led to the formalized WHO classification, 
according to which these lesions are now referred to as gastric marginal zone lymphomas 
MALT type. (44) Also, the term high-grade MALT lymphoma was replaced by Diffuse Large 
B-Cell Lymphoma (DLBCL) in this new classification, as it was discovered that low-grade and 
high-grade gMALTs have a different histogenesis. (44) These DLBCLs may contain a low-grade 
MALT lymphoma component. However, it remains unclear to which extent they transformed 
from low-grade MALT lymphomas versus de novo DLBCLs. (45) For these reasons, it is likely 
that a small proportion of the high-grade gastric MALT lymphomas in our cohort included 
DLBCLs unrelated to MALT. However, these changes of nomenclature have not led to a major 
change in diagnoses and therefore unlikely affected the main outcome parameters of our 
study, i.e. the incidence of gMALTs and the risk for gastric cancer in these patients.
Secondly, we could not evaluate the extension of pre-malignant gastric lesions in the 
mucosa surrounding the MALT lymphomas, as the relatively low percentage of patients with 
gastric atrophy, intestinal metaplasia and dysplasia prior to or simultaneous with gMALT 
diagnosis made this impossible. In addition, details on location and invasion of the MALT lym-
phomas were not provided. Lymphomas tend to occur proximally in the stomach, whereas 
gastric adenocarcinomas occur more distal. (36) For these reasons, details on extension of 
pre-malignant gastric lesion, and size and depth of MALT lymphoma might identify patients 
at higher risk and consequently lead to more accurate surveillance. Similarly, evaluating the 
gastric cancer risk in the cohort after stratification by H. pylori and translocation status may 
also result in more accurate surveillance and prognosis. Previous studies observed the spe-
cific API2-MALT1 t(11;18) chromosomal translocation in approximately 30% (range 18–40%) 
of gMALT patients. (2,46,47) Most patients with this specific translocation do not respond to 
H. pylori eradication and demonstrate dissemination to regional lymph nodes or distal sites 
than the stomach more frequently. Development of gastric cancer was reported to occur in 
translocation-positive patients. However, these case series were very small and the exact risk 
of developing gastric cancer remained unclear. (48,49) For these reasons, a large prospective 
study of patients with gMALT and determination of their translocation status is essential to 
evaluate patients at high risk of developing gastric cancer, however, the rare appearance of 
gMALTs will make this study hardly feasible.
Thirdly, as limited numbers of biopsies can provide insufficient information for subtyping, 
and determination of horizontal extension and multifocality of gMALTs, previous studies 
described the need for a standardised protocol taking 20–30 biopsies from involved and 
uninvolved mucosa both at baseline and during follow-up. (32,50) However, we could not 
evaluate the number and distribution of biopsies obtained within each individual case and at 
every time point. Therefore, the number of patients with in particular pre-malignant gastric 
lesions after a diagnosis of gMALT may have been overdiagnosed. (51)
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Finally, a previous study proposed that gMALT patients treated with chemo- and/or ra-
diotherapy were particularly at increased risk for gastric cancer (52), but we were unable to 
assess this in our study population as we lack details with respect to chemoradiotherapy that 
without doubt has been given to patients during the first years of our study period.
In conclusion, the overall incidence of gMALT is low and currently declining, which is likely 
related to the current decline in the prevalence of H. pylori infections, but also has to be 
due to other unidentified factors as the decline is considerably more rapid than the decline 
of H. pylori prevalence. After a diagnosis of gMALT, an accurate endoscopic and histological 
re-evaluation of the gastric mucosa seem to be warranted as gastric cancer risk in patients 
with gMALT is substantial and the majority who develop gastric cancer are diagnosed con-
comitantly or after their gMALT. Future research is needed to clarify the clinical course of 
these patients in order to improve treatment and prognosis of patients with gMALT.
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APPenDIx
The following SNOMED-like codes were used:
Stomach: T63000.
Atrophic gastritis: M58000, M58001, M58010.
Intestinal metaplasia: M73000, M73200, M73320, M73321, M73300.
Dysplasia: M74000, M74006, M74007, M74008, M74009.
Gastric cancer: M81403, M80103, M84803, M81443, M81453, M84903, M82113, M80503, 
M82603, M69360, M81404, M80104, M80105, M80123, M80193, M80213, M80203. 
MALT lymphoma: M97153, M97183, M97163, M96993, M97183.
Malignant lymphoma/malignant non-Hodgkin lymfoma: M95903, F40640.
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AbSTrAcT
Gastric cancer is an important worldwide health problem and causes considerable morbidity 
and mortality. It represents the second leading cause of cancer-related death worldwide. A 
cascade of recognizable precursor lesions precedes most distal gastric carcinomas. In this 
multistep model of gastric carcinogenesis, Helicobacter pylori causes chronic active inflam-
mation of the gastric mucosa, which slowly progresses through the premalignant stages of 
atrophic gastritis, intestinal metaplasia and dysplasia to gastric carcinoma. Detection and 
treatment of premalignant lesions may thus provide a basis for gastric cancer prevention. 
However, at present, premalignant changes of the gastric mucosa are frequently disregarded 
in clinical practice or result in widely varying follow-up frequency or treatment. This review 
provides an overview of current knowledge on detection, surveillance and treatment of pa-
tients with premalignant gastric lesions, and identifies the uncertainties that require further 
research.
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InTroDucTIon
Gastric cancer is the fourth most common cancer and second leading cause of cancer-related 
death worldwide. Although the incidence of gastric cancer is declining, in particular in the 
Western world, the absolute annual number of new cases increases, due to aging of the 
world population and expansion of the population in developing countries with a high 
gastric cancer incidence. The estimated current incidence of gastric cancer is approximately 
16.2/100,000 persons per year (world standardized rate), with highest incidences in Eastern 
Asia, Eastern Europe, and South America (1).
As symptoms are often absent or nonspecific in patients with an early stage of disease, 
gastric cancer is usually diagnosed in an advanced stage, when curative options are limited. 
Consequently, gastric cancer carries a poor prognosis, with an overall 5-year survival rate of 
less than 20% (2).
The vast majority of gastric malignancies are adenocarcinomas, which can be divided into 
two types: intestinal type and diffuse (undifferentiated) type (3). Most gastric carcinomas are 
of the intestinal type. Helicobacter pylori infection increases the risk of developing gastric 
cancer more than sixfold and is therefore considered an important carcinogenic trigger (4). 
In contrast to diffuse-type carcinomas, intestinal-type carcinomas are generally thought to 
be preceded by a sequence of precursor lesions. In this multistep model of gastric carcino-
genesis, H. pylori causes chronic inflammation of the gastric mucosa, which slowly progresses 
through the premalignant stages of atrophic gastritis, intestinal metaplasia and dysplasia to 
gastric adenocarcinomas (5). Some authors have suggested that the presence of corpus-pre-
dominant gastritis by itself predisposes to gastric cancer rather than the progression through 
different premalignant stages; however, the presence of corpus-predominant gastritis cor-
relates highly with the presence of atrophic gastritis (6-8). Although several other gastric 
conditions with an increased cancer risk have been described, e.g. adenomatous polyps, 
previous distal gastric resection, Ménétrier’s disease, fundic gland polyps in subjects with the 
familial adenomatous polyposis syndrome, and hamartomas in patients with Peutz-Jeghers 
syndrome, this review will focus on atrophic gastritis, intestinal metaplasia and dysplasia.
Premalignant changes of the gastric mucosa are commonly observed in routine biopsies 
obtained during gastroscopy. Nevertheless, clear guidelines for follow-up and treatment of 
these patients are lacking, which means that in clinical practice follow-up frequency and 
treatment of individual patients vary widely. An overview of current knowledge on detection, 
surveillance and treatment of patients with premalignant gastric lesions will be provided 
in this review. Furthermore, uncertainties that hinder clinical decision-making and require 
further research prior to development of guidelines, will be identified.
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hISToLoGIc cLASSIfIcATIon
Atrophic Gastritis
Atrophic gastritis (AG) is defined as loss of glandular structures of the gastric mucosa. This is 
associated with a loss of specialized cells and thus a reduction of gastric secretory function 
(9). Various classifications of AG have been proposed over the years, with definitions such as 
A/B/AB/C types, “superficial” versus “diffuse”, “diffuse antral-predominant” versus “multifocal 
atrophic gastritis”, and “nonulcer pangastritis” versus “progressive intestinalized pangastritis”. 
However, these classifications are difficult to use in clinical practice and suffer from consid-
erable interobserver variation (10–14). At present, the updated Sydney System is generally 
used both in clinical practice and in research (Table 1) (9). In this classification system, which 
has proven its value over the past decade, several features of inflammation, atrophy and 
intestinal metaplasia need to be assessed individually. A visual analogue scale was added 
to facilitate grading of the individual features. The evaluation of most features displays good 
reproducibility, but agreement on the recognition and grading of gastric atrophy remains 
inadequate (15–17). New methods to classify AG objectively, in particular by quantification 
of the loss of glandular structures, have been developed (18–20). However, these have not 
yet been implemented in routine assessment, since clinical consequences of grading AG are 
commonly absent.
Table 1. Sydney System: Classification of chronic gastritis (9).
Type of gastritis Etiologic factors 
Non atrophic Helicobacter pylori
Atrophic
Autoimmune Autoimmunity
Multifocal atrophic Helicobacter pylori, Dietary, Environmental factors
Special forms
Chemical Chemical irritation: Bile, NSAID’s, Other agents
Radiation Radiation injury
Lymphocytic Idiopathic? Immune mechanisms, Gluten, Drug, 
Helicobacter pylori
Noninfectious
Granulomatous M. Crohn, M. Wegener, Sarcoidosis, Foreign 
substances, Idiopathic
Eosinophilic Food sensitivity, Other allergies
Other infectious gastritides Bacteria (other than H. pylori), Viruses, Fungi, 
Parasites
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Intestinal Metaplasia
Intestinal metaplasia (IM) is defined as replacement of gastric columnar epithelial cells by 
cells of intestinal morphology. IM probably results from diverted differentiation of gastric 
stem cells towards cells of small intestine or colonic phenotype. IM is characterized by the 
presence of intestinal-type, mucin-containing goblet cells, Paneth cells and absorptive cells 
(Figure 1). Several classifications of IM have been described; the most widely used is that 
of Filipe and Jass (Table 2) (21). The interobserver agreement of this classification system is 
satisfactory. However, a disadvantage is the labour-intensiveness, since additional staining is 
required to differentiate between types. Furthermore, differentiation between subtypes of IM 
has no proven relevance for clinical practice and is therefore usually omitted. 
Figure 1. Intestinal metaplasia in gastric antrum (H&E staining).
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Atrophic Gastritis
 
Atrophic gastritis (AG) is defined as loss of glandular
structures of the gastric mucosa. This is associated with a loss
of specialized cells and thus a reduction of gastric secretory
function [9]. Various classifications of AG have been proposed
over the years, with definitions such as A/B/AB/C types,
“superficial” versus “diffuse”, “diffuse antral-predominant”
versus “multifocal atrophic gastritis”, and “nonulcer pan-
gastritis” versus “progressive intestinalized pangastritis”.
However, these classifications are difficult to use in clinical
practice and suffer from considerable interobserver variation
[10–14]. At present, the updated Sydney System is generally
used both in clinical practice and in research (Table 1) [9].
In this classification system, which has proven its value
over the past decade, several features of inflammation,
atrophy and intestinal metaplasia need to be assessed
individually. A visual analogue scale was added to facilitate
grading of the individual features. The evaluation of most
features displays good reproducibility, but agreement on
the recognition and grading of gastric atrophy remains
inadequate [15–17]. New methods to classify AG objectively,
in particular by quantification of the loss of glandular
structures, have been developed [18–20]. However, these
have not yet been implemented in routine assessment, since
clinical consequences of grading AG are commonly absent.
 
Intestinal Metaplasia
 
Intestinal metaplasia (IM) is defined as replacement of gastric
columnar epithelial cells by cells of intestinal morphology.
IM probably results from diverted differentiation of gastric
stem cells towards cells of small intestine or colonic pheno-
type. IM is characterized by the presence of intestinal-type,
mucin-containing goblet cells, Paneth cells and absorptive
cells (Fig. 1). Several classifications of IM have been described;
the most widely used is that of Filipe and Jass (Table 2)
[21]. The interobserver agreement of this classification
system is satisfactory. However, a disadvantage is the labour-
intensiveness, since additional staining is required to
differentiate between types. Furthermore, differentiation
between subtypes of IM has no proven relevance for
clinical practice and is therefore usually omitted.
 
Dysplasia
 
Gastric dysplasia is characterized by variation in size, shape
and orientation of epithelial cells, enlargement and atypia
of nuclei, and distortion of normal glandular arrangement
(Fig. 2). Assessment of dysplasia is often difficult and
interobserver agreement in grading dysplasia is poor. In
addition, differences exist between Japanese and Western
gastrointestinal pathologists in classification of gastric
dysplasia and cancer. Japanese pathologists diagnose cancer
Type of gastritis Etiologic factors
Non-atrophic Helicobacter pylori,
Atrophic
Autoimmune Autoimmunity
Multifocal atrophic H. pylori, dietary, environmental factors
Special forms
Chemical Chemical irritation: bile, NSAIDs, other agents
Radiation Radiation injury
Lymphocytic Idiopathic Immune mechanisms, gluten, drug, H. pylori
Noninfectious granulomatous M. Crohn, M. Wegener, sarcoidosis, foreign substances, idiopathic
Eosinophilic Food sensitivity, other allergies
Other infectious gastritides Bacteria (other than H. pylori), viruses, fungi, parasites
Table 1 Sydney System: Classification of chronic
gastritis [9]
Figure 1 Intestinal metaplasia in gastric antrum (H&E staining).
Table 2. Types of gastric intestinal metaplasia (21).
Types of gastric intestinal metaplasia
Type I, Complete, small intestinal type absorptive cells with brush borders 
goblet cells secreting sialomucin
Paneth cells
Type II, Incomplete, enterocolic type few absorptive cells 
goblet cells secreting sialomucin, but also sulphomucin
columnar c lls secreting sialomucin
few Paneth cells
Type III, Incomplete, colonic type no absorptive cells
goblet cells secreting sialomucin or sulphomucin
columnar cells secreting mainly sulphomucin
rare Paneth cells
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Dysplasia
Gastric dysplasia is characterized by variation in size, shape and orientation of epithelial cells, 
enlargement and atypia of nuclei, and distortion of normal glandular arrangement (Figure 2). 
Assessment of dysplasia is often difficult and interobserver agreement in grading dysplasia is 
poor. In addition, differences exist between Japanese and Western gastrointestinal patholo-
gists in classification of gastric dysplasia and cancer. Japanese pathologists diagnose cancer 
based on cellular and structural abnormalities, whereas Western pathologists focus on the 
presence of tissue invasion as a prerequisite for a diagnosis of cancer (22). In 2000, the unified 
Padova classification was proposed, which divided dysplasia and adenocarcinoma into five 
categories. The Vienna classification further subdivided the categories of low-grade dysplasia 
and high-grade dysplasia and was revised to improve the correlation with clinical manage-
ment (Table 3) (23–25).
LocALIzATIon
Premalignant gastric lesions are most frequently localized in the antrum up onto the transi-
tional zone between antrum and corpus, with exception of AG related to pernicious anemia, 
which tends to be corpus-predominant. More detailed intragastric distribution of the lesions 
is unclear. It has long been assumed that AG has a largely multifocal distribution, with indi-
vidual foci of AG initially arising at the incisura angularis. These foci may subsequently spread 
and interconnect along the lesser curvature and anterior and posterior wall (9). However, a 
recent study showed that the majority of intestinal gastric carcinomas arise within a con-
tinuous sheet of AG with small, scattered islands of IM, according to an “advancing atrophic 
front pattern”. In this pattern the continuous sheet of AG seems to progress proximally and 
Figure 2. Gastric dysplasia (H&E Staining).
 
de Vries et al.
 
Premalignant Gastric Lesions
 
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Helicobacter 
 
12
 
: 1–15
 
3
 
based on cellular and structural abnormalities, whereas
Western pathologists focus on the presence of tissue
invasion as a prerequisite for a diagnosis of cancer [22].
In 2000, the unified Padova classification was proposed,
which divided dysplasia and adenocarcinoma into five
categories. The Vienna classification further subdivided the
categories of low-grade dysplasia and high-grade dysplasia
and was revised to improve the correlation with clinical
management (Table 3) [23–25].
 
Localization
 
Premalignant gastric lesions are most frequently localized in
the antrum up onto the transitional zone between antrum
and corpus, with exception of AG related to pernicious
anemia, which tends to be corpus-predominant. More
detailed intragastric distribution of the lesions is unclear. It
has long been assumed that AG has a largely multifocal
distribution, with individual foci of AG initially arising at
the incisura angularis. These foci may subsequently spread
and interconnect along the lesser curvature and anterior
and posterior wall [9]. However, a recent study showed
that the majority of intestinal gastric carcinomas arise
within a continuous sheet of AG with small, scattered
islands of IM, according to an “advancing atrophic front
pattern”. In this pattern the continuous sheet of AG seems
to progress proximally and towards the greater curvature
Types of gastric intestinal metaplasia
Type I, complete, small intestinal type Absorptive cells with brush borders
Goblet cells secreting sialomucin
Paneth cells
Type II, incomplete, enterocolic type Few absorptive cells
Goblet cells secreting sialomucin, but also sulfomucin
Columnar cells secreting sialomucin
Few Paneth cells
Type III, incomplete, colonic type No absorptive cells
Goblet cells secreting sialomucin or sulfomucin
Columnar cells secreting mainly sulfomucin
Rare Paneth cells
Table 3 The revised Vienna classification of gastrointestinal neoplasia [24]
Category Diagnosis Clinical management
1. Negative for neoplasia Optional follow-up
2. Indefinite for neoplasia Follow-up
3. Mucosal low-grade dysplasia Endoscopic resection/Follow-up
Low-grade adenoma
Low-grade dysplasia
4. Mucosal high-grade dysplasia Endoscopic or surgical local resection
4.1 High-grade adenoma/dysplasia
4.2 Noninvasive carcinoma (carcinom in situ)
4.3 Suspicious for invasive carcinoma
4.4 Intramucosal carcinoma
5. Submucosal invasion by carcinoma Surgical resection
Table 2 Types of gastric intestinal metaplasia
[21]
Figure 2 Gastric dysplasia (H&E Staining).
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towards the greater curvature with advancing disease (26). A minority of carcinomas arise in 
an “atrophic antrum”, in which the antrum is almost completely replaced with IM, whereas 
the corpus is non-atrophic. Multifocal dysplasia was detected both in areas with and without 
IM. At present, the Sydney System recommends two biopsies from the corpus, two from 
the antrum and one from the incisura angularis during gastroscopy to classify and grade 
gastritis. As knowledge of the exact intragastric distribution of premalignant lesions should 
guide biopsy sampling during surveillance endoscopy, clarification of distribution by further 
research is essential.
PrevALence
In parallel to the prevalence of H. pylori infection and the incidence of intestinal type gastric 
cancer, the incidence of AG and IM is declining in Western countries (27). However, prema-
lignant gastric lesions are still commonly encountered conditions in routine biopsies after 
endoscopy.
The prevalence of premalignant gastric lesions is influenced by a number of factors. First, 
the prevalence of these lesions shows considerable geographic differences. As their devel-
opment is strongly linked to H. pylori infection (28), the prevalence is elevated in countries 
with a higher prevalence of H. pylori infection. Nonetheless, some reports describe regions 
with a low prevalence of gastric cancer and premalignant gastric lesions, despite a high H. 
pylori infection rate (29). Therefore, other factors, including diet, H. pylori strain characteris-
tics and host immune response probably also play a role in geographic variation. Second, 
longitudinal analyses showed that the total prevalence of chronic gastritis is stable over time 
within specific birth cohorts; however, with increasing age a larger proportion of individuals 
becomes affected with AG compared to nonatrophic gastritis (28,30,31). Finally, as discussed 
Table 3. The revised Vienna classification of gastrointestinal neoplasia (24).
Category Diagnosis Clinical management
1. Negative for neoplasia Optional follow-up
2. Indefinite for neoplasia Follow-up
3. Mucosal low grade dysplasia
Low grade adenoma
Low grade dysplasia
Endoscopic resection/ Follow-up
4. Mucosal high grade dysplasia Endoscopic or surgical local resection
4.1 High grade adenoma/ dysplasia
4.2 Non-invasive carcinoma (carcinoma in situ)
4.3 Suspicious for invasive carcinoma
4.4 Intramucosal carcinoma
5. Submucosal invasion by carcinoma Surgical resection
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previously, the variation in prevalence of dysplasia may in part be a reflection of differences 
in applied classification criteria.
In the West European population H. pylori infection prevalence is approximately 40%. AG 
occurs in up to 60% and IM in 40–50% of H. pylori -infected individuals during their lifetime, 
whereas 5–10% of uninfected individuals are affected with these lesions (28,32,33). In Japan, 
the overall prevalence of H. pylori infection prevalence is approximately 60%. AG is present in 
about 80% of H. pylori infected and 10% of uninfected individuals, whereas IM is present in, 
respectively, 40% and 5% of individuals (34). Overall, AG and IM are present in approximately 
one third and one quarter of individuals in Western Europe, and in, respectively, more than 
half and one third of individuals in Japan. Prevalences of dysplasia vary from 0.5% to 4% in 
a Western population and between 9% and 20% in high-risk areas for gastric carcinomas. 
However, these percentages could be influenced by differences in classification criteria (35). 
nATurAL hISTory
After recognition of the neoplastic cascade of premalignant gastric lesions, various studies 
in subsequent decades further investigated the progression rate of AG, IM, and dysplasia to 
gastric cancer (Table 4) (36–75).
The reported progression rates of AG, both related and unrelated to pernicious anemia, to 
gastric cancer are remarkably stable despite diverse geographic setting of the studies, and 
vary roughly between 0% and 1.8% per year. In contrast, the reported progression rates of IM 
and dysplasia to cancer vary greatly, from 0% to 10% per year for IM, and from 0% to 73% per 
year for dysplasia.These variations can probably be explained by a variety of factors such as 
differences in study design and included populations, and variations in definitions of IM and 
dysplasia. For instance, the number and sites of biopsies have not been standardized in most 
studies. Therefore, sampling errors due to multifocal distribution of IM and dysplasia could 
have led to inaccurate estimates of progression rates, even more so when smaller cohorts 
are followed for shorter periods of time. Second, some studies excluded cases from analysis 
when gastric cancer was detected within 1 year after the diagnosis of dysplasia based on the 
argument that dysplasia and cancer in these cases might already have coexisted at baseline 
(39,47,62,63). Other studies did not use this approach, which is a further explanation for the 
discrepant results between studies. Third, some studies defined preneoplastic lesions only 
vaguely and grouped IM and dysplasia as one entity (41,58,72), and/or considered in particu-
lar type III metaplasia as synonymous to low-grade dysplasia.
For each of the categorized premalignant lesions, the gastric cancer risk is related to the 
extent of the lesion (71,76–78). For atrophic gastritis, gastric cancer risk particularly increases 
with extensive atrophic gastritis of the corpus. It seems plausible that the risk of cancer also 
increases with severity of lesions within these categories. This assumption has been proven 
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for AG, but is still controversial for IM as there is still considerable debate on whether intes-
tinal metaplasia type III represents a more pro-carcinogenic phenotype (45,46,51,71). One 
retrospective study claimed that patients with type III IM had a more than twofold increased 
risk for gastric cancer compared to subjects with atrophic gastritis without IM or with type I or 
II IM (51). However, upon re-analysis of the archival histology samples, this claim was refuted 
as a diagnosis of type III IM could not be confirmed in many patients. A cohort study from 
the UK did also not observe that the risk of gastric cancer was related to IM subtypes (45). 
This could also explain why the vast majority of patients with gastric cancer do not have any 
evidence of type III IM.
SurveILLAnce
The necessity of re-evaluation or surveillance of patients with premalignant gastric lesions 
is controversial (35,39,43,44,47,50,57,63,74,79,80). As a consequence, clear guidelines are 
still not available and recommended follow-up frequencies vary widely. This is remarkable, 
since guidelines for surveillance of other gastrointestinal premalignant conditions have been 
widely developed, as for instance for Barrett’s esophagus or colonic adenomas.
As only a small minority of patients with premalignant lesions will eventually develop 
gastric cancer, surveillance of all patients with premalignant gastric lesions is probably not 
indicated. Some authors have tried to identify patients with premalignant gastric lesions at 
increased risk of gastric cancer. In a study from Japan, investigators observed an increased 
gastric cancer risk in patients with extensive atrophic gastritis, as measured by low serum pep-
sinogen levels (81). Cancer risk was increased in those with and without serologic evidence 
of H. pylori infection. Extent and severity of the lesion, persistent H. pylori infection, age, male 
sex, alcohol use, and drinking water from a well were identified as risk factors for progression 
of premalignant lesions (81–83). Nevertheless, selection of individuals for surveillance in 
clinical practice is still difficult.
At this moment, regular surveillance of at least patients with mild or moderate dysplasia of 
the gastric mucosa seems indicated after initial diagnosis, given their high risk for a diagnosis 
of gastric cancer within the first two years. When repeated endoscopy with surveillance bi-
opsy sampling confirms the presence of dysplasia, continued surveillance is warranted. When 
dysplasia cannot be confirmed during reevaluation endoscopy, it is unclear for how long 
surveillance has to be continued. For patients with severe dysplasia surgical or endoscopic 
resection is indicated, although some authors recommend close endoscopic surveillance 
(24,43,47,50,84).
In Japan, a country with a high incidence of gastric cancer, repeated endoscopic population 
screening for gastric neoplasia is routine practice. However, also in low-incidence countries, 
surveillance of patients with premalignant gastric may lead to early detection of gastric 
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cancer and thereby reduced mortality. To evaluate the exact value of surveillance in patients 
with premalignant gastric lesions and establish follow-up frequencies, more precise data on 
progression are needed. These data should preferably be obtained in large prospective stud-
ies with adequate follow-up of patients with premalignant gastric lesions and these should 
be performed in different geographic areas. 
DeTecTIon
The implementation of nationwide mass screening programs in Japan has resulted in detec-
tion of more gastric carcinomas at an early stage. Several uncontrolled trials have suggested 
that cancer mortality has thereby been reduced (85–88). However, an invasive mass-screening 
program in countries with a relatively low incidence of gastric cancer is less appropriate, con-
sidering for instance the burden for patients, ethical objections, and costs. In these countries 
a more targeted approach is required to detect gastric cancer at an early and curable stage. 
Case finding, i.e. screening of patients who have sought health care for disorders that may 
be unrelated to the chief complaint, on the initiative of individual physicians will inevitably 
lead to disorganized screening. An approach with several screening stages with stepwise 
increasing invasiveness in proportion to gastric cancer risk seems therefore more suitable 
(Figure 3).
In this approach, the first step should be to select a population sample of the general 
population that should be offered noninvasive screening. This selection should probably 
be based on epidemiologic risk factors, as symptoms cannot predict the presence of pre-
Figure 3. Flow chart gastric cancer screening in low-incidence countries.
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malignant lesions or early gastric cancer (i.e. gastric carcinomas confined to the mucosa or 
submucosa). A risk profile could be defined based on known epidemiologic risk factors, as for 
instance low socioeconomic class, blood group A, and familial occurrence of gastric cancer 
(5,89,90). The next step, noninvasive, serologic screening is attractive to identify a population 
at high risk of gastric cancer in low-incidence countries, since costs and burden for patients 
are acceptable and thereby a large population sample can be screened. The aim of sero-
logic screening would be to identify patients with premalignant gastric lesions that require 
histologic confirmation after endoscopy. Finally, endoscopic surveillance should be offered 
to individuals with premalignant lesions at high risk of progression. Yet, this proposal may 
obviously also be debated and requires testing in appropriately designed trials. 
Non-Invasive Screening
Since H. pylori is probably the most important and most prevalent risk factor of gastric cancer, 
screening for H. pylori antibodies is an appropriate first approach to identify subjects at risk 
for (pre)malignant lesions of the gastric mucosa. However, the specificity of this test for the 
detection of (pre)malignant lesions is low, since the presence of H. pylori antibodies does not 
differentiate between chronic, nonatrophic gastritis, and (pre)malignant lesions. In addition, 
with longstanding, widespread AG or the presence of IM, H. pylori colonization can disap-
pear and serology then becomes negative. Specific strains of H. pylori contain determinants, 
e.g. cagA , vacA and babA , which are associated with increased gastric cancer risk. Testing 
for these markers adds to the sensitivity of H. pylori tests to detect (pre)malignant lesions, 
however, the specificity of these tests remains low (91). As a result, these tests are not useful 
as single screening tests.
Other potential tests are pepsinogens I and II, and gastrin, which provide valuable informa-
tion on the status of gastric mucosa. Pepsinogen I is produced by chief cells in the gastric 
fundus and corpus, whereas pepsinogen II is produced throughout the whole stomach. Gas-
tric inflammation causes increased production of both pepsinogens, with a larger increase in 
pepsinogen II production in comparison to pepsinogen I. AG causes a decreased production 
of both pepsinogens, with a more pronounced decrease of the production of pepsinogen 
I in comparison with pepsinogen II. As a result of these changes, chronic gastritis is associ-
ated with a reduced pepsinogen I/II ratio, and this ratio further decreases when AG occurs 
(92) IM and dysplasia are probably associated with even greater decreases in pepsinogen I/II 
ratios (93). In addition, gastrin is synthesized and secreted almost solely from antral G-cells. 
H. pylori gastritis tends to raise the serum levels of gastrin, probably due to hyperplasia of the 
antral G-cells. Increased production of gastrin also occurs in patients with AG in the corpus 
in response to reduced acid secretion, whereas in patients with antral-predominant AG, the 
level of gastrin decreases (94).
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By combining pepsinogens and gastrin levels with H. pylori serology in a decision algo-
rithm, it is possible to establish the presence of gastritis, distinguish AG, and locate atrophic 
changes with high sensitivity and specificity (95). However, the value of these tests to discern 
a population at risk of IM and dysplasia is still unclear. Thus, serologic screening is suited 
for clinical use in countries with a relatively low incidence of gastric cancer when further 
endoscopic follow-up is given to cases with an abnormal serologic profile suggestive of AG. 
Endoscopy
In Western countries, premalignant gastric lesions and early gastric cancer are generally 
diagnosed on histologic examination of random biopsies, whereas in Asian countries, es-
pecially in Japan, the presence and extension of these lesions are frequently established at 
endoscopy (96,97). These remarkable differences are explained by training and a different 
attitude towards inspection of the stomach. In Japan, endoscopists spend considerably more 
time on a thorough inspection of the stomach and are trained in endoscopic recognition of 
discrete mucosal alterations compatible with atrophy and early cancer.
Although the image quality of standard endoscopes has improved dramatically over the 
last decades, findings at conventional endoscopy often still correlate poorly with histologic 
diagnoses of AG, IM, and dysplasia (98–102). This results from unsatisfactory visualization 
of structure, color, and vascularity by conventional techniques, as all these features seem 
to play a role in adequate distinction of premalignant and early gastric cancer lesions. As 
a consequence, several alternative and supplementary strategies have been developed to 
overcome the limitations of standard endoscopic imaging.
Several studies have been performed to evaluate magnification endoscopy in patients with 
premalignant gastric lesions or early gastric cancer. An excellent correlation with histologic 
diagnoses was shown (103–108). The detailed visualization of the superficial gastric mucosa 
has resulted in classifications of pit and sulci patterns. In addition, the superficial capillary 
networks can be viewed in detail (109). Specific surface and microvascular patterns can 
identify H. pylori-induced chronic gastritis and the entities of premalignant gastric lesions. In 
H. pylori gastritis, collecting venules lose their regular starfish pattern and can even become 
completely invisible. In AG, changes in the subepithelial capillary network and collecting 
venules correlate with the degree of atrophy. Areas with IM are suspected in case of depres-
sion with large and long epithelial crests by deep sulci (103).
Several in vivo staining techniques can be used as an adjunctive to plain visualization of 
gastric mucosal lesions at conventional or magnifying endoscopy. Methylene blue utilizes 
the absorptive capability of cells to stain IM, whereas indigo carmine can be useful to en-
hance minute architectural changes in neoplastic lesions. The use of chromoendoscopy in 
detection of premalignant gastric lesions has long been based on expert opinion rather than 
scientific evidence. However, a recent study confirmed the validity of chromoendoscopy in 
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a surveillance setting for hereditary gastric cancer (110). This study showed that the use of 
chromoendoscopy facilitated detection of small foci of early gastric carcinoma not visible 
with white light gastroscopy.
A number of techniques that use specific spectral and absorptive features of light have 
been developed; these include narrow-band imaging, autofluorescence, and hemoglobin 
enhancement. Narrow-band imaging has been evaluated in combination with magnifica-
tion endoscopy. This technique uses narrow filtered bands in the excitation light to thereby 
improve imaging of the superficial capillary network and surface contrast within the mucosa. 
Seemingly, this technique is also suited to visualize in-depth invasion and could thereby 
assist the excision of lesions by endoscopic techniques (111,112). However, data are still 
preliminary. Autofluorescence endoscopy is characterized by exposure of tissue to light of 
shorter wavelength, typically blue light, and emission of the light by endogenous fluoro-
phores. The results of studies into the role of autofluorescence in patients with gastric cancer 
have been highly conflicting and its value in gastric cancer surveillance is therefore probably 
small (113–116). Super-addition of a pseudocolor image based on the hemoglobin content 
in the mucosa (hemoglobin enhancement) can be used to facilitate the delineation of lesions 
(117).
In spite of promising results of these new techniques, the added value in detection of 
premalignant gastric lesions still awaits confirmation in controlled trials and development 
of validated, uniform classification criteria. Thereafter, evaluation in a surveillance setting is 
indicated. Nonetheless, the reliance on visual subjective judgement is a drawback of these 
techniques. Therefore, in vivo measurement of tissue characteristics by spectroscopy tech-
niques could add to existent techniques, as for instance fluorescence spectroscopy, elastic 
scattering spectroscopy, and Raman spectroscopy (118–120). Yet, as many of these advanced 
techniques will remain in the hands of a few experts, the most effective approach to improve 
the initial detection of (pre)malignant lesions would probably be to train endoscopists in 
scrutinizing areas of mucosa at risk and recognizing the subtle visible changes using standard 
equipment (121).
TreATmenT
The importance of premalignant gastric lesions in the neoplastic cascade of gastric cancer is 
increasingly recognized. This leads to an augmenting interest in therapeutic options for these 
conditions. These therapeutic options can be divided into chemopreventive and endoscopic 
strategies. 
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Chemoprevention
Chemoprevention is defined as the use of pharmacologic agents to reverse or halt carcino-
genesis. Chemoprevention by means of H. pylori eradication therapy is frequently prescribed 
in patients with premalignant gastric lesions. However, controversy remains whether eradica-
tion halts the progression or can even cause regression of premalignant lesions, since the 
evidence from several clinical prospective trials is conflicting. Nevertheless, trials with a 
randomized controlled design have suggested that H. pylori eradication can lead to a regres-
sion of atrophic gastritis (83,122–135). Whether this is also true for intestinal metaplasia is 
less clear. From five prospective studies that have evaluated the effect of H. pylori eradication 
in patients with premalignant lesions to the endpoint of gastric cancer (83,122,129,136,137), 
only one nonrandomized prospective study demonstrated a significant reduction of gastric 
cancer development after H. pylori eradication in comparison with persistent H. pylori-
positives (136). Almost all gastric carcinomas (37 of 43 cases, 86%) in these prospective 
studies occurred in patients who already had intestinal metaplasia or dysplasia at baseline. 
Unfortunately, the total number of patients with premalignant lesions at baseline included in 
these studies was relatively low in some studies and not specified in others. Therefore, data of 
more intervention studies with adequate follow-up after H. pylori eradication of large popula-
tions of patients with premalignant gastric lesions, especially with intestinal metaplasia and 
dysplasia, are still eagerly awaited.
So far, the conclusion from the available prospective studies can only be that H. pylori 
eradication does not reverse or halt progression of premalignant lesions in all infected pa-
tients. This finding suggests that premalignant lesions can either pass a point of no return, 
or that other pathogenetic mechanisms besides infection play a role in the progression from 
preneoplasia to invasive cancer of the stomach. Factors that may be involved include bile re-
flux, dietary deficiencies, and autoimmunity. Therefore, alternative chemopreventive agents 
may have an additional effect to H. pylori eradication. In addition, H. pylori-negative patients 
with premalignant lesions, possibly through loss of colonization of H. pylori, may benefit from 
alternative chemoprevention too.
Potential alternative chemoprevention agents are dietary supplementation and COX-2 
inhibitors (138). Adequate consumption of fruit and vegetables seems to reduce the risk 
of cancer and the declining incidence of gastric cancer in Western countries appears partly 
caused by diet changes. Although some studies have shown promising results of folic acid, 
vitamin C, and beta-carotene supplementation, these results were not confirmed in a large 
meta-analysis (123,139–142). It is therefore doubtful that feeding supplements will favorably 
affect premalignant gastric lesions in individuals with an adequate nutritional status. In addi-
tion, as the expression of COX-2 is upregulated early in gastric carcinogenesis, COX-2 inhibi-
tion may inhibit carcinogenesis. Several experimental and animal studies have focused on 
the chemopreventive effect of COX-2 inhibitors and have demonstrated reduced progression 
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of premalignant gastric lesions (143–149). Moreover, epidemiologic and meta-analysis have 
shown that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce gastric cancer risk 
(150). Nevertheless, a recently published randomized controlled trial failed to demonstrate 
significant regression of IM by rofecoxib after 2 years’ follow-up (151). Unfortunately, the risk 
of gastrointestinal, renal, and cardiovascular side-effects will probably preclude future clini-
cal trials with COX-2 inhibitors in patients with premalignant gastric lesions (152).
Endoscopic Treatment
Over the past decades endoscopic alternatives to gastrectomy have been developed to 
treat severe dysplasia and early invasive cancers with limited risk for lymph node metastasis. 
Endoscopic mucosal resection (EMR) is designed to remove mucosal lesions by dissection 
through the submucosa. This technique is an accepted alternative to surgical resection in 
patients with intestinal type well-differentiated malignant lesions that are confined to the 
mucosa. According to the Japanese gastric cancer guidelines, lesions should be smaller than 
2 cm in size (153).
A wide variety of EMR techniques and instruments have been described, for instance lift-
and-cut, band-and-cut and capped EMR. A new development is endoscopic submucosal dis-
section (ESD) of gastric lesions larger than 2 cm without lymph node metastasis. In contrast to 
standard EMR in which a snare is used to dissect the lesion, this technique uses a needle-knife 
to separate the lesion from the surrounding mucosa and basal layer underneath. Basically, 
all EMR techniques may be of equal quality when performed by experienced endoscopists, 
however, comparative studies are not yet available.
From an oncological point of view, en-bloc resection is obviously preferable to piecemeal 
resection, since lateral margins can be assessed and recurrence rates are significantly lower 
(154). Local recurrence rates are 2% after en-bloc resections and 15% for piecemeal resections 
(Table 5). Compared to conventional EMR techniques, ESD results in higher en-bloc resection 
rates, especially in lesions larger than 2 cm (155). Since experience with a large number of 
cases is necessary to select eligible lesions and perform this procedure safely and effectively, 
Table 5. Curability and local recurrence rate after endoscopic mucosal resection (155).
Curative Non-curative Not evaluable
En-bloc resections
(N=1115) 911 (82%) 16 (1.4%) 44 (4%)
Local recurrence 0 16 8
Piecemeal resections
(N=326) 146 (45%) 80 (25%) 100 (30%)
Local recurrence 7 26 17
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EMR and especially ESD should only be performed in specialized centers by experienced 
interventional endoscopists (156–159).
A Japanese study showed that after EMR allowed complete free-margin resection of 69% 
of intramucosal lesions (160). No gastric cancer-related deaths occurred after a median 
follow-up of 38 months and major complications, bleeding and perforation, occurred in 5% 
of interventions. Based on these excellent treatment results, EMR has been implemented in 
the routine management for early gastric cancer in several countries. However, a recently 
published Cochrane review retrieved no randomized controlled trials to substantiate this 
policy and concluded that there is still a need for randomized controlled trials to determine 
the effects of EMR compared to gastrectomy (161). As EMR is nowadays used as a first ap-
proach allowing extensive histology in many expert centers, it is very doubtful whether such 
randomized trials will be performed. Another debatable issue is the necessity and the timing 
of endoscopic follow-up after EMR to detect recurrence of the index lesion or development of 
metachronous tumors. A recently published retrospective study suggests annual endoscopic 
examinations after successful EMR; however, more data are needed (162). 
concLuSIonS
The understanding of gastric carcinogenesis has advanced considerably over the past 
decades. Especially the insights into the role of H. pylori infection and the progression of 
chronic gastritis through premalignant stages to gastric cancer have shifted the focus of 
gastric cancer research from merely palliative strategies to the development of preventive 
strategies. H. pylori eradication may provide an important basis for gastric cancer prevention; 
however, controversy still remains whether eradication halts progression or can even cause 
regression of premalignant gastric lesions. To improve survival of patients with gastric cancer, 
detection and treatment in an early stage of disease are essential, and both require further 
research. Moreover, the development of an approachable population-screening program 
is likely to become mandatory, although in countries with relatively low incidence rates of 
gastric cancer cost-benefit evaluation will be required. 
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AbSTrAcT
background & Aims: A cascade of precursor lesions (eg, atrophic gastritis, intestinal meta-
plasia, and dysplasia) precedes most gastric adenocarcinomas. Quantification of gastric 
cancer risk in patients with premalignant gastric lesions is unclear, however. Consequently, 
endoscopic surveillance is controversial, especially in Western populations.
methods: To analyze current surveillance practice and gastric cancer risk in patients with 
premalignant gastric lesions, all patients with a first diagnosis between 1991 and 2004 were 
identified in the Dutch nationwide histopathology registry (PALGA); follow-up data were 
evaluated until December 2005.
results: In total, 22,365 (24%) patients were diagnosed with atrophic gastritis, 61,707 (67%) 
with intestinal metaplasia, 7616 (8%) with mild-to-moderate dysplasia, and 562 (0.6%) with 
severe dysplasia. Patients with a diagnosis of atrophic gastritis, intestinal metaplasia, or mild-
to-moderate dysplasia received re-evaluation in 26%, 28%, and 38% of cases, respectively, 
compared with 61% after a diagnosis of severe dysplasia (P < .001). The annual incidence of 
gastric cancer was 0.1% for patients with atrophic gastritis, 0.25% for intestinal metaplasia, 
0.6% for mild-to-moderate dysplasia, and 6% for severe dysplasia within 5 years after diag-
nosis. Risk factors for gastric cancer development were increasing severity of premalignant 
gastric lesions at initial diagnosis (eg, severe dysplasia, hazard ratio 40.14, 95% confidence 
interval 32.2– 50.1), increased age (eg, 75– 84 years, hazard ratio 3.75, 95% confidence inter-
val 2.8 –5.1), and male gender (hazard ratio 1.50, 95% CI 1.3–1.7). 
conclusions: Patients with premalignant gastric lesions are at considerable risk of gastric 
cancer. As current surveillance of these patients is inconsistent with their cancer risk, devel-
opment of guidelines is indicated.
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InTroDucTIon
Gastric cancer represents the fourth most common cancer and second leading cause of 
cancer-related death worldwide. (1) Although the incidence of gastric cancer has declined 
over the past decades, especially in Western countries, the mortality rate due to this disease 
remains high. As symptoms are frequently absent or only vague until the disease reaches an 
advanced stage, curative therapeutic options are usually limited at the time of diagnosis. (2)
Detection of gastric cancer at a curable stage substantially improves morbidity and sur-
vival. For instance, nationwide mass screening programs for gastric neoplasia in Japan have 
resulted in a higher detection rate of early gastric cancer. It has been suggested that cancer 
mortality has thereby been reduced. (3) However, population screening is presumably less 
appropriate in regions with low incidences of gastric cancer, such as Western Europe and 
North America. Therefore, a more targeted approach seems necessary to reduce mortality in 
these regions. Identification and surveillance of individuals at high risk for gastric cancer may 
provide the basis for such a strategy.
An important risk factor for gastric cancer development is the presence of premalignant 
changes of the gastric mucosa. (4) These lesions are involved in a widely accepted model 
leading to intestinal-type gastric carcinomas. In this multistep model of gastric carcinogen-
esis, Helicobacter pylori causes chronic inflammation of the gastric mucosa, which over years 
progresses through the premalignant stages of atrophic gastritis, intestinal metaplasia, and 
dysplasia to eventually gastric adenocarcinomas. (4,5)
The detection and surveillance of patients with these premalignant lesions could poten-
tially lead to early detection and treatment of advanced precursors and gastric carcinomas. 
Quantification of gastric cancer risk in patients with premalignant gastric lesions is unclear, 
however, as studies evaluating the progression of premalignant lesions to gastric cancer have 
shown conflicting results. Reported progression rates to gastric cancer varied between 0% 
and 2% per year for atrophic gastritis. (6) However, for intestinal metaplasia and dysplasia, 
progression rates to gastric cancer varied widely from 0% to 10% per year and from 0% to 
73% per year, respectively. (6) As a result, the efficacy of re-evaluation or surveillance of pa-
tients with premalignant gastric lesions remains highly controversial. (7–10) In particular, in 
Western countries, only very limited recent data are available on this issue. Even for patients 
with gastric dysplasia, a condition carrying a presumed high cancer risk, clear guidelines on 
clinical management are lacking, and recommendations on timing and frequency of follow-
up investigations vary widely.
In this study, we therefore investigated the progression rates of premalignant gastric 
conditions to gastric cancer in a Western population, and in addition evaluated whether the 
surveillance practice of patients with these premalignant gastric lesions matches their cancer 
risk. The resulting data should provide a basis for decisions on gastric cancer surveillance 
practice in Western populations.
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mATerIALS AnD meThoDS
Histopathology Database
In the Netherlands, all histopathology and cytopathology reports are collected in a national 
archive (PALGA database), which has nationwide coverage since 1991. (11) Each report can be 
tracked to an individual patient with a unique identifier, allowing follow-up on an individual 
basis regardless of whether treatment is received at the same or different institutes. Every 
record in the database contains a summary of the original pathology report and diagnostic 
codes similar to the Systematized Nomenclature of Medicine classification of the College of 
American Pathologists that are given by the pathologist who made the diagnosis. (12) The 
diagnostic code contains a term indicating the anatomical location, type of sample, and a 
morphological term describing the finding (eg, “stomach*biopsy*intestinal metaplasia”). 
Details regarding the number and intragastric location of biopsies and presence of H. pylori 
are not uniformly registered. The present study was based on data recorded in the PALGA 
database between 1991 and 2005.
Surveillance and Progression Analysis
Patients with histologically confirmed diagnoses of premalignant gastric lesions, (eg, atrophic 
gastritis, intestinal metaplasia, or dysplasia) were identified in the database (see Appendix). 
Only the most severe premalignant lesion at baseline (ie, the first observation of a premalig-
nant lesion) was evaluated as the initial diagnosis.
Patients with either gastric or esophageal surgery or malignancy registered before or 
simultaneously with the first diagnosis of a premalignant gastric lesion were excluded from 
the cohort. In addition, a period of at least 1-year follow-up to receive a re-evaluation upper-
gastrointestinal (GI) endoscopy was taken into consideration; consequently, patients with 
a first diagnosis in 2005 were excluded from analysis. For each patient, all summary texts 
and diagnostic codes concerning gastric biopsies from the first diagnosis of a premalignant 
gastric lesion to the end of the study period (December 2005) were retrieved.
In order to analyze surveillance, patients with a diagnosis of Barrett’s esophagus prior to or 
simultaneously with the diagnosis of a premalignant gastric lesion were excluded from analy-
sis, as most of them participated in an endoscopic surveillance program for this indication.
For diagnoses of esophageal and cardia adenocarcinomas, the pathology report of the sur-
gical resection specimen was reviewed; only carcinomas of which the bulk was macroscopi-
cally located below the esophagogastric junction were evaluated as primary gastric cancer. 
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Statistical Analysis
As the PALGA registry does not contain the patients’ date of death, unless an autopsy had 
been performed, censoring because of death was imputed to evaluate the length of follow-
up, using survival data from the general Dutch population (Dutch Cancer Registry personal 
communication, October 2007). Within each category of premalignant gastric lesions, inter-
vals between initial and repeated upper GI endoscopies with biopsies and between initial 
premalignant and gastric cancer diagnosis were evaluated by Kaplan–Meier survival analysis; 
equality between the categories of premalignant gastric lesions was tested with the log-rank 
test. Univariate and multivariate Cox-regression analysis was performed to identify indepen-
dent risk factors for progression of premalignant gastric lesions to more advanced gastric 
lesions in general or gastric cancer.
reSuLTS
A cohort of 92,250 patients with a first diagnosis of a premalignant gastric lesion was identi-
fied, with a 1:1 male-to-female ratio (Table 1). Median age at initial diagnosis was significantly 
higher with increasing severity of the categories of premalignant gastric lesions (P < .001) 
(Table 1). Women were significantly older than men at the initial diagnosis of atrophic gastritis 
(median age 63.2 years vs 57.8 years), intestinal metaplasia (68.7 vs 64.6), mild-to-moderate 
dysplasia (70.9 vs 66.9), and severe dysplasia (77.6 vs 72.1) (all P < .001). The mean age differ-
ence between men and women did not increase significantly with increasing severity of the 
categories of premalignant lesions (P = .35 univariate analysis of variance).
Surveillance
After excluding patients with Barrett’s esophagus, surveillance was evaluated in 90,316 
patients using the unique identifier of each individual patient (Table 1). Patients with a di-
Table 1. Baseline characteristics of our study population.
Total Atrophic gastritis Intestinal 
metaplasia
Mild to moderate 
dysplasia
Severe 
dysplasia
Number of patients (n) 
(%)
92,250 22,365 (24%) 61,707 (67%) 7,616 (8.3%) 562 (0.6%)
Male/ Female 46,985/ 45,265 10,110/ 12,255 32,415/ 29,292 4,153/ 3,463 307/ 255
Age 
 Median
 25th-75th percentile
65.7
53.1-75.5
60.7
46.4-73.3
66.5
54.9-75.8
68.7
56.8- 77.2
75.3
64.9- 81.4
Barrett’s esophagus (%) 1934 (2.1%) 460 (2.1%) 1219 (2.0%) 244 (3.2%) 11 (2.0%)
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agnosis of gastric atrophy or intestinal metaplasia received at least 1 re-evaluation upper GI 
endoscopy with histological re-evaluation in 26% and 28% of cases, respectively, compared 
with 38% after a diagnosis of mild or moderate dysplasia and 61% of patients with severe 
dysplasia (P < .001) (Figure 1). In all categories of premalignant gastric lesions, patients who 
underwent subsequent histological re-evaluation were significantly younger than patients 
who did not (P < .001) (Figure 2). The mean interval between initial diagnosis and histological 
re-evaluation was 2.6 years (standard deviation [SD] 2.9) in patients with atrophic gastritis, 
2.0 years (SD 2.6) for patients with intestinal metaplasia, 1.6 years (SD 2.4) in patients with 
mild-to-moderate dysplasia, and 0.4 years (SD 1.0) in patients with severe dysplasia (P < .001) 
(Figure 3). These findings show that the majority of patients with premalignant gastric lesions 
do not receive endoscopic follow-up, not even those with a diagnosis of dysplasia.
Figure 1. The proportion of patients with atrophic gastritis, intestinal metaplasia, and dysplasia receiving 1 
or more follow-up upper-gastrointestinal endoscopies.
Figure 2. The proportion of patients with atrophic gastritis, intestinal metaplasia, and dysplasia receiving 
histological follow-up according to 5-year age categories.
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Progression
Histological follow-up data on the gastric mucosa were available on 26,538 patients (Figure 
4). Progression to more advanced lesions overall, was significantly more common in patients 
with severe dysplasia as compared with patients with atrophic gastritis, intestinal metaplasia, 
and mild-to-moderate dysplasia (P < .001).
Figure 3. Timing of re-examination in patients who received histological re-evaluation of premalignant 
gastric lesions.
Figure 4. Follow-up results in patients in whom histological re-evaluation was performed. The results are 
presented as most advanced gastric lesion during follow-up for each category of premalignant gastric 
lesions at baseline. The outcome of patients who developed esophageal or cancer at the esophagogastric 
junction is not mentioned in this figure. Mean length of follow-up for patients with atrophic gastritis, 
intestinal metaplasia, mild-to-moderate dysplasia, and severe dysplasia: 3.5, 2.8, 2.5, and 1.0 years, 
respectively.
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Progression to gastric cancer was evaluated for the whole cohort of 92,250 patients (Fig-
ure 5). During follow-up, 1470 patients developed gastric cancer at a median age of 73.5 
years (SD 11.5) (61% men, 39% women). In total, 161 of these patients had at baseline been 
diagnosed with atrophic gastritis, 874 patients with intestinal metaplasia, 270 patients with 
mild-to-moderate dysplasia, and 165 patients with severe dysplasia. The age at diagnosis of 
gastric cancer was not significantly different between different diagnoses of premalignant 
gastric lesions at baseline (P = .34). Men were significantly younger at diagnosis of gastric 
cancer (median age, 72.3 years) as compared with women (75.5 years) (P < .001). The median 
interval between initial diagnosis and gastric cancer was 1.6 years (SD 3.2) in patients with 
atrophic gastritis, 0.90 years (SD 3.4) for patients with intestinal metaplasia, 0.45 years (SD 3.1) 
in patients with mild-to-moderate dysplasia, and 0.13 years (SD 2.7) in patients with severe 
dysplasia (P < .001). Within 1, 5, and 10 years of follow-up after initial diagnosis, gastric cancer 
was diagnosed in 0.3%, 0.6%, and 0.8% of patients with atrophic gastritis; 0.7%, 1.2%, and 
1.8% of patients with intestinal metaplasia; 2.1%, 3.1%, and 3.9% of patients with mild-to-
moderate dysplasia; and 24.9%, 29.5%, and 32.7% of patients with severe dysplasia (P < .001) 
(Figure 5). Men with intestinal metaplasia or mild-to-moderate dysplasia showed faster pro-
gression to gastric cancer as compared with women (both P < .001), whereas no significant 
difference was shown for men and women with atrophic gastritis or severe dysplasia (P = .16, 
respectively P = .45).
Figure 5. Progression rate of premalignant gastric lesions to gastric cancer in 92,250 patients with 
premalignant gastric lesions (90,780 censored patients).
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The high number of gastric cancer diagnoses within 1 year of follow-up in patients with 
severe dysplasia suggests that these patients need to be re-examined shortly after diagnosis. 
Periodical surveillance seems indicated in all patients with gastric dysplasia; however, in 
patients with atrophic gastritis or intestinal metaplasia, risk of progression to gastric cancer is 
too low to recommend surveillance in all patients. Surveillance may be considered, however, 
at larger intervals in younger patients with more severe or widespread atrophic gastritis and 
intestinal metaplasia.
Risk Factors for Progression
Within multivariate Cox-regression analysis, male gender was independently associated with 
an increased risk of progression to more advanced lesions overall (hazard ratio [HR] 1.55, 95% 
confidence interval [CI] 1.4 –1.7) and with an increased risk of gastric cancer (HR 1.50, 95% CI 
1.3–1.7), as compared with female gender (Table 2). In addition, increasing age at initial di-
agnosis was also independently associated with both progression to more advanced lesions 
and gastric cancer development. Moreover, gastric cancer risk increased significantly with 
the severity of premalignant gastric lesions at baseline and was clearly elevated in patients 
with intestinal metaplasia (HR 1.74, 95% CI 1.5–2.1), mild-to-moderate dysplasia (HR 3.93, 
95% CI 3.2– 4.8), and severe dysplasia (HR 40.14, 95% CI 32.2–50.1) as compared with patients 
Table 2. Risk factors for progression to advanced precursor lesions and gastric cancer in univariate and 
multivariate Cox-regression analysis.
Overall progression Gastric cancer
Baseline HR uni-
variate 95% CI
HR multi-
variate 95% CI
HR uni-
variate 95% CI
HR multi-
variate 95% CI
Sex
- Female
- Male
1.0
1.29 [1.2-1.4]
1.0
1.55 [1.4-1.7]
1.0
1.49 [1.3-1.7]
1.0
1.50 [1.3-1.7]
Age
- 35-44 years
- 45-54 years
- 55-64 years
- 65-74 years
- 75-84 years
- >85 years
1.0
0.97
1.43
2.04
3.46
5.34
[0.8-1.2]
[1.2-1.7]
[1.8-2.4]
[3.0-4.1]
[4.3-6.7]
1.0
1.06
1.62
2.33
3.94
6.45
[0.9-1.3]
[1.4-1.9]
[2.0-2.7]
[3.4-4.6]
[5.1-8.1]
1.0
1.47
2.62
3.93
4.53
3.27
[1.0-2.1]
[1.9-3.6]
[2.9-5.3]
[3.3-6.2]
[2.3-4.7]
1.0
1.39
2.38
3.44
3.75
2.64
[1.0-2.0]
[1.7-3.3]
[2.5-4.7]
[2.8-5.1]
[1.8-3.8]
Histopathology
- Atrophic gastritis
- Intestinal metaplasia
-  Mild to moderate 
dysplasia
- Severe dysplasia
1.0
0.52
0.68
6.11
[0.5-0.6]
[0.6-0.8]
[5.2-7.2]
1.0
0.43
0.53
3.57
[0.4-0.5]
[0.5-0.6]
[3.0-4.2]
1.0
2.10
5.05
55.94
[1.8-2.5]
[4.2-6.1]
[45.0-69.5]
1.0
1.74
3.93
40.14
[1.5-2.1]
[3.2-4.8]
[32.2-50.1]
Period of initial diagnosis
- 1991-1995
- 1996-2000
- 2001-2004
1.0
1.32
2.02
[1.2-1.4]
[1.8-2.3]
1.0
1.26
1.83
[1.2-1.4]
[1.6-2.1]
1.0
0.88
0.83
[0.8-1.0]
[0.7-1.0]
1.0
0.92
0.82
[0.8-1.0]
[0.7-1.0]
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with atrophic gastritis. Time period at initial diagnosis seemed an irrelevant risk factor for 
neoplastic progression, because a diagnosis in the period from 2001 to 2005 was associated 
with an increased risk of progression to more advanced lesions as compared with a diagnosis 
in the period from 1991 to 1995 (HR 1.83, 95% CI 1.6 –2.1); however, gastric cancer risk was 
lower (HR 0.82, 95% CI 0.7–1.0). These findings show that male patients with premalignant 
gastric lesions carry a higher risk of gastric cancer development than female patients. Gastric 
cancer risk is especially elevated at an older age and after a diagnosis of more severe lesions 
at baseline. 
DIScuSSIon
This large, nationwide study shows that patients with premalignant gastric lesions carry a 
significant risk of gastric cancer within 10 years of follow-up (Figure 6). However, in Dutch 
clinical practice, which is likely to be representative for many Western countries, surveillance 
of these patients is regularly omitted, even in patients with overt dysplasia.
Within 5 years of follow-up, the annual incidence of gastric cancer in our Western population 
was 0.1% for patients with atrophic gastritis, 0.25% for intestinal metaplasia, 0.6% for mild-
to-moderate dysplasia, and 6% for severe dysplasia. These observations are in line with the 
multistep cascade described by Correa. (4,13,14) Although this multistep cascade has been 
accepted for many years, quantification of gastric cancer risk in men and women with differ-
ent premalignant gastric lesions has remained unclear, in particular in Western populations. 
Figure 6. Progression from intestinal metaplasia to gastric adenocarcinoma after 10 years’ follow-up 
within the same patient. (A) Gastric mucosa (corpus) showing mild gastritis with marked intestinal 
metaplasia, no dysplasia (1993). (B) Gastric mucosa (angulus) showing moderately differentiated gastric 
adenocarcinoma (2003). H&E staining, original magnification x100.
between different diagnoses of premalignant gastric lesions
at baseline (P � .34). Men were significantly younger at
diagnosis of gastric cancer (median age, 72.3 years) as
compared with women (75.5 years) (P � .001). The me-
dian interval between initial diagnosis and gastric cancer
was 1.6 years (SD 3.2) in patients with atrophic gastritis,
0.90 years (SD 3.4) for patients with intestinal metapla-
sia, 0.45 years (SD 3.1) in patients with mild-to-moderate
dysplasia, and 0.13 years (SD 2.7) in patients with severe
dysplasia (P � .001). Within 1, 5, and 10 years of fol-
low-up after initial diagnosis, gastric cancer was diag-
nosed in 0.3%, 0.6%, and 0.8% of patients with atrophic
gastritis; 0.7%, 1.2 %, and 1.8% of patients with intestinal
metaplasia; 2.1%, 3.1%, and 3.9% of patients with mild-
to-moderate dysplasia; and 24.9%, 29.5%, and 32.7% of
patients with severe dysplasia (P � .001) (Figure 5). Men
with intestinal metaplasia or mild-to-moderate dysplasia
showed faster progression to gastric cancer as compared
with women (both P � .001), whereas no significant
difference was shown for men and women with atrophic
gastritis or severe dysplasia (P� .16, respectively P� .45).
The high number of gastric cancer diagnoses within 1
year of follow-up in patients with severe dysplasia sug-
gests that these patients need to be re-examined shortly
after diagnosis. Periodical surveillance seems indicated in
ll atients with g stric dysplasia; however, in patients
with atrophic gastritis or inte tinal metaplasia, risk of
progression to gastric cancer is too low to recommend
surveillance in all patie ts. Surveillance may be co sid-
ered, howev r, at larger intervals in yo nger patients with
Figure 3. Timing of re-examination in patients who received histolog-
ical re-evaluation of premalignant gastric lesions.
Figure 4. Follow-up results in patients in whom histological re-evalu-
ation was performed. The results are presented as most advanced
gastric lesion during follow-up for each category of premalignant gastric
lesions at baseline. The outcome of patients who developed esopha-
geal or cancer at the esophagogastric junction is not mentioned in this
figure. Mean length of follow-up for patients with atrophic gastritis,
intestinal metaplasia, mild-to-moderate dysplasia, and severe dyspla-
sia: 3.5, 2.8, 2.5, and 1.0 years, respectively.
Figure 5. Progression rate of premalignant gastric lesions to gastric
cancer in 92,250 patients with premalignant gastric lesions (90,780
ce sored patients).
Figure 6. Progression from intestinal metaplasia to gastric adenocar-
cinoma after 10 years’ follow-up within the same patient. (A) Gastric
mucosa (corpus) showing mild gastritis with marked intestinal metapla-
sia, no dysplasia (1993). (B) Gastric mucosa (angulus) showing moder-
ately differentiated gastric adenocarcinoma (2003). H&E staining, orig-
inal magnification x100.
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Previous cohort studies had limited sample sizes, used older histological classifications, in 
part specifically focused on patients with pernicious anemia, and the first studies used blindly 
obtained instead of endoscopic gastric biopsy samples. For these reasons, those data are of 
limited use for current daily practice. As a result, endoscopic surveillance of premalignant 
gastric lesions is highly controversial. The present data provide important insights in cancer 
risk and current management of patients with premalignant gastric lesions. They show that 
surveillance with endoscopy and biopsy sampling is relevant in patients with more advanced 
premalignant lesions and may lead to early detection of cancer. The improved prognosis after 
such early detection underlines the importance of development of surveillance guidelines.
As only a small proportion of patients with atrophic gastritis or intestinal metaplasia even-
tually develops gastric cancer, endoscopic follow-up of all patients with these lesions is not 
indicated but should be limited to patients at high risk. Previous studies have identified the 
intragastric location, severity, and distribution of atrophy and intestinal metaplasia, as well 
as the concomitant presence of associated lesions, especially, mucosa-associated lymphoid 
tissue (MALT) lymphoma or gastric ulcer, as markers of increased risk. (9,15,16 ) Furthermore, 
the risk is influenced by H. pylori virulence factors, a family history of gastric cancer, host 
genetics, and environmental factors (cigarette smoking, in particular). (17–21 )
From our data, we can conclude that the cancer risk in patients with mild-to-moderate 
gastric dysplasia is similar to or even considerably higher than the risk of cancer after re-
moval of colonic adenomas, as well as in patients with Barrett’s esophagus or long-standing 
inflammatory bowel disease. (22–24) It is remarkable that surveillance guidelines have been 
widely accepted for these conditions, whereas similar guidelines for follow-up of patients 
with dysplastic gastric lesions are lacking. Such a guideline should include the need for 
follow-up biopsy, confirming the presence of dysplasia, as well as recommendations on H. 
pylori eradication.
Patients with severe dysplasia, currently classified as noninvasive high-grade neoplasia ac-
cording to the revised Vienna classification, are at high risk to develop gastric cancer within 
2 years of follow-up. (25,26) This finding is in line with the results of previous studies. (27–29) 
Given this high cancer risk, thorough endoscopic and histological re-evaluation shortly after 
initial diagnosis is strongly indicated. (26) New endoscopic techniques, such as magnification 
endoscopy and narrow band imaging may help the identification of neoplastic lesions, en-
able targeted biopsies, and assist endoscopic resection. (30–32) All patients with identified 
dysplasia should be kept under strict surveillance with repeated multiple biopsy sampling. 
Preliminary data show that endoscopic resection of early neoplastic lesions needs to be 
considered. (33)
This study identifies male gender as an important independent risk factor for progression 
to more advanced lesions and gastric cancer. Moreover, men showed a significantly faster 
progression of premalignant lesions to gastric cancer as compared with women (P < .001). This 
observation remained unchanged after stratifying patients by age. In addition, premalignant 
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gastric lesions were diagnosed at a significantly higher age in women. These findings are in 
accordance with the male predominance in gastric cancer incidence and imply that women 
not only enter the carcinogenic cascade at an older age but also progress slower through 
subsequent stages. The explanations for these differences are unknown; however, plausible 
explanations are an increased use of non-steroidal anti-inflammatory drugs, less smoking, 
a lower prevalence of virulent H. pylori strains, and a preventive effect of female hormones. 
(34–36) However, the influence of sex hormones is contradicted by the fact that differences in 
progression rate to gastric cancer between genders persisted after menopause.
Although this study describes a large nationwide cohort, potential weaknesses warrant 
consideration. First, it was impossible to evaluate clinicians’ motivation to choose for or 
against surveillance. The majority of subjects never received endoscopic follow-up, not even 
those with advanced lesions at a young age. This supports the hypothesis that clinicians are 
insufficiently aware of the cancer risk of these patients and remain uncertain about the clinical 
management in the absence of guidelines. Second, as patients were treated in all hospitals 
throughout the country, differences in biopsy sampling protocol and histological assessment 
cannot be excluded. (37) Nevertheless, for grading of gastritis, it has long been routine to 
obtain antrum biopsies. It is at this same location that premalignant lesions predominate, 
with spread along the lesser curvature. (38) As we have categorized patients according to the 
most severe lesion, this is likely to reflect the true status of their gastric mucosa. The finding 
that this categorization correlates strongly with gastric cancer risk supports this assumption. 
In addition, the large number of patients in this study generously compensates for biopsy 
sampling and observer variation. Third, to evaluate progression rates to gastric cancer, a 
virtual life expectancy was calculated for all patients without follow-up until December 2005 
based on the life expectancy of the general population. This assumption may have led to a 
slight underestimation of gastric cancer risk, however, as a population undergoing endos-
copy tends to have increased comorbidity and mortality rates. In particular, risk factors for 
the development of premalignant gastric lesions may have caused a higher overall mortality 
rate. (15,21,39) Fourth, it was impossible to evaluate the influence of H. pylori eradication 
on the reported progression rates of premalignant gastric lesions in our study population. 
During most of our study period, however, the presence of premalignant gastric lesions was 
not an indication for H. pylori eradication. Also, previous studies have suggested that H pylori 
eradication may only have a very limited effect on subsequent gastric cancer incidence in 
patients with pre-existent premalignant gastric lesions, such as our population. (40–43) For 
these reasons, it is unlikely that the observed annual cancer incidences were strongly influ-
enced by H. pylori eradication treatments in our population. Finally, an important problem in 
studies evaluating progression of premalignant lesions is the occurrence of sampling errors 
(ie, the inability to biopsy the exact same intragastric location twice), which is even more 
relevant when the preneoplastic lesion has a patchy distribution. (44) In patients with dys-
plasia, lesions are more likely to be visible endoscopically, thus allowing for targeted biopsy 
Ch
ap
te
r 8
139
Gastric cancer risk in patients with premalignant gastric lesions
sampling. In contrast, atrophic gastritis and intestinal metaplasia are mostly diagnosed in 
random biopsies, reflecting the background status of the gastric mucosa in these patients. 
Our results show that this background status allows differentiation into risk categories for 
gastric cancer.
Judgment on the efficacy of surveillance of patients with premalignant gastric lesions 
requires consideration of burden for patients, costs, and capacity of hospital care. Detailed 
research into these aspects is required to identify individuals who should be offered sur-
veillance. In case surveillance is performed, more research is needed on the exact design of 
strategies, including the most optimal endoscopic surveillance frequency, techniques, and 
biopsy sampling protocols.
In conclusion, gastric cancer risk in patients with atrophic gastritis, intestinal metaplasia, 
and dysplasia of the stomach increases significantly with progressive severity of the lesions. 
The occurrence and progression of these lesions are more pronounced in men than in women. 
Most importantly, the risk of cancer is comparable or even higher in patients with prema-
lignant gastric lesions than in patients with other premalignant gastrointestinal conditions, 
which are routinely monitored. Therefore, follow-up should also be seriously considered in 
patients with premalignant gastric lesions. As current surveillance of premalignant gastric 
lesions is discrepant with the substantial gastric cancer risk of these lesions, development of 
clinical guidelines on endoscopic surveillance or treatment of premalignant gastric lesions is 
strongly indicated. Our data show that routine endoscopic surveillance at short intervals is 
warranted in patients with gastric dysplasia, whereas surveillance at longer intervals should 
be considered for patients with atrophic gastritis and intestinal metaplasia. Knowledge of 
detailed individual risk of progression to gastric cancer is important and requires further 
investigation.
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APPenDIx
PALGA diagnosis codes used in the analysis:
Atrophic gastritis: M58000, M58001, M58010
Intestinal metaplasia: M73000, M73200, M73320, M73321, M73300
Dysplasia: M74000, M74006, M74007, M74008, M74009
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Gastric adenocarcinomas: M80011, M80101, M80102, M81403, M80103, M84803, M81443, 
M81453, M84903, M82113, M80503, M82603, M69360, M80104, M80105, M80123, 
M80193, M80203, M81404, M80213
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AbSTrAcT
background: Surveillance of intestinal metaplasia (IM) of the gastric mucosa should be 
limited to patients at high risk of gastric cancer. Patients with extensive IM are at increased 
cancer risk; however, the intragastric extent of IM is usually unknown at the time of initial 
diagnosis.
objective: To assess the predictive value of clinical, histological and serological parameters 
for the intragastric extent of IM.
Design and Setting: Prospective, multi-center study. 
Patients: 88 patients with a previous diagnosis of IM of the gastric mucosa.
Intervention: Surveillance gastroscopy with extensive random biopsy sampling.
main outcome measurements: Biopsies were evaluated according to the Sydney classifica-
tion system. In addition, serological testing of Helicobacter pylori and CagA status, pepsino-
gens I and II, gastrin, and intrinsic factor antibodies was performed. The association between 
available parameters and extensive IM was evaluated with logistic regression analysis.
results: In 51 patients (58%) IM was present in the biopsies from at least two intragastric lo-
cations. The most important predictors of extensive IM were a family history of gastric cancer, 
alcohol use ≥ 1 unit/ day, moderate or marked IM at the index biopsy, and a pepsinogen I to 
II ratio <3.0. A simple risk score based on these factors could identify extensive IM in 24/25 
(96% sensitivity) patients.
Limitation: A prospective cohort study should confirm the proposed risk stratification.
conclusions: A risk score of clinical, histological and serological parameters can predict 
extensive intragastric IM and may serve as a practical tool to select patients for surveillance 
endoscopy in routine clinical practice.
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InTroDucTIon
In the model of gastric carcinogenesis, Helicobacter pylori plays a pivotal role in causing 
chronic active gastritis. Chronic H. pylori-induced gastritis progresses over years through 
the sequential stages of atrophic gastritis, intestinal metaplasia and dysplasia to gastric 
adenocarcinomas. (1;2) The identification and surveillance of these pre-malignant lesions 
could potentially lead to early detection and treatment of advanced precursors and gastric 
carcinomas. (3-5)
To date, pre-malignant gastric lesions are often accidentally diagnosed in random biopsy 
samples obtained during routine upper gastrointestinal endoscopy. As the management of 
patients with pre-malignant gastric lesions is controversial, the performance of endoscopic 
surveillance largely depends on the personal experience of clinicians and is frequently omit-
ted in current clinical practice. (3;6)
Surveillance of patients with pre-malignant gastric lesions should preferably be limited to 
patients at high risk of gastric cancer. The substantial cancer risk in patients with gastric dys-
plasia demands periodical surveillance or endoscopic intervention. Since atrophic gastritis 
and intestinal metaplasia eventually progress to gastric cancer in only a small proportion of 
patients, surveillance in these individuals should preferentially be offered to those at highest 
risk. (3)
Previous studies have shown that the intragastric extent of intestinal metaplasia is an 
important indicator of this cancer risk. (7-9) However, the degree of intestinal metaplasia can 
only be judged accurately after repeated endoscopy with multiple biopsy samples. This has 
significant disadvantages, such as burden for patients, high work load and high costs. There-
fore, other methods to estimate the extent of intestinal metaplasia at the time of diagnosis 
are highly relevant to select patients for endoscopic surveillance.
In this study, we aimed to determine the value of clinical characteristics, histological as-
sessment of routine gastric biopsies, and serological markers as predictors for the intragastric 
extent of intestinal metaplasia.
meThoDS
Patient selection
Consecutive outpatients with a previous histological confirmed diagnosis of intestinal 
metaplasia of the gastric mucosa (index diagnosis) were invited to undergo a surveillance 
endoscopy between March 2006 and June 2007. The surveillance endoscopy was performed 
within six years after the initial diagnosis of intestinal metaplasia. Patients with a previous 
diagnosis of upper gastrointestinal malignancy or a history of esophageal or gastric surgery 
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were excluded. The institutional review boards of the participating hospitals approved this 
study and written informed consent was obtained from all patients prior to surveillance 
endoscopy.
Clinical characteristics
A structured questionnaire was used, which comprised information on lifestyle factors, 
medication use, medical history, and family history of gastric cancer. In addition, information 
with regard to macroscopic lesions detected at the baseline endoscopy was retrieved from 
endoscopy reports. 
Endoscopy
All patients underwent a conventional upper gastrointestinal endoscopy using a standard 
forward-viewing video gastroscope (Olympus GIF-Q160, Olympus Optical Co., Tokyo, Japan). 
Biopsies for histological assessment were taken from five standardized intragastric locations: 
4 quadrant biopsies from the antrum (2-3 cm proximal to the pylorus), 2 from the angulus, 4 
from the mid corpus (2 from the lesser curvature, 2 from the greater curvature) and 2 from the 
cardia (Figure 1). In case of endoscopically visible lesions or suspicion of Barrett’s esophagus, 
additional targeted biopsy samples were obtained. These additional biopsies were not part 
of this study.
Figure 1. Random biopsy scheme: biopsies were obtained from five standardized intragastric locations. 
(Adapted from Dixon et al. (10))
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Figure 1. Random biopsy scheme: biopsies were obtained from five standardized 
intragastric locations. 
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Histological assessment
Gastric biopsy specimens were fixed in buffered formalin and embedded in paraffin. The 
slide sections were stained with haematoxylin and eosin (H&E). An expert gastro-intestinal 
pathologist (HVD) assessed all histological sections from the baseline and surveillance endos-
copy. The pathologist was blinded to the patient data, index diagnosis, and endoscopic find-
ings. All histological sections were assessed according to the updated Sydney classification 
system. The following items were evaluated separately: H. pylori density, acute inflammation 
(neutrophil infiltration), chronic inflammation (mononuclear infiltration), gastric atrophy, and 
intestinal metaplasia. (10) All these items were scored from 0 (absent), to 1 (mild), 2 (moder-
ate), or 3 (marked). In addition, gastritis was evaluated with the OLGA staging system and 
classified into four stages (I-IV), provided that at least two antrum and two corpus biopsies 
were available for histological assessment. (11) Dysplasia was assessed according to the 
revised Vienna classification. (12;13)
Serological markers
Fasting blood samples were obtained from all included patients. Separated serum samples 
were stored at -80°C until analysis. Serological testing of H. pylori and CagA status, pepsino-
gens I and II, gastrin, and intrinsic factor antibodies was performed using commercial ELISA 
tests (Orion Diagnostica, Ravo diagnostica, Biohit, Euroimmun). The tests were performed 
according to the instructions of the manufacturers.
Statistical analysis
Two definitions were used for the identification of extensive intragastric intestinal metaplasia 
at surveillance endoscopy: 1) intestinal metaplasia in the random biopsies from at least two 
different intragastric locations (multifocal intestinal metaplasia); 2) moderate or marked 
intestinal metaplasia in at least two random biopsies (severe grades of intestinal metaplasia). 
Chi-square tests and t-tests were used to evaluate clinical, histological and serological pa-
rameters in patients with extensive intestinal metaplasia as compared to patients with no or 
only limited intestinal metaplasia at surveillance endoscopy. Associations with the presence 
of extensive intestinal metaplasia were estimated with univariate and multivariable logistic 
regression analysis. The most important predictors were selected using Akaike’s Information 
Criterion (AIC) (14). The use of AIC corresponds roughly to a p-value < 0.15 for selection of 
predictors. Multivariable logistic regression analysis was initially performed within the differ-
ent categories of parameters, i.e. clinical, histological and serological parameters. Thereafter, 
the most important parameters were combined in a simple clinical score, based on the 
regression coefficients. The odds ratio (OR) with 95% confidence intervals (CIs) was used as 
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measure of association. A two-sided p-value < 0.05 was considered statistically significant. 
Discriminative ability of the clinical score was quantified by the area under the receiver op-
erating characteristic curve (AUC). The internal validity of the regression model was assessed 
by “bootstrapping” techniques. Random bootstrap samples were drawn with replacement 
from the full sample. The discriminative ability of the regression model was determined on 
the bootstrap samples and on the full sample, in which predictions were based on the re-
gression models fitted on the bootstrap samples. This technique gives an impression of how 
“over-optimistic” the model is, i.e. how much the performance of the model may deteriorate 
when applied to a new group of similar patients. (15-17) Analyses were performed with SPSS 
software (v 11.5, SPSS Inc, Chicago, Ill) and R software (v 2.5.1, R: A Language and Environ-
ment for Statistical Computing, Vienna, Austria, http://www.R-project.org).
reSuLTS
In total, 88 patients (43 men, 45 women) with a mean age of 60.4 years (range 24.0-75.9) 
underwent a surveillance endoscopy at a mean follow-up interval of 1.7 years (SD 1.5) after 
initial diagnosis. Seventy-one patients (81%) were from native Dutch and 17 (19%) from non-
Dutch origin. Previous peptic ulcer disease was reported in the medical records of 25 patients 
(28%), and H. pylori eradication therapy in the records of 36 patients (41%).
Baseline endoscopy
At the initial baseline endoscopy, a gastric ulcer was present in one patient (1%), gastric ero-
sions in nine patients (10%), and a gastric polyp in five patients (6%) (histology of polyps 
showed intestinal metaplasia in four patients and hyperplasia in one patient). The gastritis 
stage according to the OLGA system was assessed in 68 patients (77%), and showed stage 
0 gastritis in 22 patients, stage I in one patient, stage II in 27 patients, stage III in 14 patients 
and stage IV in four patients.
Surveillance endoscopy
At surveillance endoscopy, the presence of intestinal metaplasia was confirmed histologi-
cally in 63/88 patients (72%), whereas in 25/88 patients (28%) no intestinal metaplasia was 
detected in the random biopsies. Of these latter patients, atrophic gastritis was diagnosed 
as most severe histological finding in only one patient, and moderate or marked chronic 
gastritis in three patients. The remainder had only mild chronic gastritis or no histological 
abnormalities. In total, 7/25 (28%) patients in whom the presence of intestinal metaplasia 
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was not confirmed, had received H. pylori eradication between baseline and surveillance 
endoscopy. 
In patients with intestinal metaplasia at surveillance endoscopy, the most severe grade of 
intestinal metaplasia was mild in 12/63 patients (14%), moderate in 19/63 patients (22%), and 
marked in 32/63 patients (36%) (Table 1). Dysplasia was detected in 7/32 patients (22%) with 
marked intestinal metaplasia. Intestinal metaplasia was located in the distal part of the stom-
ach (antrum and/ or angulus) in 23/88 patients (26%), in 13/88 patients (15%) in the proximal 
part of the stomach (corpus and/ or cardia) and in 27/88 patients (31%) in both parts of the 
stomach. According to the OLGA classification system, stage 0 gastritis was detected in most 
patients (40%), whereas stage I, stage II, stage III, and stage IV were present in respectively 
5%, 24%, 23%, and 9% of patients. 
Intragastric extent of intestinal metaplasia
The prevalence of extensive intestinal metaplasia at surveillance endoscopy within the study 
population varied dependent on the definition used for this diagnosis (multifocal intestinal 
metaplasia vs. severe grades of intestinal metaplasia) (Table 1). Intestinal metaplasia was 
present in the biopsies from at least two different intragastric locations (multifocal intestinal 
metaplasia) in 51 patients (51/88 (58%) of included patients; 51/63 (81%) of patients with 
histologically confirmed intestinal metaplasia, 6/51 (12%) had gastric dysplasia in the ran-
dom biopsies. Forty-two patients (respectively 48%; 67%) had moderate or marked intestinal 
metaplasia in two or more biopsies (severe grades of intestinal metaplasia); five (12%) of 
whom had gastric dysplasia in the random biopsies. The OLGA gastritis stage at surveillance 
endoscopy was strongly associated with both intestinal metaplasia in the biopsies from at 
least two different intragastric locations (multifocal intestinal metaplasia) and moderate or 
marked intestinal metaplasia in two or more biopsies (severe grades of intestinal metaplasia) 
(both p<0.001). 
Patients with multifocal intestinal metaplasia significantly more often had a first-degree 
relative with gastric cancer (p=0.05), moderate or marked intestinal metaplasia (p=0.005), 
and a high OLGA gastritis stage at the index biopsy (p=0.01). They also used alcohol more 
frequently (p=0.002) and had a lower mean pepsinogen I to II ratio (p<0.001), and lower mean 
gastrin level (p=0.04) as compared to patients with no or only limited intestinal metaplasia 
(Table 1). Most of these factors were also significantly associated with severe grades of intes-
tinal metaplasia, but most odds ratios were closer to one (Table 1). In multivariable analysis, 
alcohol use, moderate or marked intestinal metaplasia at index biopsy, and a pepsinogen 
I to II ratio <3.0 were identified as most important for finding intestinal metaplasia in the 
biopsies from at least two different intragastric locations (multifocal intestinal metaplasia) 
and moderate or marked intestinal metaplasia in two or more biopsies (severe grades of 
intestinal metaplasia) (Table 1).
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A predictive score included a family history of gastric cancer (2 points), alcohol use ≥ 1 
unit/day (1 point), the grade of intestinal metaplasia at the index biopsy (moderate 1 point; 
marked 3 points), and a pepsinogen I to II ratio <3 (3 points) (Table 2). With a score ≥ 4 points, 
multifocal intestinal metaplasia was present in 96% of patients and severe grades of intestinal 
metaplasia in 92% of patients (Table 2).
 The area under the receiver operating characteristic curve (AUC) for having intestinal 
metaplasia at at least two different intragastric locations (multifocal intestinal metaplasia) 
was 0.90, which was expected to decrease to 0.86 for future patients according to a bootstrap 
procedure that included the model selection. For moderate or marked intestinal metaplasia 
in two or more biopsies (severe grades of intestinal metaplasia), the AUC was expected to 
decrease from 0.88 to 0.86. 
Table 2. Clinical risk score for the prediction of extensive intestinal metaplasia. The score is based on the 
regression co-efficients in multivariable logistic regression analysis of risk factors for intestinal metaplasia 
in biopsies from at least two intragastric locations (multifocal intestinal metaplasia).
At least two locations with IM Moderate/ marked IM in two or more biopsies
Score 0-1
n=32
8 (25%) 5 (16%)
Score 2-3
n=19
13 (68%) 10 (53%)
Score ≥ 4
n=25
24 (96%) 23 (92%)
Score (0 – 9 points):
a. Family history of gastric cancer: 2 points
b. Alcohol use ≥ 1 unit/ day: 1 point
c. Intestinal metaplasia at index biopsy: moderate =1 point/ marked= 3 points
d. Pepsinogen I to II ratio <3.0: 3 points
DIScuSSIon
This study clearly identifies a family history of gastric cancer, a pepsinogen I to II ratio <3.0, 
the presence of moderate or marked intestinal metaplasia in the index biopsy and alcohol use 
with an average of at least one unit per day as important predictive parameters for extensive 
intestinal metaplasia at surveillance endoscopy. Our study adds to existing knowledge of risk 
factors for progression of pre-malignant gastric lesions to gastric cancer by combining these 
individual risk factors into a risk stratification rule that can be used as a simple clinical tool 
to select high-risk patients for endoscopic surveillance. As extensive intestinal metaplasia 
can be predicted with high sensitivity by a predictive score ≥4, surveillance of intestinal 
metaplasia can be recommended in routine clinical practice in these patients. 
The predictive factors of this study are consistent with observations in various previous 
studies, yet none of them is routinely used to select patients for endoscopic surveillance. 
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Firstly, family members of patients with gastric cancer are known to suffer more frequently 
of pre-malignant gastric lesions. They have for instance been reported to have a seven times 
higher prevalence of atrophic gastritis as compared to patients with non-ulcer dyspepsia. 
(18;19) Therefore, prophylactic H. pylori screening and eradication has been recommended 
in these subjects. (18;20-22) Secondly, previous studies have shown that the presence and 
intragastric extent of atrophic gastritis can be assessed with serological testing of pepsino-
gen levels. (23-26) In addition, high negative predictive values for intestinal metaplasia and 
dysplasia have been demonstrated by these serological markers as well. (27) Moreover, a pro-
spective cohort study showed that the combination of serum pepsinogen levels indicative 
of atrophic gastritis and absence of anti-H. pylori antibodies was associated with a more than 
eight times higher risk to develop gastric cancer, as compared to subjects with normal pep-
sinogen levels and absence of H. pylori antibodies. (28) These results have led to implementa-
tion of risk stratification with serological parameters in gastric cancer screening programs in 
some regions of Japan. (29) Pepsinogen testing is performed with standard ELISA techniques. 
Thirdly, the severity of intestinal metaplasia according to the Sydney classification system 
has been described as an important predictor of gastric cancer risk, which seems superior to 
classification into complete or incomplete intestinal metaplasia. (9;30-32) Fourthly, frequent 
alcohol use has also been shown to contribute to gastric cancer risk in previous studies. (9)
Although the association between extensive intragastric intestinal metaplasia and the 
above-mentioned risk factors has been confirmed in this study, an association with a few 
other risk factors, which would have been expected on the basis of previous study results, has 
not been demonstrated. Strikingly, we observed no association between extensive intragas-
tric intestinal metaplasia and age, smoking or male sex, which are established risk factors for 
the development of gastric cancer. (9;33-35) It may well be that these factors are less strongly 
associated with extensive intestinal metaplasia in this specific selection of patients with pre-
existing changes of the gastric mucosa, however, these findings may have also resulted from 
the relatively limited number of patients included in this study. 
Although our study describes a systematic cross-sectional study of several predictive fac-
tors of extensive intestinal metaplasia, potential limitations warrant consideration. We used 
extensive intragastric intestinal metaplasia as a marker of gastric cancer risk. Unfortunately, 
no definitions of extensive intragastric intestinal metaplasia have been published previ-
ously. Current histological classifications provide guidelines to score the severity of intestinal 
metaplasia in individual biopsy specimens, but do not provide any instructions for combined 
intragastric scores of both severity and extent of intestinal metaplasia. Therefore, two new 
definitions were used in this study (multifocal intestinal metaplasia vs. severe grades of 
intestinal metaplasia). A high correlation was shown between both definitions, and both 
definitions were also highly associated with the presence of dysplasia and with the gastritis 
stage according to the OLGA classification system. Therefore, the use of these definitions to 
identify risk factors for carcinogenic progression seems justified. Nevertheless, a prospec-
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tive cohort study should confirm the proposed risk stratification in patients with intestinal 
metaplasia and validate the definitions of extensive intestinal metaplasia as risk factors for 
development of gastric cancer, even though such a study may require considerable costs 
and time as follow-up of a large cohort of patients is required. Also, sampling error and pos-
sibly also H. pylori eradication are the most likely explanations for the inability to confirm the 
diagnosis of intestinal metaplasia in a fourth of patients and for the detection of dysplasia 
in seven patients in this study. As intestinal metaplasia is known to be a multifocal condition 
and all patients were selected on the basis of their histological abnormalities at baseline, the 
‘regression’ observation was fully according to expectation. A similar phenomenon has been 
observed in previous studies with a cohort follow-up design. (2) These findings emphasize 
the need for the development of an accurate biopsy strategy during surveillance endoscopy 
of pre-malignant gastric lesions. Moreover, a relatively small number of patients was included 
in the multivariable analysis of this study. From a clinical background perspective, we have 
categorized the input parameters into a limited number of groups and these showed to be 
valuable for risk categorization. In the analysis, 16 potential risk factors were considered with 
a total of 22 degrees of freedom, while we had 51 events in the statistical analyses. Therefore, 
external validation of our findings is required. Finally, the proposed risk score and its exact 
cut-off point to omit or perform a surveillance endoscopy need further validation before it 
can routinely be applied in clinical practice. The discriminative ability remained good (>0.85) 
at internal validation with bootstrapping, but differences between clinical settings may affect 
the external validity of the proposed score.
In conclusion, the presence of a family history of gastric cancer, alcohol intake of at least 
one unit daily, moderate or marked intestinal metaplasia in a routine biopsy, and a low pep-
sinogen I to II ratio are associated with high risk of extensive intragastric intestinal metaplasia. 
A high risk score based on the presence of these parameters indicates a severely affected 
gastric mucosa and the need to consider surveillance endoscopy in due time.
SummAry
Patients with extensive intragastric intestinal metaplasia are at increased gastric cancer risk. 
However, the intragastric extent of intestinal metaplasia is usually unknown at the time of 
diagnosis. In this study, we showed that a risk score of clinical, histological and serological 
parameters can predict the presence of extensive intragastric intestinal metaplasia and may 
serve as a tool to select patients for surveillance endoscopy in routine clinical practice.
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AbSTrAcT
background: Endoscopic surveillance of pre-malignant gastric lesions may add to gastric 
cancer prevention. However, the appropriate biopsy regimen for optimal detection of the 
most advanced lesions remains to be determined. Therefore, we evaluated the yield of endo-
scopic surveillance by standardized and targeted biopsy protocols.
methods: In a prospective, multi-center study, patients with intestinal metaplasia (IM) or 
dysplasia (DYS) underwent a surveillance gastroscopy. Both targeted biopsies from macro-
scopic lesions and 12 random biopsies from standardized locations (antrum, angulus, corpus, 
cardia) were obtained. Appropriate biopsy locations and the yield of targeted versus random 
biopsies were evaluated.
results: In total, 112 patients with IM (n=101), or low-grade (n=5) and high-grade DYS (n=6) 
were included. Diagnosis at surveillance endoscopy was atrophic gastritis (AG) in 1, IM in 
77, low-grade DYS in 2, high-grade DYS in 3, and gastric cancer in 1 patient. The angulus 
(40%), antrum (35%) and lesser curvature of the corpus (33%) showed the highest prevalence 
of pre-malignant conditions. Random biopsies from the lesser curvature had a significantly 
higher yield as compared to the greater curvature of the corpus in diagnosing AG and IM 
(p=0.05 and p=0.03). Patients with IM at the cardia were at high risk of a concurrent diagnosis 
of dysplasia or gastric cancer. High-grade DYS was detected in targeted biopsies only. 
conclusions: Surveillance endoscopies of pre-malignant gastric lesions in a population at 
an overall low gastric cancer risk require both targeted and random biopsies from antrum, 
angulus, corpus, in particular along the lesser curvature, and cardia.
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InTroDucTIon
Most gastric carcinomas are preceded by a cascade of detectable precursor lesions, i.e. atro-
phic gastritis, intestinal metaplasia and dysplasia. (1) Endoscopic surveillance of patients with 
these lesions may lead to early detection of advanced precursor lesions and early cancer. (2;3) 
Yet, the appropriate biopsy strategy during endoscopic surveillance of pre-malignant gastric 
lesions is unclear. 
Even though image quality of standard video endoscopes has improved considerably over 
the past decade, the correlation between findings at conventional endoscopy and the histo-
logical diagnoses of pre-malignant gastric lesions remains far from satisfactory. (4) Although 
advanced endoscopic techniques may improve the detection of pre-malignant gastric lesions, 
current detection and surveillance in routine practice still relies on histological assessment of 
random biopsies, obtained during conventional endoscopy. (5;6)
The updated Sydney classification system is currently the most widely accepted guideline 
to classify and grade gastritis. (7) According to this guideline, two biopsies from the antrum, 
two from the corpus and one from the incisura angularis should be obtained. Although this 
biopsy protocol generally establishes the correct Helicobacter pylori status and the presence 
of gastritis, it is controversial whether five gastric biopsies are sufficient for an adequate diag-
nosis of pre-malignant gastric lesions. (8-10) This controversy probably results from variation 
in the intragastric extent of pre-malignant lesions in different populations. (11-13) It can be 
assumed that in patients from populations at high risk of gastric cancer the occurrence of 
extensive atrophic gastritis and intestinal metaplasia is higher. Therefore, fewer biopsies for 
an accurate diagnosis of precursor lesions are likely to be required in comparison to patients 
from a population at low risk. In addition, for the detection of gastric dysplasia, it has been 
argued that random biopsies are insignificant in comparison to targeted biopsies, since 
dysplastic mucosal changes tend to be focal. (14) Against this background, the appropriate 
biopsy protocol for endoscopic surveillance of pre-malignant gastric lesions is unclear.
In this study, we aimed to evaluate the yield of endoscopic surveillance with a standard-
ized biopsy protocol in patients with pre-malignant gastric lesions, within a population at 
an overall low gastric cancer risk. In order to identify the most optimal biopsy strategy dur-
ing surveillance endoscopy, we evaluated the appropriate biopsy locations and number of 
biopsies, and the yield of targeted versus random biopsies.
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meThoDS
Patients
Consecutive outpatients with a previous histologically confirmed diagnosis of intestinal 
metaplasia or dysplasia of the gastric mucosa were invited to participate in this prospective, 
multi-center study. All patients underwent a surveillance endoscopy between March 2006 
and June 2007. Patients with a previous diagnosis of upper gastrointestinal malignancy, 
and/ or a history of oesophageal or gastric surgery were excluded. The institutional review 
boards of the participating hospitals approved this study and written informed consent was 
obtained from all patients prior to surveillance endoscopy. 
Endoscopy
All patients underwent a conventional upper gastrointestinal endoscopy using a standard 
forward-viewing video gastroscope (Olympus GIF-Q160, Olympus Optical Co., Tokyo, Japan). 
All procedures were performed by experienced senior endoscopists. Biopsy samples were 
first obtained from any endoscopically detected focal lesion. In addition, twelve biopsies for 
histological assessment were taken from five standardized intragastric locations: 4 quadrant 
biopsies from the antrum (2-3 cm proximal to the pylorus), 2 from the angulus, 4 from the 
mid corpus (2 from the lesser curvature, 2 from the greater curvature) and 2 from the cardia 
(Figure 1). Furthermore, two additional biopsies (one corpus and one antrum) were used for 
H. pylori culture.
Figure 1. Random biopsy scheme: biopsies were obtained from five standardized intragastric locations. 
(Adapted from Dixon et al. (7))
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Figure 1. Random biopsy scheme: biopsies were obtained from five standardized 
intragastric locations. 
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Histological assessment
Gastric biopsy specimens were fixed in buffered formalin and embedded in paraffin. The slide 
sections were stained with haematoxylin and eosin (H&E). Two expert gastro-intestinal pa-
thologists assessed all histological sections from the index and surveillance endoscopy (HVD, 
NVG). In case of disagreement on the presence of intestinal metaplasia or grade of dysplasia, 
a third expert gastrointestinal pathologist was consulted (GM). The final diagnosis was based 
on the majority diagnosis, i.e. two of three pathologists agreed upon the diagnosis. The pa-
thologists were unaware of the identity of patients, initial (routine) histological diagnosis of 
the index biopsy, endoscopic findings, and histological diagnosis of the other pathologists. 
All histological sections were assessed according to the updated Sydney classification system. 
The following items were evaluated separately: H. pylori density, acute inflammation (neutro-
phil infiltration), chronic inflammation (mononuclear infiltration), gastric glandular atrophy, 
and intestinal metaplasia. All items were scored from 0 (absent), to 1 (mild), 2 (moderate), or 
3 (marked), as defined in the Sydney classification system. (7) The revised Vienna classification 
was used for the assessment of neoplasia. (15;16)
Statistical analysis
Continuous data were compared using the Student’s t-test; categorical data were analyzed 
using the chi-square test. Two-sided statistical significance was set at a p-value < 0.05. In order 
to identify the optimal number and location of random biopsies, the following fictive random 
biopsy schemes were tested for the accuracy to detect intestinal metaplasia, and dysplasia 
or gastric cancer in comparison to the study random biopsy scheme: A) conventional Sydney 
system biopsy regimen (2 antrum, 1 angulus, 1 greater curvature corpus, 1 lesser curvature 
corpus), B) 7 random biopsies (3 antrum, 1 angulus, 1 greater curvature corpus, 2 lesser cur-
vature corpus), and C) 9 random biopsies (3 antrum, 2 angulus, 1 greater curvature corpus, 
2 lesser curvature corpus, 1 cardia). The fictive biopsy schemes were composed of randomly 
selected biopsies originating from the study biopsy scheme. 
reSuLTS
Baseline characteristics
A total of 112 patients were included. All had in the past undergone upper gastrointestinal 
endoscopy with gastric biopsy sampling, and according to the main inclusion criteria all had 
been histologically diagnosed with gastric intestinal metaplasia (n=101) or dysplasia (n=11; 
5 low-grade and 6 high-grade) at baseline (Table 1). The mean interval between the former 
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endoscopy and the current surveillance endoscopy was 2.3 years (SD 2.4) for patients with 
intestinal metaplasia, 2.9 years (SD 1.7) for patients with low-grade dysplasia, and 2.6 years 
(SD 2.7) for patients with high-grade dysplasia. 
Outcome at surveillance endoscopy
A total of 37/ 112 (33%) patients had histological evidence of moderate or marked chronic 
active gastritis. In nine of them the presence of H. pylori infection was confirmed by either 
culture (n=4) or histology (n=5). The remaining 103 (92%) patients had no signs of H. pylori 
infection, 22 (21%) of them had received H. pylori eradication treatment prior to the baseline 
endoscopy of this study and 21 (20%) received H. pylori eradication treatment between both 
study endoscopies. A total of 4 of the 82 patients (5%) who did not receive H. pylori eradica-
tion treatment between both study endoscopies and had no current evidence of H. pylori, still 
had histological evidence of this bacterium during the previous baseline endoscopy several 
years before. In these patients H. pylori colonization was lost spontaneously in the presence 
of atrophy and intestinal metaplasia.
The presence of intestinal metaplasia was confirmed at surveillance endoscopy in 72 of 101 
patients (71%) with intestinal metaplasia at baseline, in 1/ 101 patient (1%) atrophic gastritis 
was detected and in 26/ 101 patients (26%) no pre-malignant lesion was diagnosed (Table 
2). Two (2%) of 101 patients showed progression to low-grade dysplasia. Amongst the five 
Table 1. Baseline characteristics of our study population.
Intestinal 
metaplasia
n=101
Low-grade dysplasia
n=5
High-grade 
dysplasia
n=6
Age (mean) (SD) 60.7 (11.6) 59.5 (9.7) 70.1 (7.7)
Sex (M/ F) 50/ 51 4/ 1 4/ 2
Ethnicity
- Caucasian
- Non-Caucasian
80
21
3
2
6
0
Smoking
- Non-smoker
- Current smoker
- Former smoker
44
16
37
2
1
2
3
0
3
Alcohol
- Non- drinker (<1 unit/day)
- Drinker (≥1 unit/day)
63
34
4
1
4
2
Medication use
- PPI
- NSAIDs/ Aspirin
54
18
4
1
5
2
Dyspeptic complaints 43 1 2
Family history of gastric cancer (≥ 1 first-degree 
relative)
10 0 2
H. pylori eradication therapy 41 3 4
Ch
ap
te
r 1
0
167
Biopsy strategies in patients with pre-malignant gastric lesions
patients with low-grade dysplasia at baseline, intestinal metaplasia was diagnosed as most 
severe lesion at surveillance endoscopy in all patients and no progression was observed. 
Amongst the six patients with high-grade dysplasia at baseline, one had at the index en-
doscopy undergone a mucosal resection of a polypoid lesion, and no further pre-malignant 
gastric lesion was diagnosed at surveillance endoscopy. A second patient was at follow-up 
diagnosed with intestinal metaplasia as most advanced lesion, and endoscopic surveillance 
is being continued. In three patients with high-grade dysplasia at baseline this diagnosis was 
confirmed at surveillance endoscopy. Subsequently, these patients respectively underwent 
endoscopic mucosal resection, endoscopic submucosal dissection, and a partial gastrectomy. 
Histology of the resection specimens revealed an intramucosal well-differentiated adenocar-
cinoma, high-grade dysplasia and a moderately-differentiated adenocarcinoma with invasion 
into the muscularis mucosae (TisN0Mx), respectively. One patient with a previous diagnosis 
of high-grade dysplasia was diagnosed with gastric cancer at the surveillance endoscopy 
after an interval of 5 years. In this patient, six follow-up endoscopies with random biopsy 
sampling had been performed in the interval between baseline endoscopy and inclusion 
in this study, showing only low-grade dysplasia or intestinal metaplasia. After the diagnosis 
of gastric cancer, this patient underwent a partial gastrectomy. Histology of the resection 
specimen revealed an adenocarcinoma of the intestinal type with limited invasion into the 
muscularis propria (T2N0Mx). 
In summary, no pre-malignant lesions were diagnosed at surveillance endoscopy in 28 pa-
tients, atrophic gastritis in 1, intestinal metaplasia in 77, low-grade dysplasia in 2, high-grade 
dysplasia in 3, and gastric cancer in 1 patient.
Intragastric locations of pre-malignant gastric lesions
Overall, the highest prevalence of pre-malignant diagnoses (i.e. atrophic gastritis, intestinal 
metaplasia and dysplasia) was present in random biopsies from the angulus (39%) (86 of 
221 random biopsies from the angulus), as compared to 24% in biopsies from the greater 
Table 2. Cross-tabulation comparing baseline histological diagnoses with diagnoses at surveillance 
endoscopy.
Baseline
Follow-up histology: most advanced (pre-)malignant diagnosis
None Atrophic 
gastritis
Intestinal 
metaplasia
Low-grade 
dysplasia
High-grade 
dysplasia
Gastric cancer
Intestinal metaplasia
N=101
26 1 72 2 0 0
Low-grade dysplasia
N=5
1 0 4 0 0 0
High-grade dysplasia
N=6
1 0 1 0 3* 1
Legend: * Histology of resection specimens during follow-up revealed an adenocarcinoma in two 
patients.
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curvature of the corpus, 27% in biopsies from the cardia, 31% in biopsies from the lesser 
curvature of the corpus and 35% in biopsies from the antrum (Table 3). Atrophic gastritis was 
most frequently diagnosed in random biopsies from the lesser curvature of the corpus and 
angulus, with an overall prevalence of 27% of all random biopsies at both sites. Intestinal 
metaplasia was most frequently diagnosed in random biopsies from angulus and antrum, 
with an overall prevalence of respectively 38% and 35%. Random biopsies from the lesser 
curvature had a significantly higher yield in diagnosing atrophic gastritis and intestinal meta-
plasia as compared to biopsies from the greater curvature of the corpus (p=0.05 and p=0.03). 
Within the random biopsy samples, dysplasia or gastric cancer was only detected in random 
biopsies from the lesser curvature of the corpus, angulus or antrum (prevalence respectively 
1.4%, 0.9% and 0.5%).
Intragastric extent of pre-malignant gastric lesions
Atrophic gastritis was present in the random biopsies from 67/ 112 patients (60%) at surveil-
lance endoscopy, either as most severe lesion or concomitant lesion. In 55 (82%) of these 
patients two or more random biopsies were affected. In comparison, intestinal metaplasia 
was present in the random biopsies from 82/ 112 patients (73%) at surveillance endoscopy, 
either as most severe (n=79) or concomitant lesion (n=3). The higher prevalence of intestinal 
metaplasia (73%) as compared to atrophic gastritis (60%) in the random biopsies was pre-
dominantly caused by the diagnosis of focal (mild) intestinal metaplasia within a biopsy with 
normal glandular structures in the rest of the biopsy. In 72/ 82 (88%) patients two or more 
random biopsies were affected. In patients with moderate or marked intestinal metaplasia as 
most severe histological diagnosis at surveillance endoscopy, significantly more intragastric 
biopsies were affected as compared to patients with only mild intestinal metaplasia (mean 
number of biopsies 5.2 versus 2.4, respectively) (p=0.02). Patients with three or more random 
biopsies with intestinal metaplasia were significantly older as compared to patients with no 
or only limited intestinal metaplasia (63.2 versus 58.7 years, respectively) (p=0.01) (Figure 2). 
Table 3. The prevalence of pre-malignant gastric lesions per biopsy site, based on most severe diagnosis 
within each biopsy.
Biopsy location No. random 
biopsies
Normal/only 
mild chronic 
gastritis
Moderate/
marked chronic 
gastritis
Atrophic 
gastritis
Intestinal 
metaplasia
Dysplasia Gastric 
cancer
Cardia 210 140 (67%) 14 (7%) 5 (2%) 51 (24%) 0 (0%) 0 (0%)
Corpus, lesser 
curvature
219 138 (63%) 11 (5%) 8 (4%) 59 (27%) 1 (0.5%) 2 (1%)
Corpus, greater 
curvature
224 155 (69%) 16 (7%) 11 (5%) 42 (19%) 0 (0%) 0 (0%)
Angulus 221 121 (55%) 12 (5%) 2 (1%) 84 (38%) 0 (0%) 2 (1%)
Antrum 444 265 (60%) 23 (5%) 2 (0.5%) 152 (34%) 2 (0.5%) 0 (0%)
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Low-grade dysplasia was detected as most severe lesion in a single random biopsy in three 
patients.
In 31 of 82 patients (38%) with intestinal metaplasia in the random biopsies, this lesion was 
restricted to the angulus and/ or antrum, whereas in 17 (21%) patients the lesser curvature 
of the corpus and cardia were affected in addition to the angulus and/ or antrum. Patients 
with intestinal metaplasia at the cardia, lesser curvature of the corpus and angulus and/ or 
antrum were at significantly higher risk of a concurrent diagnosis of dysplasia as compared to 
patients with intestinal metaplasia limited to the angulus and/ or antrum (p=0.005).
Random biopsy strategy
Three random biopsy schemes were tested for the accuracy to detect intestinal metaplasia, 
and dysplasia or gastric cancer, in comparison to the study random biopsy scheme consisting 
of 12 random biopsies (Table 4). The updated Sydney protocol for random biopsies detected 
90% of patients with intestinal metaplasia and only 50% of patients with dysplasia or cancer. 
A biopsy protocol consisting of seven random biopsies (3 antrum, 1 angulus, 2 lesser cur-
vature of the corpus and 1 greater curvature of the corpus) was able to diagnose intestinal 
metaplasia in 77/ 79 (97%) cases and low-grade dysplasia or gastric cancer in all four cases 
that were detected as most severe lesion by the study random biopsy protocol. 
Targeted biopsies
In 18 (16%) patients targeted biopsies of endoscopically visible lesions were obtained prior 
to the random biopsy scheme. In nine patients (50%) the lesions were present in the antrum, 
Figure 2. The number of random biopsies affected by intestinal metaplasia for different age categories. 
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in four (22%) in the angulus, in 2 (11%) in the corpus, in 2 (11%) in the cardia and in one (6%) 
in both antrum and corpus. These biopsies showed no pre-malignant gastric lesion in 4/ 18 
(22%), atrophic gastritis in 1/ 18 (6%), intestinal metaplasia in 10/ 18 (56%) and high-grade 
dysplasia in 3/ 18 (17%) patients. 
For the diagnoses of atrophic gastritis or intestinal metaplasia as most severe histological 
diagnosis at surveillance endoscopy, all diagnoses were made in random biopsies and none 
were dependent on targeted biopsies only. However, targeted biopsies were indispensable 
for the diagnosis of high-grade dysplasia in three patients, as the random biopsies showed 
only intestinal metaplasia in two patients and low-grade dysplasia in one patient. In compari-
son, the random biopsy scheme was essential for a diagnosis of low-grade dysplasia in two 
patients and the diagnosis of gastric cancer in one patient. In these patients no macroscopic 
lesions were seen during endoscopy and therefore no targeted biopsies had been obtained.
DIScuSSIon
The understanding of gastric carcinogenesis has largely advanced over the past decades. 
Especially since the recognition of the key role of H. pylori infection and the stepwise progres-
sion of pre-malignant lesions to gastric cancer, gastric cancer research has been focused on 
the development of preventive strategies. Yet, current clinical guidelines principally cover 
detection and treatment of H. pylori infection (17), whereas no clear guidelines are available 
on detection, surveillance and treatment of pre-malignant gastric lesions. As a consequence, 
surveillance of pre-malignant gastric lesions is not performed in the vast majority of patients, 
not even in patients with overt dysplasia. (3) This is remarkable because of the considerable 
cancer risk in these patients, and the fact that premalignant conditions of the stomach de-
spite a continuing decrease are still highly prevalent. (3;18) The Sydney classification system 
Table 4. The yield of fictive random biopsy protocols in accurately diagnosing intestinal metaplasia, and 
dysplasia or gastric cancer as most severe histopathological diagnosis at surveillance endoscopy in 
comparison to the study biopsy protocol.
Biopsy scheme Intestinal 
metaplasia
n=79* (%)
Dysplasia or gastric 
cancer
n=4* (%)
5 biopsies (according to Sydney system) 
  (2 antrum, 1 angulus, 1 greater curvature corpus, 1 lesser  
curvature corpus)
71
(90%)
2
(50%)
7 biopsies 
  (3 antrum, 1 angulus, 1 greater curvature corpus, 2 lesser  
curvature corpus)
75
(95%)
4
(100%)
9 biopsies 
  (3 antrum, 2 angulus, 1 greater curvature corpus, 2 lesser  
curvature corpus, 1 cardia)
77
(97%)
4
(100%)
*Number of patients with diagnosis after study random biopsy protocol. 
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currently provides the endoscopic and histological gold standard for the assessment of 
gastritis. Recently, the OLGA gastritis staging system has been proposed and validated to 
stratify the histological grading results into stages with increasing cancer risk. (19;20) Both 
systems strongly rely on histology, with a recommended biopsy sampling protocol which 
has remained unchanged for more than a decade. Although this biopsy protocol is generally 
adequate for the diagnosis of H. pylori gastritis, it does not sufficiently detect pre-malignant 
gastric lesions, especially in countries with low gastric cancer incidences. (10) 
Therefore, the development of biopsy schemes directed at an accurate diagnosis of pre-
malignant gastric lesions is indicated. Our study shows that with the biopsy protocol accord-
ing to the Sydney classification system at least 10% of patients with intestinal metaplasia 
and a considerable proportion of patients with dysplasia remain unnoticed. To improve the 
biopsy strategy during endoscopic surveillance of pre-malignant gastric lesions, this study 
provides important information on appropriate biopsy locations, number of biopsies and 
the yield of targeted versus random biopsies. With regard to biopsy locations, pre-malignant 
gastric lesions associated with H. pylori infection have been shown to occur most commonly 
in the antrum and incisura angularis. (7;21;22) Subsequently, these lesions spread along the 
lesser curvature and are especially common in the transitional zones (antrum to corpus and 
corpus to cardia). (23) Thus, the most severe (pre-) malignant lesions predominate at the 
lesser curvature of the stomach. (21) Nevertheless, biopsies from the corpus are still habitually 
taken from the greater curvature during routine upper gastrointestinal endoscopy, as these 
biopsies are most easily obtained. Our study supports previous observations, as it clearly 
shows that biopsies of the lesser curvature of the corpus carry a significantly higher yield 
for an adequate histological diagnosis as compared to biopsies from the greater curvature 
during surveillance of patients with pre-malignant gastric lesions. In this study, biopsies from 
the cardia never showed a more severe lesion as compared to other intragastric biopsy sites 
and were therefore not essential for the identification of pre-malignant gastric lesions. How-
ever, the presence of intestinal metaplasia in biopsies from the cardia identified patients with 
extensive lesions who are at increased risk of a concurrent diagnosis dysplasia and gastric 
cancer. This has also been demonstrated previous studies. (24) Therefore, we still consider 
these biopsies important in the surveillance of pre-malignant gastric lesions.
From a practical point of view, the ultimate scheme for routine biopsy sampling should 
limit the number of random biopsies. We performed this study with 12 random biopsies and 
used this number as the gold standard. With such an approach, we were able to show that the 
Sydney system biopsy protocol is insufficient for surveillance of pre-malignant lesions within 
a population at low gastric cancer risk. We showed that a biopsy protocol requires at least 7 
biopsies (3 antrum, 1 angulus, 1 greater curvature corpus, 2 lesser curvature corpus) to obtain 
an accurate histological diagnosis. With the addition of cardia biopsies for an accurate risk 
estimation of dysplasia or cancer, as mentioned previously, we recommend to obtain a total 
of 9 biopsies during surveillance endoscopies. 
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Nevertheless, caution is needed as we cannot exclude that a considerable further increase 
of the number of random biopsy samples above the 12 specimens per patient would have 
further increased the yield of pre-neoplastic lesions. This is reflected in our study by a con-
siderable proportion of patients in whom the diagnosis of intestinal metaplasia or dysplasia 
at index endoscopy was not confirmed at surveillance. This is a common problem in studies 
evaluating progression of intestinal metaplasia and the effect of H. pylori eradication. (25) 
However, it can be assumed that the majority of patients in whom intestinal metaplasia is not 
confirmed with this extensive biopsy scheme have a patchy and limited intragastric extent of 
metaplasia and in these cases gastric cancer risk is generally low. (26)
With regard to random versus targeted biopsies, atrophy has been described to show 
a more diffuse pattern, whereas intestinal metaplasia and dysplasia tend to be focal. (27) 
This latter observation has led to controversy with regard to obtaining random biopsies in 
patients with dysplastic lesions. Although a relatively low number of patients with dysplasia 
were included, our study shows that random biopsies may be essential to diagnose dyspla-
sia or even gastric cancer. Therefore, our data support the use of random biopsies during 
surveillance of pre-malignant gastric lesions. In addition, it can be argued that patients with 
dysplasia require follow-up even though the lesions are not confirmed during surveillance 
endoscopy, as these lesions may be missed using conventional endoscopy techniques, which 
is supported by the case of gastric cancer in this study. (3)
In conclusion, our study shows that both random and targeted biopsies are essential 
during endoscopic surveillance of intestinal metaplasia and dysplasia of the gastric mucosa. 
An adequate biopsy scheme requires at least 9 random biopsies from the cardia, corpus, in 
particular along the lesser curvature, angulus, and antrum in a population at an overall low 
gastric cancer risk.
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AbSTrAcT
background: Helicobacter pylori infection is a major risk factor for gastric cancer develop-
ment. However, the effect of H. pylori eradication for prevention of gastric cancer is still 
controversial, in particular in patients with pre-malignant gastric lesions.
objectives: To assess the effect of H. pylori eradication therapy on different stages of pre-
malignant lesions of the gastric mucosa, i.e. atrophic gastritis, intestinal metaplasia and 
dysplasia. 
Search strategy: Trials were identified through electronic searches of the Cochrane Library, 
MEDLINE and EMBASE databases, using appropriate subject headings and keywords.
Selection criteria: All randomized controlled trials comparing H. pylori eradication therapy 
with placebo or symptomatic treatment in patients with pre-malignant gastric lesions.
Data collection: Data were collected on histological changes of the gastric mucosa and 
functional parameters of gastric mucosal condition.
main results: Seventeen randomized controlled trials were included. These trials compared 
H. pylori eradication therapy with placebo or anti-acid inhibitory agents and evaluated the 
effect on gastric mucosal changes after 8 weeks to 12 years follow-up. Several studies demon-
strated less progression or even regression of atrophic gastritis within one to two years after 
H. pylori eradication. Significant less progression and more regression of intestinal metaplasia 
after H. pylori eradication has also been reported by three trials, however, another trial with 
relatively long-term follow-up did not confirm this finding. The effect of H. pylori eradication 
on the progression of dysplasia was only reported in two trials, which reached contradictory 
results. Since the outcome measures varied between studies using non-interchangeable 
parameters, quantification of outcomes was not performed.
reviewers’ conclusions: Clinical evidence for the prevention of carcinogenic progression in 
patients with atrophic gastritis is highly suggestive, whereas the evidence in patients with 
intestinal metaplasia and dysplasia is scarce.
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bAckGrounD
Gastric cancer is the fourth most common cancer and second leading cause of cancer-related 
death worldwide. Although the incidence is declining in many populations, the absolute 
number of new cases per year is increasing, due to ageing of the world population. The 
estimated incidence of gastric cancer is approximately 934,000 cases per year, with highest 
rates in Eastern Asia, Eastern Europe and South America. (1)
As symptoms are often absent or non-specific, gastric cancer is frequently diagnosed at an 
advanced stage, with limited therapeutic options. Consequently, gastric cancer carries a poor 
prognosis, with overall five-year survival of less than 20 percent. (2)
The vast majority of gastric malignancies are adenocarcinomas, which can be divided into 
two types: intestinal and diffuse (undifferentiated) type. Intestinal type gastric carcinomas 
account for at least 60 to 75 percent of cancers; in comparison approximately 30% of the 
carcinomas are of the diffuse type. (3;4) In contrast to diffuse type carcinomas, intestinal 
type carcinomas have recognizable precursors: atrophic gastritis, intestinal metaplasia and 
dysplasia. (5) No international guidelines exist for the surveillance or treatment of patients 
with these pre-malignant gastric lesions.
Helicobacter pylori infection is considered to be an important initial step in gastric carcino-
genesis. Infection with H. pylori increases the risk of developing gastric cancer at least six-
fold. (6) In the model of gastric carcinogenesis, H. pylori causes chronic inflammation of the 
gastric mucosa, which slowly progresses through the aforementioned pre-malignant stages 
to gastric adenocarcinoma. It has been estimated that 50 percent of the world population is 
infected with H. pylori. Eradication of this bacterium seems a logical step in the prevention 
of gastric cancer and generally heals chronic H. pylori gastritis. Several studies have shown 
that eradication of H. pylori could be cost-effective for gastric cancer prevention. (7;8) How-
ever, despite data from a considerable number of clinical trials, controversy remains whether 
eradication halts the progression and/or causes the regression of pre-malignant lesions.
objecTIveS
To assess the effect of H. pylori eradication therapy on different stages of pre-malignant le-
sions of the gastric mucosa, i.e. atrophic gastritis, intestinal metaplasia and dysplasia.
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crITerIA for conSIDerInG STuDIeS for ThIS revIew
Types of studies
Inclusion criteria: randomized controlled trials, blinded or unblinded. Both studies evaluating 
the effect of H. pylori eradication on pre-malignant gastric lesions as a primary outcome mea-
sure as well as studies evaluating this effect as a secondary outcome measure were included. 
Abstracts and unpublished studies were also collected with the intention to include these 
studies in future analysis. 
Exclusion criteria: clinical trials without randomization, cross-over studies. We excluded 
studies in which H. pylori eradication was part of a treatment comparison containing ad-
ditional variables which could not be evaluated separately.
Types of participants
H. pylori-positive subjects with pre-malignant gastric lesions (atrophic gastritis, intestinal 
metaplasia, dysplasia) were included. From studies that comprised a mixture of participants, 
with and without pre-malignant gastric lesions, we extracted the data concerning partici-
pants with pre-malignant gastric lesions. The H. pylori status was considered positive when 
assessed by any one of histology, rapid urease test, culture (from antral/ corpus biopsies 
obtained during endoscopy), serology or urea breath test.
Types of interventions
We compared H. pylori eradication versus no treatment (or placebo) and H. pylori eradication 
versus symptomatic treatment (anti-acid inhibitory agents).
We only included studies which used an H. pylori eradication regimen that had been 
acknowledged to achieve at least a 50% eradication rate and was defined as one of the fol-
lowing for at least one week:
(1) PPI dual therapy (PPI plus either amoxicillin or clarithromycin)
(2) PPI triple therapy (PPI plus 2 of the following; amoxicillin, macrolide, 5 nitroimidazole)
(3) H2-receptor antagonist triple therapy (H2-receptor antagonist plus 2 of the following; 
amoxicillin, macrolide, 5 nitroimidazole)
(4) Bismuth triple therapy (bismuth salt and 5 nitroimidazole with either amoxicillin or tetra-
cycline)
(5) Bismuth quadruple therapy (as bismuth triple therapy, but PPI in addition)
(6) Ranitidine Bismuth Citrate dual/triple therapy (as for PPI)
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Types of outcome measures
Primary outcome: improvement of pre-malignant lesions of the gastric mucosa, i.e. atrophic 
gastritis, intestinal metaplasia and dysplasia based on histological assessment. 
Secondary outcomes: deterioration of pre-malignant lesions of the gastric mucosa. 
Other secondary outcomes were functional parameters of gastric mucosal condition (serum 
pepsinogen level, serum gastrin level, vitamin B12 level, acid secretion), as well as adverse 
effects.
SeArch STrATeGy for IDenTIfIcATIon of STuDIeS
A search was conducted to identify all published and unpublished randomized controlled 
trials.
Trials were identified by searching the following electronic databases - The Cochrane 
Library, MEDLINE and EMBASE. Reference lists from trials selected by electronic searching 
were hand searched to identify further relevant trials.
The search strategy for this review was constructed by using a combination of MESH subject 
headings and text words relating to the use of H. pylori eradication therapies in the treatment 
of pre-malignant lesions of the gastric mucosa. No language restrictions were used.
To identify randomized controlled trials, the following search was combined with the 
Cochrane highly sensitive search strategy phases one, two and three as contained in the 
Reviewer’s Handbook (Clarke 2000). 
exp Precancerous Conditions/ 
(pre adj2 (neoplas$ or carcino$ or cancer$ or malignan$ or
cursor)).tw. 
(preneoplas$ or precarcino$ or precancer$ or premalignan$ or
precursor).tw. 
1 or 2 or 3 
exp Gastric Mucosa/ 
(gastric adj2 mucosa).tw. 
5 or 6 
4 and 7 
(gastric adj2 (lesion$ or tissue$ or change$ or alter$)).tw.
Gastritis, Atrophic/ 
(atroph$ adj2 gastr$).tw. 
(intestinal adj2 metaplas$).tw. 
exp Metaplasia/ 
exp Intestinal Neoplasms/ 
13 and 14 
dysplasia.tw. 
(correa$ adj1 cascade).mp. [mp=title, original title, abstract,name of substance word, subject heading word] 
8 or 9 or 10 or 11 or 12 or 15 or 16 or 17 
Helicobacter pylori/ 
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Helicobacter Infections/ 
(helicobacter adj3 pylori).tw. 
(h adj1 pylori).tw. 
(pylori adj3 infect$).tw. 
(pylori adj3 therap$).tw. 
(pylori adj3 eradicat$).tw. 
(pylori adj3 treat$).tw. 
(pylori adj3 positive).tw. 
(pylori adj3 cure).tw. 
(pylori adj3 inhibit$).tw. 
(pylori adj3 coloni$).tw. 
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 
exp Proton Pumps/ 
(proton adj3 pump adj3 inhibit$).mp. [mp=title, original title,abstract, name of substance word, subject heading 
word] 
ppi.tw. 
esomeprazole.mp. 
lanzoprazole.mp. 
Omeprazole/ 
omeprazole.mp. 
pantoprazole.mp. 
rabeprazole.mp. 
exp Histamine H2 Antagonists/ 
(histamine adj1 h2 adj1 antagonist$).tw. 
(h2 adj1 receptor adj2 antagonist adj1 triple).tw. 
burimamide.mp. 
cimetidine.mp. 
famotidine.mp. 
metiamide.mp. 
nizatidine.mp. 
ranitidine.mp. 
exp Amoxicillin/ 
amoxycillin.mp. 
amoxicillin.mp. 
exp Macrolides/ 
macrolide$.mp. 
Clarithromycin/ 
clarithromycin.mp. 
exp Erythromycin/ 
erythromycin.mp. 
azithromycin.mp. 
telithromycin.mp. 
(bismuth adj1 salt$).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
(bismuth adj1 citrate$).tw. 
(bismuth adj1 subcitrate$).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
(colloidal adj1 bismuth).tw. 
(bismuth adj3 therap$).tw. 
Nitroimidazoles/ 
nitroimidazole$.mp. 
(“5” adj1 nitroimidazole$).mp. 
Metronidazole/ 
metronidazole.mp. 
Tinidazole/ 
tinidazole.mp. 
(tripotassium adj1 dicitratobismuthate).mp.
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Tetracycline/ 
tetracycline.mp. 
or/32-75 
31 or 76 
18 and 77
randomized controlled trial.pt.
controlled clinical trial.pt. 
randomized controlled trials.sh. 
random allocation.sh. 
double blind method.sh. 
single blind method.sh. 
clinical trial.pt.
exp clinical trials/ 
(clin$ adj25 trial$).ti,ab. 
((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$)).ti,ab. 
placebos.sh. 
placebo$.ti,ab. 
random$.ti,ab. 
research design.sh. 
comparative study.sh. 
exp evaluation studies/ 
follow up studies.sh. 
prospective studies.sh. 
(control$ or prospectiv$ or volunteer$).ti,ab.
or/79-97 
(animals not humans).sh. 
98 not 99
78 and 100
meThoDS of The revIew
Study selection
The title and abstract of all retrieved references was scanned. The full-text of relevant, eligible 
studies was collected and further assessed.
Data extraction
The following data were extracted:
General information: title, authors, source, year of publication, full text/ abstract, published/ 
unpublished, language 
Trial characteristics: RCT, blinding, duration (follow-up), setting
Study population: in- and exclusion criteria (in particular coexisting gastro-oesophageal 
diseases), number of patients, baseline characteristics, similarity of groups at baseline, 
region (Asian/ non-Asian)
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Intervention: H. pylori eradication method, therapy after eradication failure, treatment of 
control group (no eradication/ placebo/ symptomatic treatment)
Outcome measurement: method of assessment of gastric mucosa (histology, endoscopy, 
functional parameters), method of diagnosing H. pylori infection, method of diagnosing 
H. pylori eradication, number and timing of follow-up gastroscopies, number and site of 
biopsies per gastroscopy 
Outcome:
- Improvement of pre-malignant lesions of the gastric mucosa 
- Deterioration of pre-malignant lesions of the gastric mucosa 
- Change in functional parameters of gastric mucosal condition (pepsinogens, gastrin, 
vitamin B12, acid secretion)
- Adverse effects of H. pylori eradication therapy
Quality assessment 
The quality of included studies was assessed according to the Cochrane Reviewer’s hand-
book. 
The quality assessment criteria include:
1.  Method of randomization
 A. Truly random: computer generated random numbers, coin toss etc.
 B. Quasi random: birth-date, patient registration-number etc.
 C. Not stated/unclear
2.  Allocation concealment
 A.  Adequate: trialist unaware of each participant’s allocation, by for instance central 
randomization systems or serially numbered opaque envelopes etc.
 B. Inadequate: trialist aware of allocations at recruitment
 C. Not stated/ unclear
3.  Blinding
 A. Double blind
 B. Patient/ Doctor blinded 
 C. Unblinded
4.  Blinding of outcome assessment
 A. Blinded
 B. Unblinded
5.  Participant flow
 A. Loss to follow-up described
6.  Intention to treat analysis
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DeScrIPTIon of STuDIeS
A total of 2036 articles were identified by the search strategy. We excluded 1940 clearly 
irrelevant references or unrandomized studies through reading abstracts. Accordingly, 96 
references were retrieved for further assessment. After further assessment, a total of 71 refer-
ences were excluded, mostly because they were not randomized, or duplicated (the data 
of ) other references. One additional reference was identified through scanning reference 
lists of the identified randomized trials and relevant reviews. (9) Five references described 
the study design of ongoing or unpublished trials. (10-14) In addition, one study is awaiting 
assessment after translation from Chinese to English. (15) In total, 20 references fulfilled the 
inclusion criteria. (9;16-34) Five references described different periods of follow-up of two 
original study cohorts. (18;24;26;31;34) Therefore, 17 relevant randomized controlled trials 
were identified. Details of the included trials are shown in Table 1 ‘Characteristics of included 
studies’.
Methodological quality of included studies
An overview of the methodological quality of included randomized controlled trials is 
provided in Table 2 ‘Methodological quality of included studies’. Nine trials mentioned the 
method of randomization and were truly randomized, and seven studies mentioned adequate 
concealment of allocation. Nine studies had a double-blind design, in three studies only the 
doctor or patient was blinded, whereas five studies did not mention any details on blinding. 
In 14 studies the pathologist was blinded to the treatment allocation of study subjects when 
assessing the outcome measures. The loss to follow-up varied from 0% after eight weeks to 
three years follow-up (9;20;23) to 35% after 6 years follow-up (18). Seven studies evaluated 
the effect of H. pylori according to H. pylori status at the end of follow-up, whereas ten studies 
performed an intention to treat analysis.
reSuLTS
Baseline characteristics
Six trials were performed in Asian countries; the other eleven trials were performed in vari-
ous parts of the world (Table 1). Only four studies aimed to evaluate the effect of H. pylori 
on pre-malignant gastric lesions as a primary outcome measure and only included patients 
with these conditions (16;18;23;25;26), whereas the other trials were either population-
based studies or included patients with various gastro-intestinal conditions at baseline. The 
number of patients with pre-malignant gastric lesions that were randomized to the H. pylori 
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eradication treatment or control groups was not clearly mentioned in several studies. This 
has probably resulted from the evaluation of different primary outcome measures, variations 
in presentation of data, for instance, separate evaluation of lesions in corpus and antrum (21), 
and in a few studies from the evaluation of H. pylori eradication in combination with dietary 
supplements. (18;26;33)
Study design
The H. pylori eradication regimens resulted in eradication rates ranging from 48% (19) to 
97% (16). In all trials, histology was used for the diagnosis of pre-malignant gastric lesions. 
Only two studies also used pepsinogen or gastrin serology to evaluate the effect of H. pylori 
eradication on the gastric mucosa (9;20), and one of these studies reported details on the 
effect of H. pylori eradication on gastric acid secretion (20). The biopsy schemes to obtain his-
Table 2. Methodological quality of included studies.
Author Method of 
randomization
(A/B/C)*
Allocation 
concealment
(A/B/C)*
Blinding
(A/B/C)*
Blinding of 
pathologist
(A/B/C)*
Partcipant flow
(n lost to follow-up 
of total study 
population) (%)
Intention to 
treat analysis
Arkkila A C B A 16/92 (17%) No
You A A A A 440/3365 (13%) Yes
Ley A A A A 69/316 (22%) Yes
Befrits C C A A 2/125 (2%) No
Wong A A B A 192/1630 (12%) Yes
Kuipers A C C A NS Yes
Kamada C C A A 0 (0%) No
Correa# A C C A 345/976 (35%) Yes
Mera# A C C A 186/795 (23%) Yes
Sung## A A A A 72/587 (12%) No
Zhou## A A A A 109/552 (20%) No
Leung## A A A A 152/587 (26%) Yes
Mones A A A C 2/85 (2%) No
Schenk C C B A 17/100 (17%) No
Miwa C A A A 5/90 (6%) Yes
Gisbert C C C A 13/135 (10%) No
Moayyedi A A A A 8/41 (20%) Yes
Leri C C C C 0 (0%) Yes
Ohkusa C C C A 0 (0%) Yes
Lazzaroni C C A C 10/59 (17%) No
Legend: * A/B/C-coding as described in ‘Quality assessment’.
#studies desribing the same study cohort
##studies desribing the same study cohort
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tological specimens varied greatly between the trials, from two (27) to seven gastric biopsies 
(33). Similarly, the follow-up period varied greatly, as the effect of H. pylori eradication on the 
gastric mucosa was evaluated after 8 weeks (23) to a maximum of 12 years (26). However, the 
latter study was unblinded after six years and all subjects who were H. pylori positive at that 
time received H. pylori eradication.
Effect of H. pylori eradication on pre-malignant gastric lesions
Several studies demonstrated less progression or even regression of atrophic gastritis within 
one to two years after H. pylori eradication (16-18;20;21;25;28;30;31;33), although some rela-
tively small studies of overall low to moderate methodological quality showed no significant 
difference (9;19;22;23;27;29). Significant less progression and more regression of intestinal 
metaplasia after H. pylori eradication has also been reported by three trials after five months, 
five and six years follow-up. (18;24;29;34) However, another trial did not confirm this find-
ing after nine years follow-up. (33) The effect of H. pylori eradication on the progression of 
gastric dysplasia was only reported in two trials, which reached contradictory results after six 
and nine years follow-up. (18;33) Unfortunately, two other studies with relatively long-term 
follow-up do not report data on progression or regression of the different categories of pre-
malignant gastric lesions. (26;32) Only Wong et al. analyzed the effect of H. pylori eradication 
on the development of gastric cancer in patients with pre-malignant gastric lesions. This 
study demonstrated no significant difference in gastric cancer development between the 
H. pylori eradication and control group. In this study, gastric cancer within patients with pre-
malignant gastric lesions at baseline only occurred in patients who had been diagnosed with 
intestinal metaplasia and dysplasia previously.
DIScuSSIon
Unfortunately, several factors hinder overall evaluation of these randomized controlled trials. 
For instance, the number of included patients with pre-malignant lesions was generally low, 
frequently even unclear, and follow-up in most studies was relatively short. Furthermore, the 
number of biopsies obtained in individual patients was mostly small, leading to imprecise 
results as a consequence of sampling errors. In addition, study outcomes were by some 
evaluated in an intention-to-treat analysis and by others according to H. pylori status at the 
end of follow-up. Most importantly, outcome measures varied between studies using non-
interchangeable parameters such as prevalence changes, histological scores and transition 
percentages. Quantification of the outcomes is therefore difficult. 
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revIewerS’ concLuSIonS
Implications for practice
H. pylori eradication harbours great potential for prevention of gastric cancer. Clinical 
evidence for the prevention of carcinogenic progression in patients with atrophic gastritis is 
highly suggestive, whereas the evidence in patients with intestinal metaplasia and dysplasia 
is scarce. Possibly, frequent loss of H. pylori colonization in these patients indicates limited 
benefit from H. pylori eradication. At this moment, we advise to consider H. pylori eradication 
for prevention of gastric cancer at the earliest stage of gastric carcinogenesis. However, it 
must be realized that H. pylori eradication may be insufficient to halt gastric carcinogenesis in 
patients with intestinal metaplasia and dysplasia.
Implications for research
Although several randomized controlled trials are available on the effect of H. pylori eradica-
tion on pre-malignant gastric lesions, overall evaluation and quantification of the effect are 
hindered by the heterogeneity of the outcome parameters. A meta-analysis of the available 
trials is needed. In this meta-analysis histological improvement of the lesions versus no im-
provement (no change or deterioration) and histological deterioration versus no deteriora-
tion (no change or improvement) need to be investigated. In addition, additional randomized 
controlled trials with long-term follow-up on the effect of H. pylori eradication on intestinal 
metaplasia and dysplasia are required.
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AbSTrAcT
Helicobacter pylori infection is a major risk factor for gastric cancer development. Therefore, H. 
pylori eradication may be an important approach in the prevention of gastric cancer. However, 
long-term data proving the efficacy of this approach are lacking. This report describes two 
patients who developed gastric cancer at respectively 4 and 14 years after H. pylori eradica-
tion therapy. These patients were included in a study cohort of H. pylori-infected subjects 
who received anti-H. pylori therapy during the early years of development of H. pylori eradica-
tion therapy, and underwent strict endoscopic follow-up for several years. In both patients, 
gastric ulcer disease and pre-malignant gastric lesions, i.e. intestinal metaplasia at baseline 
and dysplasia during follow-up, were diagnosed before gastric cancer development. These 
case reports demonstrate that H. pylori eradication does not prevent gastric cancer develop-
ment in all infected patients after long-term follow-up. In patients with pre-malignant gastric 
lesions, in particular in patients with a history of gastric ulcer disease, adequate endoscopic 
follow-up is essential for early detection of gastric neoplasia.
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InTroDucTIon
The development of gastric cancer is strongly associated with Helicobacter pylori infection. 
(1;2) This is in particular true for the development of distal gastric cancer, for which the pres-
ence of H. pylori may be a conditio sine qua non, as in more than 90% of patients current 
or past H. pylori colonization can be demonstrated. (3-5) The association between cancer 
of the gastric cardia appears partly related to H. pylori and partly to other conditions, in 
particular gastro-esophageal reflux disease. (6;7) In the multi-step pathogenesis of intestinal 
type gastric cancer, H. pylori-induced chronic active gastritis slowly progresses through the 
pre-malignant stages of atrophic gastritis, intestinal metaplasia and dysplasia to gastric 
adenocarcinomas. (8-10)
Given its central role in gastric carcinogenesis, eradication of H. pylori may be an effec-
tive approach for prevention of gastric cancer. This hypothesis was firstly supported by the 
concept that gastritis is a key feature in gastric carcinogenesis, and that H. pylori eradication 
virtually always leads to a gradual, complete resolution of chronic active gastritis. (11) Further 
studies showed that H. pylori eradication can also lead to regression of atrophic gastritis. 
(12-17) Therefore, H. pylori eradication has been accepted by many for treatment of atrophic 
gastritis aiming at prevention of gastric cancer. (18) Nevertheless, in patients with lesions that 
have progressed beyond the stage of atrophic gastritis, i.e. patients with intestinal metaplasia 
or dysplasia, H. pylori eradication may have little beneficial effect to prevent gastric cancer. 
(19) These lesions are often associated with decreased colonization density, and ultimately 
even with frequent loss of H. pylori colonization even without active intervention. Therefore, 
further progression of pre-malignant lesions may be less dependent on H. pylori infection. 
These findings implicate that H. pylori eradication would in particular have a long-term 
preventive effect for the development of gastric cancer over the time-frame that it takes to 
progress from non-atrophic gastritis to intestinal metaplasia and gastric dysplasia.
To prove this concept, truly long-term studies are needed. Such long-term data will only 
slowly become available given the fact that H. pylori eradication was only first given twenty 
years ago, in the mid eighties. (11;20) In this case report we describe two patients who re-
ceived eradication therapy for peptic ulcer disease in the first years after the discovery of H. 
pylori, but nevertheless developed gastric cancer during long-term follow-up. Both patients 
belonged to a cohort of patients who were endoscopically diagnosed in the period of 1985 
– 1987 with peptic ulcers or histological evidence of chronic active gastritis, and had a posi-
tive Campylobacter pylori culture. (21) These patients were among the first worldwide to be 
treated for H. pylori and they were followed periodically after H. pylori eradication as part of 
a study protocol. (22;23) 
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cASe 1
A 58-year-old female patient with a past medical history of gastric ulcer disease, underwent 
endoscopic examination because of upper abdominal pain in 1984. Gastroscopy showed 
an erythematous mucosa without erosions or ulcerations, and antral biopsies revealed 
chronic active gastritis with Campylobacter pylori micro-organisms and intestinal metaplasia. 
An attempt to eradicate this bacterium with bismuth subcitrate mono-therapy failed, but 
subsequent treatment with a combination of ranitidin and furazolidone led in 1985 to H. 
pylori eradication as demonstrated by a negative Campylobacter pylori culture and confirmed 
by repeatedly negative histology and culture results in subsequent years. Between 1984 and 
1989, she underwent a total of 23 surveillance endoscopies with intervals ranging from 1 to 
4 months. During follow-up, in 1985, an ulcer was detected at the angulus, which persisted 
for several years despite the absence of H. pylori bacteria. Biopsies from this ulcer were ob-
tained during several follow-up endoscopies and repeatedly showed intestinal metaplasia 
and low-grade dysplasia. In 1989, four years after H. pylori eradication, a well-differentiated 
intramucosal adenocarcinoma (T2N0M0) was diagnosed in biopsies from this persistent 
ulcer. Subsequently, she underwent an intentionally curative total gastrectomy. In 1993, she 
presented with metastasized primary lung cancer and deceased at the age of 67 years, eight 
years after H. pylori eradication.
cASe 2
A 35-year-old male patient presented with dyspeptic complaints in 1985 and was subsequently 
diagnosed with a gastric angular ulcer at gastroscopy. Biopsies from the angulus and antrum 
Figure 1. Case 2: Histological examination of initial antral biopsy (1985) only shows intestinal metaplasia 
without dysplasia. Original magnification 100x, H&E staining.
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Figure 1. 
Case 2: Histological examination of initial antral biopsy (1985) only shows intestinal 
metaplasia without dysplasia. Original magnification 100x, H&E staining. 
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showed active chronic gastritis with presence of Campylobacter pylori micro-organisms and 
intestinal metaplasia (Figure 1). Various treatment attempts to eradicate the infection were 
performed, using H2-receptor antagonists, bismuth subcitrate, sucralfate, and triple therapy 
consisting of a combination of bismuth subcitrate, amoxicillin and metronidazole. After 
five years of repeated treatment, H. pylori was eradicated in 1990 as confirmed by histology 
showing disappearance of the bacteria and resolution of gastritis, and the angular ulcer 
finally healed. Within ten years of follow-up after initial treatment, this patient underwent 19 
follow-up endoscopies with histological evaluation at intervals ranging from 1 to 12 months. 
During further follow-up, no macroscopic abnormalities of the gastric mucosa were detected 
at endoscopy and antral biopsies showed no H. pylori bacteria or active chronic gastritis. 
However, intestinal metaplasia and low-grade dysplasia were repeatedly observed. In 2004, 
14 years after H. pylori eradication, he was endoscopically re-examined because of recurrent 
complaints of dyspepsia and heartburn. At this endoscopy, a pyloric ulcer was detected 
(Figure 2), and histological examination of biopsies showed a poorly-differentiated adeno-
carcinoma of the intestinal type (T4N1M0) (Figure 3). Subsequently, an intentionally curative 
distal gastric resection with subtotal pancreaticoduodenectomy was performed. However, in 
2006 at the age of 56 years, he presented with distant liver metastases and deceased shortly 
thereafter, 16 years after H. pylori eradication.
DIScuSSIon
This report describes two patients who were once included in one of the first study cohorts 
that underwent H. pylori eradication treatment for gastritis or peptic ulcer disease. The length 
and intensity of follow-up of these patients is therefore unique, even more so because data 
from Western populations on the effect of H. pylori eradication for gastric cancer prevention 
Figure 2. Case 2: Endoscopic image of the ulcerative, pyloric lesion during follow-up (2004). 
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Figure 2. 
Case 2: Endoscopic image of the ulcerative, pyloric lesion during follow-up (2004).
Figure 3.
Case 2: Histological examination of biopsies of ulcerative, pyloric lesion (2004)
s ows a poorly-differentiated adenocarcin ma of the intestinal type. Original 
magnification 150x, H&E staining. 
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are scarce. These case reports show that H. pylori eradication does not prevent the develop-
ment of gastric cancer in all patients during long-term follow-up, in particular not in patients 
who already developed pre-malignant gastric lesions prior to H. pylori eradication.
As progression from H. pylori gastritis to gastric cancer generally takes years to decades, 
evaluation of long-term follow-up after eradication, such as provided in these case reports, 
is essential to assess the true impact of H. pylori eradication on gastric carcinogenesis. The 
reported follow-up in previous studies that assessed the effect of H. pylori eradication on the 
development of gastric cancer as primary endpoint varied between 5 years to 12 years, which 
is too short to adequately assess the true progression to cancer and the preventive effect of 
H. pylori eradication. (16;19;24)
Both patients presented in this report suffered from gastric ulcer disease before the devel-
opment of gastric cancer. It has been described previously that patients with gastric ulcers 
are at increased risk of gastric cancer development, whereas patients with duodenal ulcers 
seem to be protected. (3;25) This probably results from the presence of atrophic gastritis and 
corpus-predominant gastritis in patients with gastric ulcers, whereas these conditions are 
commonly absent in patients with duodenal ulcers.
In case H. pylori eradication therapy is prescribed in patients with pre-malignant gastric 
lesions aiming at gastric cancer prevention, proof of eradication should be obtained. The 
reduced colonization density in these patients may impair the sensitivity of histology and 
culture, as well as that of urea breath testing. Further confirmation of eradication can there-
fore be sought by demonstration of resolution of gastritis or negative seroconversion. The 
latter rarely occurs without active intervention, unless the bacterium spontaneously disap-
pears when severe atrophy and intestinal metaplasia have occurred. (26) In addition, the 
combination of H. pylori eradication with endoscopic surveillance and histological follow-up 
is crucial to detect gastric neoplasia at an early and potentially curative stage. At this moment, 
Figure 3. Case 2: Histological examination of biopsies of ulcerative, pyloric lesion (2004) shows a poorly-
differentiated adenocarcinoma of the intestinal type. Original magnification 150x, H&E staining.
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Case 2: Endoscopic image of the ulcerative, pyloric lesion during follow-up (2004).
Figure 3.
se 2: Histological examination of biopsies of ulcerative, pyloric lesion (2004)
shows a poorly-differentiated adenocarcinoma of the intestinal type. Original 
magnif cation 150x, H&E stain g. 
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guidelines for follow-up of patients with pre-malignant gastric lesions are lacking in Western 
countries. We recommend no follow-up for patients with atrophic gastritis, yet surveillance 
endoscopy with biopsy sampling at a 2-3 year interval for patients with intestinal metaplasia, 
a 1 year interval for low-grade dysplasia, and direct re-evaluation for patients with high-
grade dysplasia. (9) This recommendation is based on previous observations of very similar 
cancer incidences in these patients as in patients with Barrett’s esophagus. (9) However, the 
yield of such surveillance, and the optimal intervals require further investigation, in which 
the appropriate biopsy protocols, additional risk stratification to identify high-risk patients, 
and the potential of serological surveillance need to be addressed.
Our report is in line with the observation in the large randomized study of Wong et al. in 
which H. pylori eradication in patients with pre-malignant gastric lesions did not prevent the 
development of gastric cancer. (19) Our data add to this important study by extending the 
follow-up from a maximum of five years to a maximum of 16 years after H. pylori eradication. 
This suggests that the progress from atrophy and intestinal metaplasia to invasive cancer is 
truly an autonomous, H. pylori-independent process. This is consistent with previous obser-
vations that H. pylori colonization and even the serological evidence of previous infection 
may completely disappear once marked atrophy and metaplasia have occurred. At this point, 
molecular changes may be too severe to be reversed. The progress towards cancer may then 
occur via different pathways in which several gene regions associated with oncogene overex-
pression, tumor suppressor loss, and defective DNA mismatch repair appear to be involved. 
(27) Recent studies have suggested that H. pylori induces repopulation of the stomach with 
bone marrow-derived cells, which may play a crucial role in gastric carcinogenesis. (28) 
The importance of our report, albeit a description of cases, lies in the observation that 
this autonomous process can take more than a decade. This means that we have to revise 
the general concept suggested by previous intervention studies that the preventive effect 
of H. pylori eradication becomes complete beyond the first few years, when patients at an 
advanced stage towards cancer have progressed to this disease. 
In conclusion, this report emphasizes the need for further systematic data collection, prefer-
ably by randomized controlled trials in different geographical areas, to elucidate the role of H. 
pylori eradication in patients with intestinal metaplasia or dysplasia to prevent gastric cancer 
after long-term follow-up. Our data confirm that H. pylori eradication is insufficient in these 
patients as single management modality and should be combined with strict endoscopic 
surveillance, and if needed endoscopic treatment.
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InTroDucTIon
The understanding of gastric carcinogenesis has advanced largely over the past decades. 
Since 1994, Helicobacter pylori has been identified as a definite carcinogen in the pathogen-
esis of distal gastric cancer. (1) H. pylori causes chronic active gastritis which can progress 
through several pre-malignant stages, i.e. atrophic gastritis, intestinal metaplasia and dys-
plasia, to eventually gastric cancer. (2;3) Especially since the recognition of the key role of 
H. pylori infection and the stepwise progression of pre-malignant lesions to gastric cancer, 
the development of preventive strategies has become an important focus in gastric cancer 
research. Current clinical guidelines principally cover detection and treatment of H. pylori 
infection. (4) Yet, no clear guidelines are available on detection, surveillance and treatment 
of subsequent pre-malignant gastric lesions.
ePIDemIoLoGy
Epidemiology of pre-malignant gastric lesions
Since most subjects with pre-malignant gastric lesions are asymptomatic, these lesions re-
main unrecognized in the majority of individuals. For this reason, data on the epidemiology 
of pre-malignant lesions are scarce, especially from populations with an overall low incidence 
of gastric cancer. (5) According to a recent population-based study from Germany, the preva-
lence of a serological diagnosis of atrophic gastritis, as defined as serum pepsinogen I < 25 
ng/ml, increased from approximately 5% in the age group from 50 to 54 years to 9% in the 
age group from 70 to 74 years. (6) Pre-malignant gastric lesions are also common diagno-
ses in routine biopsies obtained during upper gastro-intestinal endoscopies in a Western 
population, especially in the elderly. (Chapter 3) From 1991 to 2005, the average incidence 
(world standardized rate) was 2944/100,000 for atrophic gastritis, 4891/100,000 for intestinal 
metaplasia, and 614/100,000 for dysplasia relative to the total number of patients with a first 
gastric biopsy. (Chapter 3)
Although these data show that diagnoses of pre-malignant gastric lesions are common, 
the occurrence of these lesions has declined significantly over the past decades. A study 
with repeated cross-sectional endoscopic examination within the same Finnish population 
showed that the prevalence of chronic H. pylori-induced gastritis (both non-atrophic and 
atrophic) declined by 18% in the period from 1977 to 1992. (7) However, the prevalence rates 
of chronic H. pylori gastritis were stable in the same birth cohorts over the study period. So 
the decline was only caused by lower H. pylori prevalences in younger birth cohorts (cohort 
effect), a phenomenon which has also been observed in a prospective Ducth cohort study. 
(8) In our research, we showed that from 1991 to 2005, the incidence of atrophic gastritis, 
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intestinal metaplasia and dysplasia in the Netherlands declined with 8.2%, 8.1% and 2.4% 
per year, respectively. (Chapter 3) These incidence changes were caused by both cohort and 
period effects, since a declining incidence in men born after 1920 as well as an accelerating 
decline in the number of diagnoses of atrophic gastritis and intestinal metaplasia after 1996 
were demonstrated. These phenomena are probably related to a decrease in the prevalence 
of H. pylori infection in younger age cohorts, the introduction of histological classification 
systems, and the widespread introduction of H. pylori diagnosis and treatment in the early 
nineties. (9-11) Since the decline in the incidence of pre-malignant gastric lesions is stronger 
than the current decline of gastric cancer and changes in the incidence of pre-malignant le-
sions predict similar changes in gastric cancer occurrence in the next 10-15 years, we predict 
a more rapid further decline of gastric cancer incidence of approximately 24% within the next 
decade. (12) 
With regard to cost-effectiveness and burden for patients, the declining incidence of pre-
malignant gastric lesions and expected decline of gastric cancer incidence emphasize the 
need for selective screening and surveillance in Western populations. In these populations, 
an approach with several screening stages with stepwise increasing burden for subjects in 
proportion to gastric cancer risk is required. In this approach, the selection of a population 
sample of the general population that should be offered non-invasive serological screening 
could be the initial step. This selection should primarily be based on epidemiological risk 
factors, as symptoms cannot predict the presence of pre-malignant lesions or early gastric 
cancer. A risk profile could be defined based on known epidemiological risk factors, as for 
instance low socioeconomic class, blood group A and familial occurrence of gastric cancer. 
(2;13;14) In addition, migrant communities constitute a high risk population as we observed 
a high H. pylori infection rate in a population-based sample in the Netherlands. (Chapter 4) 
In addition, more infections with CagA-positive H. pylori strains and serological evidence of 
atrophic gastritis, as defined as either a pepsinogen I<70 µg/L in combination with a pep-
sinogen I/II ratio <3.0, or a pepsinogen I <28 µg/L, were observed in subjects from foreign 
origin (48% and 5.2%, respectively) as compared to subjects from Dutch origin (25% and 
0%, respectively). Serological screening is attractive to identify a population at high risk of 
gastric cancer in low incidence countries, since costs and burden for patients are acceptable 
and thereby a large population sample can be screened. By combining pepsinogens I and 
II and gastrin levels with H. pylori serology in a decision algorithm, it is possible to estimate 
the presence of H. pylori gastritis, distinguish atrophic gastritis and locate atrophic changes 
with high sensitivity and specificity. (15) The aim of serological screening would be to identify 
patients at risk of pre-malignant gastric lesions that require histological confirmation after 
endoscopy. Finally, long-term endoscopic surveillance should be offered to individuals with 
pre-malignant lesions at high risk of progression. 
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Association between pre-malignant gastric lesions and other gastro-esophageal diseases
In addition to gastric cancer, an association with chronic H. pylori infection has been inves-
tigated for several gastro-esophageal and duodenal disorders, such as Barrett’s esophagus, 
esophageal adenocarcinoma, and peptic ulcer disease. (16-20) In addition, recent studies 
have demonstrated an elevated risk of oesophageal squamous cell carcinomas (ESCC) in 
patients with atrophic changes of the gastric mucosa. (20-23) Our large, nationwide study 
confirms a positive association between these conditions, with an overall relative risk of 2.2 
for the development of ESCC in patients with gastric atrophy as compared to the general 
Dutch population. (Chapter 5) However, as the risk of ESCC in our population did not increase 
with the severity of gastric atrophy, a causal relationship between gastric atrophy and ESCC 
seems unlikely. Moreover, as we demonstrated a similar association between gastric atrophy 
and the anatomically unrelated small cell lung carcinoma (relative risk 1.8), these associations 
are best explained by confounding factors, such as smoking.
H. pylori infection has also been recognized in the pathogenesis of gastric Mucosa-
Associated Lymphoid Tissue (MALT) lymphomas. In patients with gastric MALT lymphomas, 
increased progression of pre-malignant gastric lesions has been observed, but the association 
with gastric cancer remained unknown. (24;25) Our long-term data presented in this thesis 
show that gastric MALT lymphoma patients indeed have a six times higher risk of developing 
gastric cancer as compared to the general Dutch population. (Chapter 6) In the majority of 
cases (53%), gastric cancer was diagnosed within one year prior to or after the diagnosis of 
MALT lymphoma. This means that strict endoscopic surveillance with careful inspection of 
the gastric mucosa after diagnosis or treatment of gastric MALT lymphoma is indicated.
DeTecTIon AnD SurveILLAnce
Gastric cancer risk of pre-malignant gastric lesions
The efficacy of endoscopic re-evaluation or surveillance of patients with pre-malignant 
gastric lesions in the prevention of gastric cancer is highly controversial. (26-28) As a result, 
the performance of endoscopic surveillance largely depends on the personal experience of 
clinicians and is frequently omitted in current clinical practice, even in patients with overt 
dysplasia. In our nationwide cohort study of patients with pre-malignant gastric lesions, at 
least one re-evaluation upper gastro-intestinal endoscopy with histological re-evaluation 
was performed in only 26% of patients with atrophic gastritis, in 28% with intestinal meta-
plasia, and in 38% with mild or moderate dysplasia. Although the frequency of surveillance 
was significantly higher in patients with severe dysplasia (61%; p<0.001) as compared to the 
other pre-malignant diagnoses, still more than one-third of patients with severe dysplasia C
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and thus at presumed very high risk for invasive gastric cancer, did not receive surveillance. 
(Chapter 8)
The most important reason for the controversy on the importance of endoscopic surveil-
lance in patients with pre-malignant gastric lesions is that quantification of gastric cancer risk 
in these patients is unclear. Previous studies that investigated the progression rate of atro-
phic gastritis, intestinal metaplasia and dysplasia to gastric cancer have reached conflicting 
results. (Chapter 7) These variations can probably be explained by a variety of factors, such as 
differences in study design and included populations, and variations in criteria for diagnosis 
of intestinal metaplasia and dysplasia. The largest prospective study was performed in China 
and included 1240 patients with severe gastritis and/or atrophic gastritis, 842 with intestinal 
metaplasia and 546 with dysplasia. (29) Progression rates to gastric cancer were 0.02% per 
year for severe gastritis and/or atrophic gastritis, 0.4% per year for intestinal metaplasia and 
0.6% per year for mild dysplasia and 1.4% for severe dysplasia within 5 years follow-up. In our 
Western study population, we studied 22,365 patients with atrophic gastritis, 61,707 with 
intestinal metaplasia, 7,616 with mild to moderate dysplasia, and 562 with severe dysplasia. 
Within this cohort, we observed remarkably similar progression rates. Within 5 years follow-
up, the annual incidence of gastric cancer was 0.1% for patients with atrophic gastritis, 0.25% 
for intestinal metaplasia, 0.6% for mild to moderate dysplasia, and 6% for severe dysplasia. 
(Chapter 8) The difference in progression rate of severe dysplasia between both studies may 
be explained by differences between Western and Asian gastro-intestinal pathologists in 
classification of gastric dysplasia and cancer. (30)
These findings on progression to gastric cancer indicate that endoscopic follow-up of 
all patients with atrophic gastritis or intestinal metaplasia is not indicated, as only a small 
proportion of patients eventually develops gastric cancer. However, a diagnosis of low-grade 
dysplasia warrants endoscopic surveillance at short intervals. In addition, in patients with 
high-grade dysplasia thorough endoscopic and histological re-evaluation shortly after initial 
diagnosis and subsequent long-term surveillance are strongly indicated, and endoscopic 
resection needs to be considered. (31;32)
Surveillance of atrophic gastritis and intestinal metaplasia of the gastric mucosa should 
preferably be limited to patients at high risk of gastric cancer. Previous studies have identified 
the severity, extent, and the intragastric location of the lesions, as well as the concomitant 
presence of associated lesions, in particular MALT lymphoma or gastric ulcer, as risk factors 
for progression of these lesions. (24;26;33) Furthermore, the risk is influenced by H. pylori 
virulence factors, a family history of gastric cancer, host genetics and environmental factors, 
in particular cigarette smoking and alcohol use. (34-39) In our nationwide cohort study, we 
identified male sex as an important independent risk factor for progression to more advanced 
lesions and gastric cancer. (Chapter 8) In addition, we performed a prospective study to 
identify risk factors for extensive intragastric intestinal metaplasia as a marker for increased 
gastric cancer risk. (Chapter 9) A total of 88 patients with a previous diagnosis of intestinal 
211
General discussion and conclusions
metaplasia underwent a surveillance endoscopy with biopsies for histological assessment 
taken from five standardized intragastric locations (antrum, angulus, lesser curvature and 
greater curvature of corpus, and cardia) In accordance with previous studies, we identified 
a family history of gastric cancer, alcohol use ≥ 1 unit/ day, moderate or marked intestinal 
metaplasia at the index biopsy, and a pepsinogen I to II ratio <3.0 as the most important pre-
dictors of extensive intestinal metaplasia, as defined as intestinal metaplasia in the random 
biopsies from at least two different intragastric locations. A simple risk score based on these 
factors could identify extensive intestinal metaplasia with 96% sensitivity.
Endoscopic surveillance strategy of pre-malignant gastric lesions
Although advanced endoscopic techniques may improve the detection of pre-malignant 
gastric lesions, current detection and surveillance in routine practice still relies on histological 
assessment of random biopsies, obtained during conventional endoscopy. (40) The Sydney 
classification system currently provides the endoscopic and histological gold standard for 
the assessment of gastritis. (9) According to this system five gastric biopsies need to be 
obtained (two antrum, two corpus and one angulus). However, this biopsy schedule insuf-
ficiently acknowledges the intragastric distribution of pre-malignant lesions, which should 
guide biopsy sampling during surveillance endoscopy. (41-43) Pre-malignant gastric lesions 
associated with H. pylori infection have been shown to occur most commonly in the antrum 
and incisura angularis. (44) Subsequently, these lesions spread along the lesser curvature 
and are especially common in the transitional zones (antrum to corpus and corpus to cardia). 
(45)
We performed a prospective study to identify the most optimal biopsy strategy during 
surveillance of intestinal metaplasia or dysplasia of the gastric mucosa. A total of 112 pa-
tients with a previous diagnosis of intestinal metaplasia or dysplasia underwent surveillance 
endoscopy and biopsy samples were obtained from any endoscopically detected focal lesion 
and 12 random biopsies were taken from five standardized intragastric locations (antrum, 
angulus, lesser curvature and greater curvature of corpus and cardia). Random biopsies 
from the lesser curvature had a significantly higher yield in diagnosing atrophic gastritis 
and intestinal metaplasia as compared to biopsies from the greater curvature of the corpus 
(p=0.05 and p=0.03). In addition, intestinal metaplasia in biopsies from the cardia identified 
patients at increased risk of a concurrent diagnosis of dysplasia or gastric cancer. Targeted 
biopsies were indispensable for the diagnosis of high-grade dysplasia in three patients. In 
comparison, the random biopsy scheme was essential for a diagnosis of low-grade dysplasia 
in two patients and the diagnosis of gastric cancer in one patient. Therefore, an adequate 
biopsy protocol requires 2 random biopsies from the cardia, 1 from the greater curvature 
of the corpus, 2 from the lesser curvature of the corpus, 1 from the angulus, and 3 from the 
antrum in a population at an overall low gastric cancer risk. Moreover, both random and C
h
ap
te
r 1
3
Chapter 13
212
targeted biopsies are essential for an adequate diagnosis during endoscopic surveillance of 
intestinal metaplasia and dysplasia of the gastric mucosa.
TreATmenT
Helicobacter pylori eradication for pre-malignant gastric lesions
With advancing insights into the pivotal role of H. pylori in gastric carcinogenesis, the preven-
tion of gastric cancer by eradication of infection seems increasingly important. However, the 
effect of H. pylori eradication for prevention of gastric cancer is still controversial. Only one 
randomized controlled trial has been published on the effect of H. pylori eradication to pre-
vent gastric cancer in subjects with chronic H. pylori-induced gastritis without pre-malignant 
gastric lesions. (46) This Chinese trial demonstrated a significantly reduced incidence of 
gastric cancer after H. pylori eradication (0% in H. pylori eradication group versus 1.2% in 
placebo-group, p=0.02). However, a significantly reduced incidence of gastric cancer by H. 
pylori eradication in patients with pre-malignant gastric lesions at baseline could not be 
demonstrated (2.2% in H. pylori eradication group versus 1.7% in placebo-group, p=0.67).
Gastric cancer prevention through H. pylori eradication in patients with pre-malignant gas-
tric lesions has been studied in several other randomized controlled trials. (46-64) (Chapter 
11) These studies evaluated the progression and regression of pre-malignant gastric lesions 
as surrogate parameters for the development of gastric cancer. Unfortunately, several factors 
hinder overall evaluation of these randomized controlled trials. For instance, the number of 
included patients with pre-malignant lesions was generally low, follow-up in most studies was 
relatively short and outcome measures varied between studies. Nevertheless, conclusions 
can be drawn with cautiousness. In patients with atrophic gastritis, lesions regress within one 
to two years after H. pylori eradication. (Chapter 11) However, the effect of H. pylori eradica-
tion in patients with intestinal metaplasia and dysplasia is highly uncertain, as was illustrated 
by the development of gastric cancer long after H. pylori eradication in two case reports. 
(Chapter 12) In these patients progression of the lesions probably occurs independent of H. 
pylori colonization. Therefore, H. pylori eradication is insufficient in these patients as single 
management modality and should be combined with long-term endoscopic surveillance.
fuTure DIrecTIonS
Although the detection, surveillance and treatment of pre-malignant gastric lesions can 
contribute to the prevention of gastric cancer, its potential is not fully explored as yet.
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For the detection of pre-malignant gastric lesions, several steps of a preventive strategy 
need further investigation in case gastric cancer screening is considered in low incidence 
countries. First of all, accurate initial selection of individuals for screening for pre-malignant 
gastric lesions in the general population is important, since most subjects with pre-malignant 
gastric lesions are asymptomatic. However, this is an almost undeveloped research area. 
Therefore, large population-based studies are necessary to identify adequate risk profiles. 
Moreover, the diagnostic options for detection of pre-malignant gastric lesions in this stage 
need to be further explored, for instance serological screening to estimate the presence of 
intestinal metaplasia and dysplasia. Lastly, all steps of screening and surveillance need further 
investigation on cost-effectiveness.
In addition, surveillance programs of pre-malignant gastric lesions need further evaluation 
too, as these lesions are frequently diagnosed in random biopsies after routine upper gastro-
intestinal endoscopy. The appropriate endoscopic surveillance frequency in these patients 
needs to be established, preferentially by individual risk stratification. For this stratification, 
clinical, serological, including new serological markers as ghrelin and leptin, and histological 
markers, as well as genetic markers (polymorphisms) need to be evaluated. In addition, ad-
vanced endoscopic techniques may improve the detection of pre-malignant gastric lesions 
during surveillance endoscopy, for instance narrow band imaging or endomicroscopy. There-
fore, the yield of endoscopic surveillance with these techniques needs to be investigated, 
and these techniques need to be studied separately in populations with an overall high and 
low gastric cancer risk.
For the treatment of pre-malignant gastric lesions, the long-term results of ongoing ran-
domized controlled clinical trials on the effect of H. pylori eradication are eagerly awaited. 
In particular the effect of H. pylori eradication in patients with intestinal metaplasia and 
dysplasia after long-term follow-up needs further investigation in well-designed randomized 
controlled trials.
concLuSIonS
The progression of chronic H. pylori-induced gastritis through several pre-malignant stages 
to gastric cancer harbours great potential for gastric cancer prevention. Although the oc-
currence of pre-malignant gastric lesions has declined significantly over the past decades, 
diagnoses of these lesions are still common. Pre-malignant gastric lesions carry a significant 
gastric cancer risk, which is insufficiently acknowledged in current clinical practice. Therefore, 
the development of clinical guidelines for management of pre-malignant gastric lesions is 
required.
In general, H. pylori eradication prevents progression along the carcinogenic cascade in 
patients with H. pylori-induced chronic active gastritis and atrophic gastritis. However, in C
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patients with intestinal metaplasia and dysplasia H. pylori eradication is insufficient to pre-
vent gastric cancer development. In these patients endoscopic surveillance with histological 
biopsy sampling is essential for early detection and treatment of advanced precursors and 
gastric cancer. Endoscopic surveillance needs to be considered in all patients with intestinal 
metaplasia and dysplasia of the gastric mucosa, although decisions on follow-up frequency 
require individual adjustment according to intragastric extent of pre-malignant lesions and 
the presence of additional risk factors.
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Summary
Gastric cancer is usually diagnosed at an advanced stage, since symptoms are often absent or 
non-specific in patients with an early stage of disease. As curative options are often limited at 
an advanced stage of disease, gastric cancer usually portrays a poor prognosis. In the multi-
step cascade of gastric carcinogenesis, Helicobacter pylori–induced gastritis slowly progresses 
through the pre-malignant stages of atrophic gastritis, intestinal metaplasia and dysplasia to 
gastric adenocarcinoma. The progression of pre-malignant gastric lesions to gastric cancer 
generally takes decades. Therefore, this cascade may provide a basis for cancer prevention by 
early intervention, such as H. pylori eradication, and potentially also for early detection and 
treatment of advanced precursor lesions and gastric adenocarcinomas.
The general aims and outline of this thesis are described in chapter 1.
chapter 2 provides an overview of current knowledge on the epidemiology of pre-
malignant gastric lesions. Geographical variations and risk factors of pre-malignant gastric 
lesions and gastric cancer are described. In addition, their implications for the development 
of screening and surveillance strategies are discussed.
chapter 3 describes a nationwide study of epidemiological trends of pre-malignant gastric 
lesions in the Netherlands in the period from 1991 to 2005. In this study, 23,278 patients with 
a first diagnosis of atrophic gastritis, 65,937 patients with intestinal metaplasia, and 8,517 
patients with dysplasia were included. The incidence of atrophic gastritis declined similarly in 
men and women with 8.2% per year [95% CI 7.9-8.6], and dysplasia with 8.1% per year [95% CI 
7.5-8.6]. The incidence of intestinal metaplasia declined with 2.9% per year [95% CI 2.7-3.1] in 
males and 2.4% [95% CI 2.2-2.6] in females. The declining incidence of pre-malignant gastric 
lesions resulted from a combined period and cohort effect. Based on these findings, a further 
decrease in incidence of gastric cancer of 24% can be expected in the next decade.
In chapter 4 the prevalence of H. pylori infection and atrophic gastritis was studied in a 
Dutch migrant community. The prevalence of H. pylori infection was high in a population-
based sample of 288 subjects, even in autochthonous inhabitants. In addition, mean pep-
sinogen I level and pepsinogen I/II ratio were significantly lower in subjects from non-Dutch 
origin as compared to Dutch subjects (both p<0.001). Serologic evidence of atrophic gastritis 
was observed in 12 subjects from non-Dutch origin, whereas Dutch subjects were not af-
fected (p=0.13). Therefore, these migrant communities may constitute a target group for 
serologic screening to prevent H. pylori-related complications in Western countries.
An association between esophageal squamous cell carcinomas and atrophic changes of 
the gastric mucosa has been demonstrated by several studies. However, the mechanism 
for this association remained unclear. In chapter 5 a relative risk of 2.2 [95% CI 1.8-2.6] for 
developing esophageal squamous cell carcinomas was demonstrated in a nationwide cohort 
of patients with gastric atrophy as compared to the general Dutch population. The risk of 
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esophageal squamous cell carcinomas did not increase in parallel with the severity of gastric 
atrophy (p=0.90). In addition, a similar association was demonstrated between small cell lung 
carcinomas and gastric atrophy. Therefore, a causal relation between esophageal squamous 
cell carcinomas and gastric atrophy seems unlikely, and this association is probably best 
explained by confounding factors, such as smoking.
In order to evaluate gastric cancer risk in patients with gastric MALT lymphoma, a nation-
wide cohort of 1419 patients with gastric MALT lymphoma was studied in chapter 6. A total 
of 34 (2.4%) patients were diagnosed with gastric cancer, which corresponds with a six times 
higher risk of gastric cancer as compared to the general Dutch population. In the majority 
of cases (53%), gastric cancer is diagnosed within one year prior to or after the diagnosis of 
MALT lymphoma. Accurate endoscopic re-evaluation after diagnosis and treatment of gastric 
MALT lymphoma is therefore indicated.
In chapter 7 an overview is provided on current knowledge on the detection, surveillance 
and treatment of patients with pre-malignant gastric lesions. The available literature on histo-
logical classifications, natural history, serological and endoscopic detection, pharmacological 
and endoscopic treatment of pre-malignant gastric lesions is summarized and discussed.
chapter 8 describes a nationwide cohort study of 22,365 patients with atrophic gastritis, 
61,707 with intestinal metaplasia, 7,616 with mild to moderate dysplasia, and 562 with severe 
dysplasia. At least one follow-up upper gastro-intestinal endoscopy with histological re-
evaluation was performed in only 26% of patients with atrophic gastritis, in 28% with intes-
tinal metaplasia, and in 38% with mild or moderate dysplasia, compared to 61% with severe 
dysplasia (p<0.001). Within 5 years follow-up, the annual incidence of gastric cancer was 0.1% 
for patients with atrophic gastritis, 0.25% for intestinal metaplasia, 0.6% for mild to moder-
ate dysplasia, and 6% for severe dysplasia. As current surveillance of pre-malignant gastric 
lesions is discrepant with the substantial gastric cancer risk of these lesions, development of 
clinical guidelines on endoscopic surveillance or treatment of pre-malignant gastric lesions 
is strongly indicated. These data show that routine endoscopic surveillance at short intervals 
is warranted in patients with gastric dysplasia, whereas surveillance at larger intervals should 
be considered for patients with atrophic gastritis and intestinal metaplasia.
In chapter 9 the value of clinical characteristics, histological assessment of routine gastric 
biopsies, and serological markers as predictors for the intragastric extent of intestinal meta-
plasia was investigated. A total of 88 patients were included in a prospective, multi-center 
study and underwent a surveillance endoscopy with extensive biopsy sampling. Multivari-
ate logistic regression analysis identified a family history of gastric cancer, a pepsinogen I 
to II ratio <3.0, the presence of moderate or marked intestinal metaplasia in the biopsy at 
baseline, and alcohol use with an average of at least one unit per day as important predictive 
parameters for extensive intestinal metaplasia at surveillance endoscopy. A high risk score 
based on the presence of these parameters indicates a severely affected gastric mucosa and 
the need to consider surveillance endoscopy.
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In chapter 10 the appropriate biopsy regimen for optimal detection of pre-malignant 
gastric lesions during surveillance endoscopy was investigated. In a prospective, multi-
center study, 112 patients with intestinal metaplasia or dysplasia underwent a surveillance 
endoscopy. During endoscopy, both targeted biopsies from macroscopic lesions and twelve 
random biopsies from standardized locations (antrum, angulus, corpus, cardia) were obtained. 
This study showed that both random and targeted biopsies are essential during endoscopic 
surveillance of intestinal metaplasia and dysplasia of the gastric mucosa. An adequate biopsy 
scheme requires at least random biopsies from the cardia, corpus, in particular from the lesser 
curvature, angulus, and antrum in a population at an overall low gastric cancer risk.
A total of 17 randomized controlled trials on H. pylori eradication in patients with pre-ma-
lignant gastric lesions were systematically reviewed in chapter 11. Several studies demon-
strated less progression or even regression of atrophic gastritis within one to two years after 
H. pylori eradication. However, as evidence on the effect of H. pylori eradication in patients 
with intestinal metaplasia or dysplasia is scarce, the effect in these patients is unclear.
chapter 12 describes two case reports of patients who developed gastric cancer at 
respectively four and twelve years after H. pylori eradication. In both patients, gastric ulcer 
disease and pre-malignant gastric lesions, i.e. intestinal metaplasia at baseline and dysplasia 
during follow-up, were diagnosed before the development of gastric cancer. These cases 
demonstrate that H. pylori eradication is insufficient as a single treatment modality in these 
patients and should be combined with endoscopic surveillance for early detection of gastric 
neoplasia.
The main findings of this thesis and directions for future research are discussed in chapter 
13.
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Samenvatting
Maagkanker wordt doorgaans pas in een laat stadium gediagnosticeerd, aangezien symp-
tomen in een vroeg stadium van de ziekte vaak ontbreken of aspecifiek zijn. Doordat de 
mogelijkheden voor een op genezing gerichte behandeling in een laat stadium van de ziekte 
beperkt zijn, is de gemiddelde prognose van patiënten met maagkanker slecht. Tijdens de 
stapsgewijze ontstaanswijze van maagkanker, schrijdt Helicobacter pylori-geïnduceerde gas-
tritis langzaam voort via de pre-maligne stadia van atrofische gastritis, intestinale metaplasie 
en dysplasie, tot uiteindelijk maagkanker. De progressie van pre-maligne maagafwijkingen 
tot maagkanker duurt doorgaans tientallen jaren. Derhalve zou deze cascade van afwijkin-
gen een basis kunnen vormen voor de preventie van kanker door vroegtijdige interventie, 
zoals H. pylori eradicatie, alsmede voor vroegtijdige detectie en behandeling van ernstige 
voorloperafwijkingen en maagkanker.
In hoofdstuk 1 staan de algemene doelstellingen van dit proefschrift beschreven.
In hoofdstuk 2 wordt een overzicht gegeven van de huidige kennis over de epidemiologie 
van pre-maligne maagafwijkingen. Geografische verschillen en risicofactoren voor de ont-
wikkeling van pre-maligne maagafwijkingen en maagkanker worden beschreven. Daarnaast 
worden de implicaties van deze gegevens voor de ontwikkeling van screening en surveil-
lance strategieën bediscussieerd. 
hoofdstuk 3 beschrijft een landelijke studie naar epidemiologische trends van pre-maligne 
maagafwijkingen in Nederland gedurende de periode van 1991 tot 2005. In deze studie wer-
den 23.278 patiënten met atrofische gastritis, 65.937 patiënten met intestinale metaplasie, en 
8.517 patiënten met dysplasie geïncludeerd. De incidentie van atrofische gastritis daalde zo-
wel bij mannen als bij vrouwen met 8.2% per jaar [95% betrouwbaarsheidsinterval (BI) 7.9-8.6], 
en van dysplasie met 8.1% per jaar [95% BI 7.5-8.6]. De incidentie van intestinale metaplasie 
daalde met 2.9% per jaar [95% BI 2.7-3.1] bij mannen en 2.4% [95% BI 2.2-2.6] bij vrouwen. De 
dalende incidentie van pre-maligne maagafwijkingen was het gevolg van een gecombineerd 
periode en cohort effect. Op basis van deze gegevens kan een verdere afname van de inciden-
tie van maagkanker van 24% worden verwacht gedurende de komende tien jaar.
In hoofdstuk 4 werd de prevalentie van H. pylori infectie en atrofische gastritis bestudeerd 
in een Nederlandse migranten populatie. De prevalentie van H. pylori was hoog in de on-
derzochte steekproef van 288 personen, zelfs bij autochtone personen. Daarnaast waren de 
gemiddelde pepsinogeen I waarde en pepsinogeen I/II ratio significant lager bij personen 
van niet Nederlandse afkomst in vergelijking tot Nederlandse personen (beide p<0.001). Er 
waren geen Nederlandse personen met serologische aanwijzingen voor atrofische gastritis, 
in vergelijking tot 12 personen van niet Nederlandse afkomst (p=0.13). Concluderend kun-
nen deze migranten populaties een doelgroep vormen voor de serologische screening ter 
preventie van H. pylori-gerelateerde complicaties in Westerse landen.
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Eerdere studies toonden een associatie tussen plaveiselcelcarcinomen van de slokdarm 
en atrofie van het maagslijmvlies aan. Echter, het mechanisme van deze associatie bleef 
onduidelijk. In hoofdstuk 5 werd een relatief risico van 2.2 [95% BI 1.8-2.6] voor het ontwik-
kelen van plaveiselcelcarcinomen van de slokdarm aangetoond in een landelijk cohort van 
patiënten met atrofie van het maagslijmvlies in vergelijking tot de algemene Nederlandse 
bevolking. Het risico van plaveiselcelcarcinomen van de slokdarm nam niet toe met de ernst 
van atrofie van het maagslijmvlies (p=0.90). Bovendien werd een vergelijkbare associatie 
aangetoond tussen kleincellige longcarcinomen en atrofie van het maagslijmvlies. Een cau-
sale relatie tussen plaveiselcelcarcinomen van de slokdarm en atrofie van het maagslijmvlies 
is derhalve onwaarschijnlijk, en deze associatie wordt meest waarschijnlijk verklaard door de 
aanwezigheid van gedeelde risicofactoren, zoals roken.
Ter evaluatie van het risico van maagkanker bij patiënten met MALT lymfomen van de maag 
werd een landelijk cohort van 1419 patiënten bestudeerd in hoofdstuk 6. In totaal werd bij 
34 (2.4%) patiënten maagkanker vastgesteld. Het risico van maagkanker bij patiënten met 
MALT lymfomen was 6 keer verhoogd ten opzichte van de algemene Nederlandse bevolking. 
In het merendeel van de gevallen (53%) werd maagkanker in het jaar voorafgaand aan of na 
de diagnose MALT lymfoom gesteld. Nauwkeurige endoscopische follow-up na diagnose en 
behandeling van MALT lymfomen van de maag is daarom aangewezen.
In hoofdstuk 7 wordt een overzicht gegeven van de huidige kennis over detectie, surveil-
lance en behandeling van patiënten met pre-maligne maagafwijkingen. De beschikbare 
literatuur over histologische classificatie, natuurlijk beloop, serologische en endoscopische 
detectie, medicamenteuze en endoscopische behandeling van pre-maligne maagafwijkin-
gen werd samengevat en bediscussieerd.
hoofdstuk 8 beschrijft een landelijke cohort studie van 22.365 patiënten met atrofische 
gastritis, 61.707 met intestinale metaplasie, 7.616 met milde tot matige dysplasie, en 562 
met ernstige dysplasie. Tenminste één her-evaluatie endoscopie met afname van biopten 
werd uitgevoerd bij slechts 26% van patiënten met atrofische gastritis, 28% met intestinale 
metaplasie en 38% met mild tot matige dysplasie, in vergelijking tot 61% van patiënten met 
ernstige dysplasie (p<0.001). Binnen 5 jaar follow-up betrof de jaarlijkse incidentie van maag-
kanker 0.1% voor patiënten met atrofische gastritis, 0.25% voor patiënten met intestinale 
metaplasie, 0.6% voor patiënten met mild tot matige dysplasie en 6% voor patiënten met 
ernstige dysplasie. Aangezien de huidige surveillance van patiënten met pre-maligne maag-
afwijkingen niet in overeenstemming is met het substantiële risico van maagkanker, is de 
ontwikkeling van klinische richtlijnen voor endoscopische surveillance of behandeling van 
pre-maligne maagafwijkingen aangewezen. De data uit deze studie benadrukken dat rou-
tinematige surveillance van patiënten met dysplasie van de maagmucosa op korte termijn 
dient te worden verricht, terwijl surveillance op langere termijn overwogen dient te worden 
bij patiënten met atrofische gastritis en intestinale metaplasie.
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In hoofdstuk 9 werd de voorspellende waarde van klinische karakteristieken, histolo-
gische beoordeling van maagbiopten en serologische markers voor de aanwezigheid van 
uitgebreide intestinale metaplasie onderzocht. In totaal werden 88 patiënten geïncludeerd 
in een prospectief, multi-center onderzoek en zij ondergingen een surveillance endoscopie 
met uitgebreide biopt afname. Multivariate logistische regressie analyse identificeerde een 
positieve familie-anamnese, pepsinogeen I tot II ratio <3.0, de aanwezigheid van matig tot 
ernstige intestinale metaplasie in het biopt bij inclusie, en alcohol gebruik van tenminste 
één eenheid per dag als belangrijke voorspellende parameters voor uitgebreide intestinale 
metaplasie bij de surveillance endoscopie. Een hoge risico score gebaseerd op de aanwe-
zigheid van deze factoren maakt de aanwezigheid van uitgebreide intestinale metaplasie 
aannemelijk en in deze gevallen dient endoscopische surveillance te worden overwogen.
In hoofdstuk 10 werd de meest geschikte strategie voor het afnemen van maagbiopten 
tijdens surveillance endoscopie ter detectie van pre-maligne maagafwijkingen onderzocht. 
In een prospectieve, multicenter studie ondergingen 112 patiënten met intestinale meta-
plasie of dysplasie een surveillance endoscopie. Tijdens deze endoscopie werden zowel 
gerichte biopten genomen van macroscopische lesies, alsmede twaalf willekeurige biopten 
van gestandaardiseerde locaties (antrum, angulus, corpus, cardia). Deze studie toonde aan 
dat zowel gerichte biopten als willekeurige biopten essentieel zijn tijdens endoscopische 
surveillance van intestinale metaplasie en dysplasie van de maagmucosa. Een optimale 
strategie voor het afnemen van biopten vereist de afname van willekeurige biopten van de 
cardia, kleine curvatuur van het corpus, angulus en antrum binnen een populatie met een 
gemiddeld laag maagkanker risico.
hoofdstuk 11 beschrijft een systematische beschouwing van 17 gerandomiseerde, gecon-
troleerde onderzoeken over het effect van H. pylori eradicatie bij patiënten met pre-maligne 
maagafwijkingen. Verscheidene onderzoeken toonden significant minder progressie of zelfs 
regressie aan van atrofische gastritis binnen één tot twee jaar na H. pylori eradicatie. Echter, 
doordat het beschikbare bewijs zeer schaars is, is het effect van H. pylori eradicatie bij patiën-
ten met intestinale metaplasie en dysplasie nog onvoldoende duidelijk.
In hoofdstuk 12 worden twee casus beschrijvingen gepresenteerd van patiënten die 
maagkanker ontwikkelden, respectievelijk vier en twaalf jaar na H. pylori eradicatie. Bij 
beide patiënten werden een maagulcus en pre-maligne maagafwijkingen, d.w.z. intestinale 
metaplasie bij initiële endoscopie en dysplasie tijdens vervolg onderzoek, gediagnosticeerd 
voorafgaand aan de ontwikkeling van maagkanker. Deze casus tonen aan dat H. pylori era-
dicatie onvoldoende is als enige behandeling bij deze patiënten en gecombineerd dient te 
worden met endoscopische surveillance teneinde neoplasieën van de maag vroegtijdig te 
ontdekken.
De belangrijkste bevindingen uit dit proefschrift en aanbevelingen voor toekomstig on-
derzoek worden beschreven in hoofdstuk 13.
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Bij het schrijven van dit proefschrift is de bijdrage van anderen onmisbaar geweest. Een 
aantal mensen wil ik bijzonder bedanken voor hun bijdrage.
Allereerst gaat mijn dank uit naar mijn directe begeleider en promotor, professor dr. E.J. 
Kuipers. Beste Ernst, je vertelde me aan het begin van mijn promotietijd dat full-time tijd voor 
onderzoek bijzonder is en je vergeleek deze kans met het hebben van vakantie, een periode 
zonder andere verplichtingen. Enigszins verbaasd heb ik me tijdens deze beginperiode zor-
gen gemaakt over jouw, en mijn toekomstige, vakanties. Echter, je onaflatende enthousiasme 
voor het onderzoek, en je ontspannenheid na vakanties, hebben me in een later stadium 
gerustgesteld. Inmiddels denk ik dat je vooral bedoelde dat vakanties altijd te kort zijn. Ik 
heb je enthousiasme als bijzonder motiverend ervaren en wil je hartelijk danken voor je 
begeleiding en voor de vrijheid die je me hebt toevertrouwd tijdens mijn promotietraject.
Ook Jelle Haringsma wil ik bedanken voor zijn begeleiding en vakkundige bijdrage aan 
dit proefschrift. Beste Jelle, mijn hartelijke dank voor de tijd die je in dit proefschrift hebt 
gestoken, en voor de goede sfeer tijdens de vele research-scopieën.
Mijn dank gaat uit naar alle leden die bereid waren zitting te nemen in de promotie-
commissie.
De endoscopie-verpleegkundigen, arts-assistenten en stafleden van de afdeling Maag-, 
Darm- en Leverziekten van het Erasmus MC, Rijnstate ziekenhuis en Deventer ziekenhuis, wil 
ik bedanken voor het informeren van patiënten over het onderzoek en het verrichten van 
de research-scopieën. In het bijzonder wil ik Frank ter Borg, Petra van Embden en Richard 
de Vries bedanken voor hun inspanningen. Ook Erik Rauws wil ik bedanken voor de prettige 
samenwerking.
De ervaren bijdrage vanuit de pathologie van Nicole van Grieken, Gerrit Meijer en Herman 
van Dekken is van groot belang geweest bij vrijwel alle studies beschreven in dit proefschrift. 
Veel dank voor de prettige samenwerking. Daarnaast wil ik Mariël Casparie hartelijk bedan-
ken voor de hulp bij het verzamelen van gegevens.
De bijdrage van Caspar Looman is onmisbaar geweest bij de statistische analyse van ver-
schillende projecten, waarvoor mijn hartelijke dank. Ook Ewout Steyerberg wil ik bedanken 
voor zijn bijdrage.
Peter Siersema, Hans Kusters en Mark van Blankenstein wil ik bedanken voor de mogelijk-
heid om onderzoeksplannen en -resultaten te bespreken tijdens de researchbespreking van 
de Barrett’s onderzoeksgroep. Ook alle andere collega’s, hartelijk dank voor jullie adviezen 
tijdens deze en latere algemene GE-bespreking.
Ook wil ik Wendy Holleman en Linda Visser, secretaresses van Maag-, Darm- en Leverziekten 
afdeling en laboratorium, bedanken voor hun ondersteuning. De diagnostiek afdeling van 
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het laboratorium, Hanneke van Vuuren, Angela Heijens, Martine Ouwendijk, Jan Francke en 
Nicole Nagtzaam, wil ik bedanken voor de praktische hulp bij de serologische bepalingen.
Niet alle onderzoeksprojecten waaraan tijdens mijn promotietijd is gewerkt, zijn uiteinde-
lijk als hoofdstuk in dit proefschrift terechtgekomen. Desalniettemin wil ik enkele mensen 
bedanken voor de prettige samenwerking aan deze projecten. Het slagen van het MucoVax 
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Natuurlijk wil ik ook mijn ‘maag-maatje’ Lisette Capelle bedanken. Lieve Lisette, dank je 
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Ook wil ik een aantal mensen bedanken die op de achtergrond een belangrijke rol hebben 
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lie gezelligheid en belangstelling. Na de hechte studietijd zijn we allemaal een andere kant 
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rijke gebeurtenissen dit jaar hebben gegeven. Lieve pap en mam, bedankt voor jullie steun; 
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